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con t en ts
General Introduction1

Part I: Clinical Aspects
In Vitro Fertilization
Ten percent of Dutch couples suffer from a fertility disorder (1;2). Of
these couples 50% are treated with i v f or Intracytoplasmic Sperm Injec-
tion (icsi) treatment. Nowadays, in the Netherlands one out of 55 chil-
dren is conceived through i v f or icsi (3). 
Infertility has been well known since ancient times (4). As long as
physicians were unable to help women satisfy their basic instincts for
procreation and motherhood, infertility was considered a devine inﬂic-
tion treated by equal measures of witchcraft, myth and good faith. Not
until the second half of the 20th century did effective treatment of infer-
tility replace magic and belief. During the ﬁfth decade of the 20th centu-
ry, clomiphene citrate emerged as the ﬁrst effective promoter of fertility.
Within the next 20 years, gonadotrophins were produced and used to
treat infertile couples. These hormones induced multiple follicle growth
of the ovaries. By the early 1980s it became world wide possible to
retrieve oocytes, fertilize them with spermatozoa outside the body and
transfer one or more embryos in the uterus, the so-called in vitro ferti-
lization (i v f) treatment. 
In 1978 the ﬁrst successful pregnancy resulting from i v f occurred
during an unstimulated normal menstrual cycle (5). i v f in the natural
cycle was soon replaced by i v f with ovarian hyperstimulation. The use
of exogenous gonadotrophins resulted in higher numbers of embryos
available for transfer, while gonadotrophin-releasing hormone ana-
logues decreased the cancellation rate (6;7). Both measures led to better
pregnancy rates. 
At present the following i v f protocol is used at the i v f department
of the University Medical Center Nijmegen. Pituitary down-regulation
(long protocol) is achieved using a gnr h analogue (Decapeptyl®; Fer-
ring, the Netherlands). Multiple follicular stimulation is realized by
recombinant follicle-stimulating hormone (Puregon®; Organon, Oss, the
Netherlands). Thirty-six hours after hcg injection (Pregnyl®; Organon,
Oss, the Netherlands) transvaginal oocyte retrieval is performed under
gener a l in t roduction
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systemic analgesia (10 mg oxazepam orally and 1mg alfentanyl, i.v.). The
retrieved oocytes are inseminated or icsi is performed according to the
method described by Van Steirteghem and colleagues (8). The morning
following injection or insemination fertilization of the oocytes is judged.
Three days after oocyte retrieval one or two best quality embryos are
transferred. The luteal phase is supported by three doses of progesterone
200 mg (Progestan®; Organon, Oss, the Netherlands) intravaginally
daily for ﬁfteen days starting from the day of oocyte retrieval. 
Iatrogenic Multiple Pregnancies
By the early 1980s the number of twins increased dramatically in the
Netherlands, from 10/1000 births to 18/1000 births in the year 2000, 
and this number is still increasing. Also the number of triplets and higher
order births increased from 1980 (0.15/1000 births) to the early 1990s
(0.6/1000 births), but this number is decreasing since 1992 (www.cbs.nl).
Increase in maternal age and medical management of subfertility are the
most important factors that contribute to the rapid increase in multiple
birth rates (9;10). Older women are at higher risk of spontaneous multi-
ple birth than younger women due to higher basal fsh levels (11;12) and
over the past 25 years a trend towards delayed childbearing has been
observed in Europe. The Netherlands even took the lead. The mean age
at which the Dutch women have their ﬁrst child increased from 24.3
years in 1970 to 29.2 years in 2001 (www.cbs.nl). 
As mentioned before, the medical management of subfertility is also
an important contributor to the huge increase in multiple births. In ovu-
lation induction as well as in mild hyperstimulation and IUI (intra uterine
insemination) multiple follicular growth is positively correlated with a
higher multiple pregnancy rate. The number of embryos obtained after
i v f is a good prognostic value for the chance of pregnancy, whereas the
multiple pregnancy rate is a direct consequence of the number of
embryos transferred (13). Due to controlled ovarian (hyper)stimulation,
with or without intrauterine inseminations, the risk of multiple births
varies from 8% with clomiphene to 20-30% with gonadotrophins (14). 
In case of i v f or related assisted reproductive technologies (a rt) the
percentage of twins is 24% and triplets 2% in Europe (15). In the Nether-
lands the number of i v f twins was 21.8% and triplets 0.8% in 2003
10
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(www.nvog.nl). In our country probably half the twin maternities are a
result of ovarian stimulation or i v f and the other half is accounted for
the increase in maternal age (16). 
Templeton showed that the chances of live births after i v f are related
to the number of oocytes fertilized, presumably because of the greater
number of embryos to select for transfer or as expression of better ovari-
an response. When more than four oocytes are fertilized and available
for transfer, the woman’s chance of a birth is not diminished by transfer-
ring only two embryos. Transferring three or more embryos increases
the risk of multiple births (13). Since the publication of this article, in the
Netherlands a maximum of two embryos are routinely transferred per
cycle to prevent higher-order multiple pregnancies. The risk for a twin
pregnancy with this regime, however, is still 20-35% (17), which is a 15-
fold increase relative to the risk of 1.6% after natural conception (17;18).
In the Netherlands in 2003 i v f resulted in 20 triplets, 806 twins and
2888 singletons. The contribution of i v f to the total number of triplets
was 28.6% (20/70). Out of a total number of 3616 twins the number of
i v f-twins was 806 (22.3%) (www.nvog.nl).
Risks of Iatrogenic Multiple Pregnancies
The high rate of multiple births resulting from in vitro fertilization is a
major health isssue. Twin pregnancies cause more maternal and perina-
tal mortality and morbidity (19-21), and imposes a steep burden on gov-
ernment expenses and health services (21-23). Furthermore, it should not
be forgotten the long-term health consequences and the psychosocial
problems related to multiple births.
Maternal complications
One of the major maternal complications associated with multiple preg-
nancies is pregnancy-induced hypertension. Even after adjustment for
age and parity, most studies indicate that the risk of developing severe
hypertension is two to three times greater for a twin pregnancy than for a
singleton pregnancy. Pre-eclampsia is also three times more common in
twin pregnancies than in singletons, among primigravid women carry-
ing a twin pregnancy this risk is even ﬁve times higher (24). The true inci-
dence of pre-eclampsia among patients with multiple pregnancies may
gener a l in t roduction
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be underestimated because of the increased number of preterm deliver-
ies before the onset of clinical symptoms of pre-eclampsia (25). Douglas
and colleagues found in the United Kingdom a relative risk of 6.0 (95%
ci 4.1-8.9) for eclampsia in multiple pregnancies as compared with sin-
gleton pregnancies (26).
Anemia, antepartum bleeding from placenta previa and abruptio pla-
centae are more common in multiple pregnancies. Greater amounts of
intrapartum blood loss as a result of higher incidence of surgical inter-
vention and postpartum hemorrhage due to atony occurs more often in
women with multiple pregnancies (27). 
Multiple gestations are associated with an increased rate of deliveries
by Caesarean section. After Caesarean section an increased rate of pul-
monary emboli, hemorrhage, postpartum infection, wound infection
and prolonged hospitalization is observed. The maternal death rate asso-
ciated with Caesarean sections is two to four times higher than with
vaginal delivery (24). 
Preterm labour and preterm premature rupture of membranes occur
more often in multiple pregnancies than in singletons. The margins of
safety of tocolytic therapy are narrower for mothers of multiples than for
mothers with singleton pregnancies because of increased maternal
blood volume and cardiac output. The side effects of beta-sympath-
omimetics occur more frequently and are more severe. Careful monitor-
ing of cardiovascular parameters en strictly ﬂuid management are criti-
cal in preventing pulmonary oedema (28).
The increased risk for serious maternal morbidity leads to a higher
incidence of maternal mortality. Senat and colleagues estimated that, in
France, the maternal mortality was more than two times higher in multi-
ple versus singleton pregnancies (10.2 versus 4.4 per 100,000 live births).
For Europe these ﬁgures were 14.9 versus 5.2 (odds ratio 2.9, 95% ci 1.4-
6.1) (24). 
Perinatal and long-term complications
Infants from multiple pregnancies are more likely to be born premature-
ly and with a lower birth weight. Martin et al. showed that 57.4% of the
twins was born prematurely (<37 weeks) and that the mean gestational
age was 32.0 (sd 4.0) weeks. Singletons, however, were born at a mean
gestational age of 38.8 (sd 2.5) weeks, 10.4% was born prematurely. The
mean birth weight of twins was 2353 (sd 647) gram, and 54.9% had a low
12
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birth weight (<2500 gram). Singletons had a mean birth weight of 3339
(sd 573) gram, and 6.0% had a low birth weight (29). Two other reports
showed the same results (21;30). Obviously many perinatal complica-
tions can be addressed to prematurity and low birth weight. Treatment
in neonatal intensive care units (nicu) was required for 15% of single-
tons and 48% of twins (22). Twins have a ﬁvefold increase in the risk of
fetal death and even a sevenfold increase in the risk of neonatal death
when compared to singletons (31). 
There is an increased risk of long-term medical and developmental
problems, in particular neurological impairment, in children from multi-
ple pregnancies. The risk of cerebral palsy in twins is approximately ﬁve
times higher than that in singletons, on the basis of 1000 ﬁrst-year sur-
vivors, but the risk increases to 8.3 times when calculated per 1000 preg-
nancies (32). The risk of handicaps increases also with the number of
fetuses. Twins have a 1.4-fold increased risk for all handicaps compared
with singletons (33).
Economic implications 
Multiple pregnancies have been shown to require more medical care
than singleton pregnancies and therefore generate more costs. Multiple
pregnancies are associated with higher maternal costs (hospital admis-
sion, frequently monitoring, preventing and treating complications),
higher delivery charges (increased Caesarean section rate, longer hospi-
tal admission), higher neonatal costs (medical problems related to pre-
maturity and low birth weight, higher nicu admission rate), and higher
childhood costs (more physical and mental handicaps) (18;21;22). 
Ettner and colleagues indicated that gestational age accounts for 50%
of the increase in total charges due to multiple gestation, birth weight
accounts for 40%, and neither gestational age nor birth weight could
account for the remaining 10% (34). Callahan et al. estimated total family
charge as 9,845 dollar for a singleton delivery and 37,947 dollar for twins
(18,974 dollar per baby). This study was performed at Brigham and
Women’s Hospital in Boston from 1986 to 1991 (22). Wolner-Hannsen et
al. chose another approach. They compared the costs of an i v f treat-
ment with single embryo transfer (set) and double embryo transfer
(det), with a live birth rate of 21% in the set and 25% in the det group
and a twin pregnancy rate in the det group of 24%. The total costs for
the det strategy were 4 times higher than for the set strategy (23).
gener a l in t roduction
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Obviously, the costs of i v f treatment and hospital admission as well as
the i v f results and prevalence of complications differ from country to
country and even within one country. 
We must be aware of the fact that costs may be higher for i v f twins
than for non-i v f twins (35), because i v f-pregnancies (singletons and
multiples) are at greater risk for obstetric and perinatal complications
than spontaneously conceived pregnancies (36-41).
Psychosocial impact
The psychological and social impact of multiples on the host family must
not be underestimated. Many parents are unprepared for the impact that
the birth of a twin has on the relationship with their partner. Couples of
i v f twins indicated that they found parenting considerably less rewar-
ding than they had expected (43). Furthermore, mothers of i v f twins
experience more parenting stress as compared with mothers of i v f sin-
gletons and naturally conceived singletons (43-45). Parents of multiples
suffer more often from fatigue and depression and are more likely to get
divorced (46;47). 
Mothers of premature twins are less responsive to their babies than
are mothers of singletons; multiples may therefore be particularly vul-
nerable to the psychological consequences of obstetric complications
(48). Even when the children are healthy, factors as shared parental
attention, triadic communication, and the unique relationship between
twins themselves may adversely affect social skills and language develop-
ment (49). 
However, we also have to consider that patients do not always share
their physicians’ concerns about multiple pregnancies or are more will-
ing to accept the associated risks (50). The ideal outcome of i v f from a
clinical perspective would be a healthy singleton child, whereas many
infertile couples are hoping for a ready-made family and ‘two for the
price of one’. Ryan and colleagues described in a prospective analysis
that 20% of the i v f patients listed a multiple birth as their most desired
outcome of i v f treatment. Only a minority of patients (30%) was aware
of all of the risks of a twin pregnancy and this lack of knowledge was pre-
dictive of the desire for multiple births. Nulliparity, lower family income,
younger patients age, prior evaluation for infertility, and longer duration
of infertility were also associated with the desire for multiple births.
Only nulliparity and lower family income were independently associated
14
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with this desire (51). Because patients are actively involved in clinical
decision-making, for example implementation of set , understanding
patient desires and knowledge about multiple births is important. It
seems that risk education may play an important role in counselling i v f
patients to understand and accept the need for set . 
Avoiding Multiple Pregnancies in I VF
Single Embryo Transfer
As will be clear from the above paragraphs, multiple pregnancies are the
most serious complication after i v f treatment. Nowadays, most clinics
in Europe transfer two embryos per cycle, to reduce chances for high-
order multiple pregnancies (13). Also in the Netherlands routinely a max-
imum of two embryos per cycle are transferred. In Europe, the multiple
birth rate in 1997 was 30%, with twins at 26% and triplets at 4% (52). The
only solution to diminish the number of multiple births dramatically is
single embryo transfer (set). There is a conﬂict of interest between the
ambitions of single birth after i v f by set on the one hand and the emo-
tional and economical aspects of the possibly lower pregnancy rate on
the other. 
One solution to overcome this dilemma is to select embryos with a
higher potential for implantation. At the present time, cytoplasmic frag-
mentation and cleavage rate are the determinants of embryo selection for
transfer. Although high quality day-3 embryos possess a greater poten-
tial for establishing a pregnancy, these selection criteria are rather poor
predictors of subsequent implantation and pregnancy rates. When day-3
embryos are cultured for a prolonged period of time until the blastocyst
stage, only viable blastocysts with a high developmental potential will
survive. The implantation rate of these day-5 blastocysts appears to be
higher, up to 50% (53-55). With optimal culture conditions about 50% of
the embryos will develop into blastocysts (53;56). A randomized con-
trolled trial comparing day 5 versus day 3 transfer of two embryos did not
result in a signiﬁcant difference in pregnancy rate between both groups
(57). Even when blastocysts are morphologically graded as optimal, 50%
appears to be aneuploid (58). With the introduction of preimplantation
genetic screening (pgs) for aneuploidy, it has become possible to ana-
lyze the ploidy status of several chromosomes from in-vitro cultured
gener a l in t roduction
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embryos (59). The exclusion of aneuploid embryos before transfer
improves the implantation rate (60) and reduces the abortion rate (61). A
disadvantage of this method is the manipulation of the embryo risking
damage and loss of embryos. It is important to study the cost-effective-
ness of pgs in i v f before introducing this as a standard procedure. Fur-
thermore, it may raise ethical objection like eugenics. 
In order to reduce the multiple pregnancy rate substantially, while
maintaining an acceptable overall pregnancy rate, the patients at risk for
multiple pregnancy and their treatment characteristics have to be identi-
ﬁed. Retrospective studies indicated age, number of embryos available
and quality of embryos as the most important predictors for multiple
births (62-64). 
Up to now only four randomized controlled trials comparing single
embryo transfer (set) and double embryo transfer (det) have been
published (65-68). The study of Gerris et al. was performed in 53
patients younger than 34 years of age. At least two top quality embryos
had to be available. The difference in the ongoing pregnancy rates
between the set group (38.5%) and the det group (74.1%) was not sig-
niﬁcant (65). The study of Martikainen et al. was performed in 144
patients with at least four good quality embryos. There was also no sta-
tistical difference in cumulative live birth rate (fresh and frozen cycles)
between the set group (39%) and the det group (51%) (66). Gardner et
al. randomized 48 i v f patients with at least 10 follicles > 12 mm on the
day of hcg administration to either the transfer of one blastocyst or two
blastocysts on day 5. There was no signiﬁcant difference in ongoing
pregnancy rate between single blastocyst transfer (61%) and double blas-
tocyst transfer (76%) (67). Finally, Thurin et al. performed a multi-centre
randomized trial in 661 women who were less than 36 years of age and
had at least two good quality embryos available. The cumulative live
birth rate in the set group (one fresh set and one frozen set cycle) was
38.8% compared with 42.9% in the det group (without a frozen det
cycle) (p = 0.3) (68). The multiple birth rate was 33.1% in the det and
0.8% in the set group. The live birth rate after only one fresh-embryo
cycle was signiﬁcantly lower in the set group than in the det group,
27.6% and 42.9% respectively. 
In Finland elective single embryo transfer is already successfully im-
plemented in daily practice, where det is only considered in patients with
two unsuccessful i v f cycles or poor embryo quality. In a retrospective
16
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Finnish study 1871 i v f cycles carried out from 1997 to 2001 were analyzed.
The number of set cycles increased from 11% to 56%. The clinical preg-
nancy rate per transfer increased from 28.3% to 30.3%, while the multiple
birth rate dropped from 25% to 7.5% (69). In Belgium, Gerris and col-
leagues studied also the effect of elective set in a large group of patients
(n=1559). They showed in a retrospective cohort analysis over a four year
period that at least one top embryo (4 or 5 blastomeres on day two, at least
7 blastomeres on day three, <20% fragments and the absence of multinu-
cleated blastomeres) could be transferred in ~70% of all cycles. Over
these four years set increased from 13% to 31%, whereas the ongoing
pregnancy rate per retrieval did not change (35.9% to 31.0%), but the mul-
tiple pregnancy rate decreased with almost 50% (33.6% to 18.6%) (70). 
Natural Cycle I VF
i v f treatment is an effective method for many couples with various
causes of infertility to become pregnant. The ﬁrst successful pregnancy
resulting from i v f occurred during a natural menstrual cycle (5). Since
then, ovarian stimulation has been widely used in assisted reproduction
programs all over the world. The advantages of ovarian hyperstimulation
are increased numbers of oocytes and subsequent embryos available for
transfer, which is associated with a higher chance of pregnancy (6;71).
Better cycle control was achieved by pituitary desensitization with the
use of gonadotrophin-releasing hormone analogues, which improved
the pregnancy rate after i v f even more (7).
There are major concerns, however, about the risks of ovarian stimu-
lation. In ovulation induction, intra uterine insemination (if combined
with ovarian hyperstimulation) and i v f the most important risk is 
the high incidence of multiple pregnancies, with its attendant obstetric
and neonatal problems (see above). Another serious risk, predominantly
occurring in i v f , is the ovarian hyperstimulation syndrome (ohss),
which is a life threatening complication (72;73). Although available data
are reassuring, concern remains about the possible increased risk of
developing ovarian, endometrial or breast cancer after repeated ovarian
stimulations (74-79). Legal and ethical dilemmas concerning the storage
and disposal of spare embryos have to be taken into account. A decrease
in endometrial receptivity as a result of hormone treatment is suggested,
but this remains controversial (80-83). Finally, natural cycle i v f offer a
low-cost alternative that may be more accessible to patients (84;85).
gener a l in t roduction
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These disadvantages have led to the revival of i v f in the natural cycle
by several research groups, especially since the i v f technique and LH
monitoring have been improved over the years. Pelinck et al. performed a
systematic review to determine the effectiveness of natural cycle i v f .
The 20 selected studies described a total of 1800 natural cycles of i v f .
The cancellation rate of oocyte retrieval was 28.9% and embryo transfer
was performed in 45.5% of the cycles. The ongoing pregnancy rate was
7.2% per cycle and 15.8% per embryo transfer (86). Daya and colleagues
calculated that the incremental direct medical treatment cost incurred
per live birth after i v f when using stimulated cycles, compared to natur-
al cycles, is approximately 48,000 dollar. Moreover, this protocol can be
performed on a monthly basis, in contrast to i v f after stimulated cycles
that takes in general three months, because the ovaries need to recover
from hormonal stimulation. For up to three unstimulated cycles no
decrease in pregnancy rate per cycle is observed (87). So, it is suggested
that in the same time span natural cycle i v f (after three consecutive
cycles) might be even effective as one stimulated cycle i v f . A cost-effec-
tiveness study comparing (multiple) natural cycle i v f treatment with
set after stimulated cycle i v f is warranted. 
It has been suggested that i v f in the natural cycle can be best per-
formed in patients with tubal factor infertility, as in these couples both
male and female gametes are supposed to be normal (88). However, in
case of severe oligozoospermia, the efﬁcacy of icsi in the natural cycle
has never been investigated serially and in a systematic way before.
Selective Embryo Reduction
Selective embryo reduction is proposed by some individuals as a manner
of dealing with high-order multiple gestations. The most commonly
used technique involves the insertion of a needle into the fetal thorax and
the injection of kcl (potassium-chloride) into the fetal heart to achieve
cardiac arrest. Individual clinic-derived data are conﬂicting with regard
to the improvement in perinatal outcome achieved by embryo reduction
of triplets to twins. However, with four or more fetuses, the improve-
ment in outcome of selective embryo reduction is dramatic (89). Selec-
tive embryo reduction is not without risks, however. Evans and col-
leagues reported that only 84% of pregnancies resulted in an ongoing
pregnancy after embryo reduction, and 5% of these pregnancies resulted
in an extreme preterm labour (25-28 weeks of gestation) (90).
18
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The preplanned use of selective embryo reduction to ‘correct’ overly
aggressive fertility treatment should be rigorously discouraged as an
unethical and inappropriate use of this procedure. Retrospective studies
show that many couples (32%) are ultimately uncomfortable with their
decision to reduce (91). The sequence of producing iatrogenic high-order
multiples that are subsequently submitted to iatrogenic termination is
considered as the ultimate paradox of infertility treatments.
When set might be put into practice in order to decrease the number of
i v f-twins and higher order multiple births, the pregnancy rate could
drop slightly as well. To facilitate the implementation of set , it is impor-
tant to improve the pregnancy rate. One way to accomplish this is a cryo-
preservation programm with good clinical results. Another way to
increase the live birth rate is to perform more fundamental research on
the process of implantation in order to improve this critical stage in preg-
nancy. The fetus is considered to be a semi-allograft that has to be
accepted by the maternal immune system. Therefore, we believe that it is
important to gain more insight into the immunological interaction
between the fetus and the mother during implantation. In this thesis we
focused on natural killer (nk) cells, because they play an important role
in human implantation.
Part II: Immunological Aspects
Immunology and Reproduction
Ovary
Unlike the testes, the ovary does not constitute an immunologically priv-
ileged site. Resident ovarian monocytes-macrophages, lymphocytes and
granulocytes can be observed at various stages of the ovarian life cycle
and actively participate in the functional and structural changes of the
follicle and corpus luteum development. The vascular network around
the dominant follicle, located in the theca-layer, shows an increased
blood ﬂow and increased permeability to attract leukocytes into the folli-
cle tissue through cytokines and chemokines leading to successful ovula-
tion (92). Until now in follicular ﬂuid the presence and function of many
cytokines have been determined (93-99). Follicular ﬂuid provides the
gener a l in t roduction
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environment in which oocyte maturation occurs and may therefore
inﬂuence the quality of the oocyte, and thus be linked to fertilization and
early embryonic development. However, there is only limited informa-
tion from dated studies evaluating the immune cells (i.e. leukocytes) pre-
sent in f f responsible for the production of those cytokines (99-105). 
In case of i v f multiple follicle growth is induced by hormonal stimu-
lation. To enhance the pregnancy rate the best quality embryo(s) are
selected for transfer into the uterus. At the present time, morphology
and cleavage rates are the determinants of embryo selection for transfer.
Unfortunately, both are poor predictors of subsequent implantation and
pregnancy. Therefore, to improve the implantation rate we are eager to
ﬁnd better prognostic markers for embryo quality in either follicular
ﬂuid or in embryo culture supernatant (ecs). The leukocytes present in
follicular ﬂuid might inﬂuence growth and development of oocytes and
subsequent embryos and could therefore be of value as a prognostic
marker in embryo selection. 
Endometrium
Even more than in the ovary immunological processes play a role in the
endometrium. The uterus is uniquely adapted to support a pregnancy,
while retaining the barrier function that is characteristic of all mucosal
tissues. The capacity to distinguish between, and appropriately respond
to, the array of foreign entities to which it is exposed is achieved through
a highly specialized local immune system. Speciﬁc mechanisms acting to
elicit immunological tolerance in the case of semen and embryos co-exist
with active immunity to defend the uterus from pathogenical bacteria
and viruses. 
Leukocytes play an important role in remodelling the endometrium
during every menstrual cycle. This remodelling is orchestrated by the
ovarian steroid hormones, estrogen and progesterone. In the prolifera-
tive phase T cells, macrophages, a few B cells and a few nk cells are pre-
sent in the uterine mucosa. T cells and macrophages remain at much the
same density throughout the luteal phase and during the process of
decidualization. In contrast, nk cell numbers increase dramatically in
the luteal phase and remain at a high level during ﬁrst trimester pregnan-
cy. In the decidua, 70% of the inﬁltrating leukocytes are nk cells, togeth-
er with macrophages (20%) and a small number of T cells (10%) (106).
The number of nk cells is particularly high in the decidua basalis at the
20
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site of embryo implantation (42;106-109). Uterine nk cell death occurs
as soon as progesterone levels drop, either pre-menstrually or when a
pregnancy fails (109).
Ovarian stimulation for i v f treatment results in supraphysiological
concentrations of sex steroids during the follicular and luteal phase. The
effect on endometrial receptivity remains controversial. In i v f both pos-
itive and negative effects on pregnancy rates have been reported (80-83).
During the menstrual cycle as well as throughout pregnancy the leuko-
cyte numbers vary, therefore an interaction with the leukocytes with the
sex steroids progesterone and oestradiol is suggested, although it is not
clear yet whether this is a direct or an indirect mechanism. DeLoia et al.
have shown that the total number of lymphocytes in endometrium as
well as in peripheral blood, particularly the nk cells, increases under
inﬂuence of supraphysiological estrogen levels (110). Because we were
anxious to ﬁnd out whether hormonal stimulation during i v f treatment
improves or deteriorates the quality of the endometrium we started a
study.
Implantation
The fetus can be considered as a semi-allograft, since fetal cells contain
both maternally and paternally derived antigens. Medawar postulated
this immunological concept of pregnancy for the ﬁrst time in 1954 (111).
However, several recent developments seriously question this statement.
The fetal-maternal relationship is more akin to a host versus tumour or
host versus parasite relationship than a host versus graft relationship
(112). The maternal-fetal relationship is a unique process representing a
step-by-step, programmed interactive symbiosis. 
Trophoblast invasion into the decidua results in the formation of a
specialized organ, the placenta. During implantation fetal cells come in
direct contact with maternal cells, therefore the immune system of the
mother has to adapt to make a successful pregnancy possible. Around 6
days after fertilization, the embryo differentiates into a blastocyst that
consists of an inner cell mass that will form the embryo and an outer tro-
phectoderm that will become the placenta and chorion. The blastocyst
becomes embedded by decidualized stroma. Columns of cytotro-
phoblast cells (villi) emerge from the blastocyst and invade the decidua
basalis. In these villi embryonic vascularisation develops. Erosion of
maternal capillaries by the invading trophoblast causes the ﬁlling of
gener a l in t roduction
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Figure 1. Anatomy of the trophoblast populations that are present at the fetal-maternal
interface in the ﬁrst trimester of pregnancy.
a: The placental villi are covered by villous trophoblast cells; an inner mononuclear
cytotrophoblast layer covered by syncytiotrophoblast. The core of each villous contains
fetal blood vessels, ﬁbroblasts and fetal macrophages (Hofbauer cells). Maternal blood
in the intervillous space reaches the placenta through the uterine spiral arteries (A). The
inner layer of villous cytotrophoblast grows out at focal points to form cell columns (CT).
These are prominent at the anchoring villi, where attachment to the maternal decidua
occurs. At the fetal-maternal boundary, the columns form a partially continuous shell.
From this shell, extravillous trophoblast cells enter the decidua as interstitial trophoblast
cells (T) to encircle and destroy the arterial media, which is replaced by ﬁbrinoid materi-
al (F). Then, endovascular trophoblast cells (E) move down the arteries in a retrograde
manner to replace the endothelial cells. The trophoblast cells move as far as the inner
myometrium, where they fuse to become placental-bed giant cells (GC). Extravillous tro-
phoblast cells include cytotrophoblast cell columns and shell, interstitial and endovascu-
lar trophoblast and placental-bed giant cells. b. A schematic representation of the
decidual stroma at the implantation site. Interstitial trophoblast cells (T) are seen
between large stromal cells (S). The maternal leukocytes that are present are uterine NK
cells (NK), as well as few macrophages (M) and occasional T cells (L).
From: Nature Reviews Immunology. © Dr. A. Moffett-King (109).
spaces within the syncytium with maternal blood. The fusion of these
lacunae allows formation of a sponge-like network, the intervillous
space. Only one layer of trophoblast cells separates the fetal and mater-
nal blood stream making exchange of nutrients and gases possible. This
is called the haemomonochorial placenta. 
At the end of the ﬁrst trimester of gestation a second very deep inva-
sion (1/3 of the uterine wall) of extra-villous trophoblast takes place.
Namely, there are two types of cytotrophoblast cells known as villous
trophoblast and extra-villous trophoblast. These two cell populations
make different contributions in establishing efﬁcient transport between
the maternal and fetal circulations. Villous trophoblast covers the chori-
onic villi, providing the barrier through which metabolic exchange
between mother and fetus occurs. A small part of the villi are anchored
to the decidua. At the tip of these anchoring villi a cell column of prolifer-
ating cytotrophoblast cells disrupts the epithelial syncytiotrophoblast
layer. These cells differentiate into a distinct population of extra-villous
trophoblast cells. The primary role of the extra-villous trophoblast is
thought to be the regulation of maternal blood ﬂow into the intervillous
space by invasion and transformation of decidual arteries. The intra-
mural, endovascular and interstitial trophoblast cells respectively invade
the maternal arterial walls, arterial lumen and interstitium (Figure 1) (113).
An important function of the invading trophoblast is to destroy the mus-
cular walls of the uterine spiral arteries converting them into large,
uncoiled vessels that are capable of high conductance and are not
responding to vasoactive stimuli. These vascular adaptations provide an
increased blood ﬂow to the intervillous space, without which a variety of
obstetrical problems, like miscarriage, pre-eclampsia, growth retarda-
tion and still birth can occur (114).
The maternal-fetal interface
Fetal side
Implantation of the developing embryo into the decidua of the maternal
uterus is a critical event in human pregnancy. Maternal tolerance to the
fetal alloantigens is essential in this stage of pregnancy. The fetus
expresses the full array of its paternally inherited mhc (Major Histo-
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compatibility Complex) genes (112). However, the fetus is surrounded by
trophoblast cells and it is these cells that make the primary contact with
maternal immune cells. These extra-embryonic cells only express a select
few of the mhc antigens at their surface.
HLA molecules on trophoblast
Antigens presented on the cell surface of nucleated cells and trombo-
cytes are called the Major Histocompatibility Complex. In humans the
antigens are called ‘Human Leukocyte Antigens’ (hl a). The molecules
can be devided into two classes. Classical class I molecules (hl a-a ,
hl a-b ,  hl a- c), non-classical class I molecules (hl a-e ,  hl a-f,
hl a- g) which are expressed on all nucleated cells and class II molecules
(hl a-dr , hl a-dq, hl a-dp) which are only presented on antigen
presenting cells, like B-cells, dendritic cells and macrophages. The non-
classical class I molecules have limited polymorphism and have a
restricted tissue distribution. 
Remarkably, villous syncytiotrophoblast that lines the intervillous
space and is in close contact with immune cells in maternal blood does
not express any mhc class I antigen. These cells are presumably
immunologically inert to a T cell-mediated attack. Cytolytic activation of
nk cells also does not occur, although nk cells are generally activated by
the absence of mhc antigens. This is probably due to lack of activating
ligands on syncytiotrophoblast and protection of the surface by high lev-
els of glycosylation. 
Extra-villous trophoblast, however, express a unique limited combi-
nation of three subtypes of mhc class I antigens, hl a- c , hl a- g and
hl a-e (112;115-118). hl a-f expression is also discovered on trophoblast
(118), but this has not yet been conﬁrmed by others. Extra-villous tro-
phoblast does not express mhc class II molecules, nor does it express
the two main classical mhc class I antigens, hl a-a and hl a-b . hl a-a
and hl a-b are the molecules that are involved in transplant rejection.
hl a- c is a polymorphic classical mhc class I molecule. The paternal
allele is expressed on the extra-villous trophoblast cell surface and may
be important for allorecognition of trophoblast. hl a- c shows ubiqui-
tous expression. A greater proportion of uterine nk cells than peripheral
blood nk cells express the k ir receptor speciﬁc for hl a- c , suggestive
of a role in implantation. 
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hl a- g is a non-classical class I molecule. hl a- g is of particularly
interest, because it is only expressed on the fetal-maternal interface 
by invasive trophoblast cells, in amniotic ﬂuid and on thymic epithelial
cells (119). Furthermore, this molecule is characterized by a reduced
polymorphism. Paternally inherited hl a- g genes expressed by the
fetus would produce proteins almost identical to those of the mother.
Thus, hl a- g is thought to be expressed on trophoblast without being
recognized as ‘foreign’ by the maternal immune system. Data suggest
that hl a- g expression is also induced in peripheral organs/tissues
under certain pathological conditions (120;121). hl a- g can be ex-
pressed as seven different isoforms, four being membrane bound 
(hl a- g1 to hl a- g4) and three being soluble (hl a- g5 to hl a- g7)
(122-126). These seven isoforms arise from alternative splicing of a
unique primary transcript. hl a- g can act on all players of immune
responses (nk cells, T cells and Antigen Presenting Cells) and directly
inhibit their functions. Furthermore, hl a- g apparently induces differ-
entiation of these players into cells whose functions are oriented toward
active inhibition (suppressor T cells and tolerogenic Antigen Presenting
Cells) (127).
Soluble hl a- g (shl a- g) produced by trophoblasts has been detect-
ed in maternal plasma and amniotic ﬂuid (128-130). Soluble hl a- g can
act as an immunoregulatory molecule. In vitro data show that shl a- g is
able to induce apoptosis in cd8 positve nk and T cells (131-133). Further-
more, in allogeneic mixed lymphocyte cultures recombinant shl a- g
showed inhibition of cytotoxicity and induced a shift from Th1 to Th2
cytokine proﬁle (134). Emmer et al. found a signiﬁcantly lower level of
amniotic ﬂuid shl a- g in pregnancies affected by neural tube defects as
compared to controls (135). This was in concert with the ﬁndings of
Seniz et al. (136). Emmer et al. suggest that shl a- g might be involved in
a mutual mechanism of on one side the association of neural tube defects
and abnormalities of the thymus and on the other side the association of
neural tube defects and changes in T cell repertoire.
The contribution of hl a- g to maternal-fetal tolerance and tro-
phoblast invasion is in doubt because reports have described healthy
individuals homozygous for the hl a- g*0105N allele who have been
delivered normally (137;138). In the case of this allele, the full-length
hl a- g1 membrane bound protein cannot be translated. Nevertheless,
in hl a- g*0105N homozygous individuals, the other hl a- g2, -g3, -g6
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and -g7 isoform might be produced normally, and their contribution to
the immune privilege of the fetus should be taken into consideration. It
has been described that, like hl a- g1, the hl a- g2, -g3 and -g4 trun-
cated isoforms are expressed at the cell surface and modulate immune
responses (139;140). 
The third hl a antigen present on trophoblast is hl a-e . This is also a
non-classical class I molecule with limited polymorphism. The cell-sur-
face expression of hl a-e is dependent on its binding of signal peptides
cleaved from other class I molecules. Signal peptides from both hl a- g
and hl a- c have been shown to bind to hl a-e (141-143). 
Maternal side
Macrophages
These extra-villous trophoblast cells at the fetal side invade the decidua
of the uterus at the maternal side. In the ﬁrst trimester around 40% of 
the cells in the decidua are leukocytes, maternal immune cells. Approxi-
mately 20% of the decidual leukocytes are macrophages. This percentage
is relatively stable throughout the menstrual cycle and also in pregnancy.
Strikingly, macrophages accumulate at the implantation site, while they
are sparse at the site where no trophoblast invasion occurs. Interestingly,
the receptor ilt2, which may recognize hl a- g , is expressed by all
decidual macrophages (144). These features suggest a role for macro-
phages in the process of implantation and placentation.
T cells
T cells account for around 10% of the leukocytes in decidua. Unlike the
macrophages, T cells do not accumulate around the implantation site.
Their number remains the same throughout the menstrual cycle and
early pregnancy. One mechanism that might explain the protection of
the fetus from the maternal immune system is the deviation of the mater-
nal immune system towards Th2 (T helper 2 cell) type of responses. This
is called the Th1/Th2 (shift of T helper 1 cells to T helper 2 cells) para-
digm. This paradigm states that established pregnancy is characterized
by low levels of Th1 cytokines (Tumor Necrosis Factor-alfa (t nf-α),
Interferon-gamma (if n-γ), Interleukin-2 (il-2)), which are known to
induce abortions in a variety of animal models (145-148). Conversely,
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Th2 cytokines, including IL-4 and IL-10, appear to play a protective role
in pregnancy (149). However, this Th1/Th2 dichotomy now appears to be
an oversimpliﬁcation, because recent data on the expression of various
cytokines at the fetal-maternal interface show a much more complex sys-
tem (150). 
Recent investigations suggest that regulatory T (Treg) cells in the
decidua and peripheral blood may play an important role in protecting
the fetus from alloreactive immune responses against paternal antigens
at the maternal-fetal interface. Regulatory T cells are a specialized popu-
lation of T cells which suppress T cell responses. The absolute number of
circulating maternal Treg cells and decidual Treg cells, deﬁned as
cd4+cd25+ cells, increases progressively at each stage in human preg-
nancy, starting from the ﬁrst trimester (151-153). 
NKT cells
Natural Killer-T (nkt) cells are a small subset of T cells that also express
nk-cell markers. These nkt cells play an immunomodulatory role in
infection, cancer and transplantation through the production of
cytokines (154). Evidence is accumulating that nkt cells might also have
a role in pregnancy. The number of nkt cells is increased in decidua as
compared with peripheral blood (155;156). Boyson et al. also described
the expression of cd1d on extravillous trophoblast, which may form
part of the nkt-cell ligand.
Natural Killer cells 
nk cells, as a part of the innate immune system, are involved in the ﬁrst
line of defence against virally infected cells and tumour cells. They also
play an important role in pregnancy. nk cells do not attack cells express-
ing sufﬁcient mhc class I molecules, whereas transformed cells or cells
with decreased or aberrant mhc class I expression are killed through
cytolytic enzymes (157).
Phenotype
nk cells are characterized by the expression of the neural cell adhesion
molecule cd56 and the concurrent absence of the T cell receptor marker
cd3. Subsets of nk cells co-express the low afﬁnity receptor cd16
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(FcγRII). Based on these two surface antigens two main nk cell subsets
can be distinguished. These subsets are deﬁned by their relative expres-
sion levels of cd16 and cd56. One main subset comprises
cd56dimcd16+ nk cells, that express relatively low levels of cd56 and
are positive for cd16. The other subset exists of cd56brightcd16- nk
cells that express relatively high levels of cd56 and lack the marker
cd16. We discovered even a third subset of nk cells, the cd56superbright
nk cells, in the endometrium, which has not yet been described previ-
ously (158).
nk cells in peripheral blood comprise <15% of circulating lympho-
cytes (159). In contrast, in decidua there is a striking abundance of uter-
ine nk cells, which constitute ~70% of resident lymphocytes (109). 90%
of the peripheral nk cells are cd56dimcd16+ nk cells, whereas the
majority of the uterine nk cells have the cd56brightcd16- phenotype.
The remaining 10% of peripheral nk cells also have this
cd56brightcd16- phenotype. Less than 4% of the uterine nk cells are
cd56dimcd16+ (160).
Function
The two different ways of nk cell response upon activation are cytokine
production and mediation of cytotoxicity. The function is depending on
nk cell phenotype. The nk cell subset cd56brightcd16- primarily 
produces immunoregulatory cytokines, including if n-γ, t nf-β, lif
(Leucaemia Inhibiting Factor), il-10, il-13, gm- csf (Granulocyte
Macrophage-Colony-Stimulating Factor) and angiogenic growth factors
(i.e. v egf (Vascular Endothelial Growth Factor)) contributing to
endometrial angiogenesis. The cd56dimcd16+ nk cell population, how-
ever, consistently produces signiﬁcantly less of these cytokines. The
cd56dimcd16+ nk cells mediate natural cytotoxicity and antibody-
dependent cellular cytotoxicity, through the expression of both k ir
(Killer cell Immunoglobulin-like Receptor) and cd16 (161-163). 
So, peripheral blood nk cells differ from uterine nk cells by number,
phenotype and function. Therefore uterine nk cells should be regarded
as a separate lymphoid subset. 
NK cell receptors
Human nk cells express both inhibitory and activating receptors that
recognize different mhc class I molecules (164). As predicted by the
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‘missing self’ hypothesis, the lack of expression of mhc molecules on
target cells leads to the susceptibility of such cells to nk cell mediated
lysis. These receptors play a crucial role in regulating the lytic and
cytokine expression capabilities of nk cells. These nk cell receptors
interact with hl a molecules expressed on the invading trophoblast
(hl a- c , hl a-e and hl a- g) and thereby affect cytokine production
and cytolytic activity of maternal unk cells (165-168). It is believed that
each individual nk cell and the nk cell subsets expresses a unique com-
bination of nk cell receptors to trigger their effector functions, depend-
ing upon the nature of the target and the cytokines available in the local
environment (164).
In humans three distinct families of genes have been deﬁned that
encode for receptors of hl a class I molecules. The ﬁrst family identiﬁed
consists of type I transmembrane molecules belonging to the
immunoglobulin (Ig) superfamily and are called Killer cell Ig-like Recep-
tors (k ir). A second group of receptors belonging to the Ig superfamily,
named ilt (Immunoglobulin Like Transcripts), has more recently been
described. ilts are expressed mainly on B, T and myeloid cells, but some
members of this group are also expressed on nk cells. The ligands for the
k ir and some of the ilt receptors include classical hl a class I mole-
cules, as well as the non-classical hl a- g molecule. The third family of
hl a class I receptors are C-type lectin family members and are com-
posed of heterodimers of cd94 covalently associated with a member of
the nkg2 family of molecules. The ligand for most members is the non-
classical class I molecule hl a-e . Each of these three families of recep-
tors has individual members that can recognize identical or similar lig-
ands that are signals for activation or inhibition of cellular functions.
This dichotomy correlates with particular structural features present in
the transmembrane and intracytoplasmic portions of these molecules.
Each nk cell expresses a different combination of receptors that are pre-
sent in the genome of an individual. 
So far, three different receptors have been identiﬁed that can puta-
tively interact with hl a- g , i.e., ilt2 (169;170), ilt4 (170) and
k ir2dl4 (171;172). These receptors are present on the different leuko-
cyte populations that are present in the endometrium, i.e. nk cells
(k ir2dl4 and ilt2), subsets of T cells (ilt2), B-cells (ilt2 and ilt4)
and monomyelocytic cells (ilt2 and ilt4). The receptors
cd94/nkg2a and cd94/nkg2c recognize hl a-e on extra-villous
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trophoblast. hl a- c ligands engage several members of the KIR family,
i.e. k ir2dl1 , k ir2dl2 and k ir2dl3 (173). 
Interestingly, the different subsets of nk cells show a different nk
receptor pattern and/or a different level of expression. Uterine
cd56brightcd16- nk cells express k ir at a higher level than
cd56dimcd16+ nk cells (174). In contrast to blood where approximately
50% of nk cells express cd94/nkg2a , all uterine nk cells are charac-
terized by the expression of high levels of cd94/nkg2a . We showed
that the cd56superbright cells also differ from cd56bright nk cells with
respect to nk cell receptor expression (158).
Interaction between NK cells and trophoblasts 
Human spiral arteries are remodeled to a depth that penetrates the
myometrium. This process is completed by weeks 16-20 of pregnancy
(175). The muscular vessels are converted into large ﬂaccid conduits to
meet the escalating demands of the human fetus. The vascular changes
are effected by extravillous trophoblast cells with the help of activated
nk cells. The enlarged vessels become lined with endovascular tro-
hoblast cells. It is believed that the spiral arteries are remodelled to a
much greater depth than in other species to supply enough blood ﬂow
for the growth of the exceptionally large brain in humans (176).
As mentioned before, of the various forms of trophoblast, only the
extravillous trophoblasts express mhc class I molecules, i.e. hl a- g ,
hl a-e and hl a- c . These molecules all have speciﬁc ligands for nk cell
receptors. These ligand-receptor pairs can cause either activating or
inhibitory signals. Two functions of hl a molecules on trophoblasts in
modulating uterine nk cells have been postulated. First, they might pro-
tect trophoblasts from nk cell mediated lysis (177). More recent data
however suggest that this protection appears to be largely independent of
hl a class I expression (165;178). Therefore, the second option is more
likely, which is to modulate production of cytokines and angiogenic fac-
tors by uterine nk cells in order to alter trophoblast invasion and diffe-
rentiation or tissue remodeling (127;161;179). This would suggest a more
ﬁnely tuned modulatory function for hl a- g , -e and –c rather than a
strictly inhibitory. 
Inadequate trophoblast invasion will lead to a reduced blood ﬂow to
30
ch a p t er 1
gener a l in t roduction
31
Figure 2. The blood ﬂow through the maternal uterine arteries is increased by the inﬁl-
tration of the arterial media and endothelium by extravillous trophoblast cells. 
A comparison between uninvaded arteries (non-pregnant), normal pregnancy and
pathological conditions of pregnancy – such as pre-eclampsia and intrauterine growth
retardation (IUGR) – is shown. Note that the extent and depth of trophoblast invasion is
less in pathological compared with normal pregnancy, which results in inadequate
transformation of the spiral arteries in the former. This results in reduced blood ﬂow to
the feto-placental unit, which leads to poor fetal growth. The ischaemic placenta can
also trigger systemic endothelial dysfunction in the mother and the onset of pre-
eclampsia.
From: Nature Reviews Immunology. © Dr. A. Moffett-King (109)
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the growing fetus and placenta. This can induce a variety of clinical
pathological conditions such as intrauterine growth retardation, pre-
eclampsia and miscarriage.
Evidence for an immunological role in several pregnancy disorders 
IVF failure 
Patients with repeated failure at i v f may include those who have an
implantation–related immune abnormality. However, only limited data
about this subject has been published. Beer and colleagues demonstrated
in peripheral blood of idiopathic infertile women with multiple i v f fail-
ures a signiﬁcantly higher level of cd56 positive nk cells as compared to
fertile controls. However, they did not determine the nk cell phenotype,
so it is not known whether these nk cells were mainly the
cd56dimcd16+ subset (180). Fukui et al. showed a higher percentage of
detrimental uterine cd56dimcd16+ nk cells in i v f patients who failed
subsequent pregnancy as compared to patients with successful implan-
tation after i v f treatment (181). A recent report of Thum et al. showed
that an increase in the absolute count of activated nk cells
(nkdimcd16+cd69+) in peripheral blood was associated with a reduced
rate of embryo implantation in i v f treatment. Furthermore, women
with high peripheral nkdimcd16+cd69+ cell count who were able to
achieve a pregnancy had a signiﬁcantly higher miscarriage rate (182). 
Preeclampsia
Preeclampsia is one of the most important obstetrical diseases world-
wide that causes severe maternal and perinatal morbidity and mortality.
Key features of preeclampsia are maternal hypertension in combination
with proteinuria. It is estimated that 6-20% of all pregnancies are affect-
ed by hypertension of which one third will develop preeclampsia (183).
Women are at increased risk for preeclampsia during their ﬁrst concep-
tion, and/or when the conception is with a new partner (new paternity)
and when conception occurs very shortly after the beginning of their
sexual relationship (short exposure to foreign semen). These features
suggest an immunological role in the pathophysiology of preeclampsia. 
Pregnancy related hypertension results from poor placental perfu-
sion that is compensated for by an increase in maternal blood pressure.
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In preeclampsia systemic endothelial cell dysfunction develops involving
the kidneys, liver and brain. Although preeclampsia becomes sympto-
matic during the late second or third trimester, histological studies show
an altered placental morphology that originates during early pregnancy
(184;185). It is believed that preeclampsia is caused by incomplete remod-
eling of the spiral arteries deep into the myometrium, which leads to high
maternal blood pressure and proteinuria and reduced blood ﬂow to the
fetus (Figure 2). 
During preeclampsia an increased percentage and over-activity of
cd56dimcd16+ nk cells are present in decidua causing disregulation of
the balanced net of local interactions (186;187). The placentas of
preeclamptic patients show a reduced extravillous trophoblast invasion
that is associated with a lack of hl a- g expression (188-190). At the same
time, recent clinical observations point to the possibility that polymor-
phism in both maternal and paternal genes contribute to preeclampsia.
Hiby et al. showed recently that some combinations of maternal nk cell
receptors and paternal hl a- c genes, which lead to the strongest
inhibitory signals to nk cells, are more frequently seen in preeclampsia
(191).
Endometriosis
Endometriosis affects approximately 5% to 15% of women within child-
bearing age (192;193). This condition is characterized by the abnormal
presence of endometrial cells, mainly in the peritoneal cavity. It is most
frequently associated with chronic pelvic pain, dysmenorrhea, dyspareu-
nia and infertility. Although the pathogenesis of endometriosis remains
unclear, the presence of endometrial cells in the peritoneal cavity is
explained by retrograde menstruations. Because this phenomenon is
prevalent in most women, several other fundamental processes must
contribute to the implantation of endometrial cells and their subsequent
development into endometriotic lesions. Ectopic endometrial cells must
exploit strategies to escape the immune system to survive and develop
into endometriotic lesions. 
Although in healthy women peritoneal leukocytes eliminate ectopic
endometrial cells, in patients with endometriosis, the capacity of peri-
toneal leukocytes to do so is signiﬁcantly impaired. Activated macro-
phages as well as impaired cytolytic function of nk cells toward endome-
trial cells attributes to endometriosis (194-196). It was shown that the
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inhibitory nk cell receptor k ir2dl1 was more frequently expressed by
peritoneal nk cells of patients with endometriosis as compared to
healthy controls. This may partly explain the decreased peritoneal nk
cell activity in patients with endometriosis (197). 
Recurrent miscarriage
About 12% to 15% of all clinically recognizable pregnancies result in
spontaneous abortion. It is estimated that 60% of embryos are lost
before clinical detection of pregnancy. Recurrent miscarriage, deﬁned as
two, three or more consecutive miscarriages, occures in 0.5-2.0% of
reproducing couples (198). Fetal chromosomal abnormalities account
for 50% of spontaneous abortion (199). It might be that immunological
disorders account for the other half of spontaneous abortion. In women
with recurrent miscarriage defective placentation was reported, in par-
ticular aberrant depth of trophoblast invasion and inadequate syncytium
formation (199;200). Recent histological data on the putative association
of antiphospholipid, anticardiolipin and antinuclear autoantibodies with
early pregnancy loss show a relation with defective endovascular tro-
phoblast invasion, rather than excessive intervillous thrombosis
(201;202). Also women affected by the autoimmune disease systemic
lupus erythematosus (sle) are particularly prone to spontaneous abor-
tions (198). 
Women with recurrent miscarriage show a signiﬁcant increase of
decidual cd56dimcd16+ nk cells as compared to normal pregnancy
(203). In recurrent miscarriage, the preconceptional cytotoxic reactivity
of peripheral blood nk cells was increased as compared to levels found
in normal pregnancy (204), although others found no difference in cyto-
toxicity (205). It appears that normal pregnancy is related to an increase
of peripheral cd56bright nk cells and low peripheral cytotoxic reactivity.
In contrast, increased numbers of cd56dimcd16+ nk cells and high
peripheral cytotoxic reactivity seem associated with recurrent miscar-
riage.
Several studies have also shown a decreased expression of hl a- g in
extravillous and endovascular trophoblast tissue obtained after miscar-
riage compared with tissue from healthy pregnancies (203;206).
Three different mechanisms have been postulated for the role of
cytokines in recurrent pregnancy loss. Firstly, increased activity of uter-
ine nk cells resulting in attack on the invading trophoblast. Secondly,
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direct detrimental effects of cytokines on trophoblast cells. And thirdly,
effects of cytokines on thrombotic events in the vasculature, resulting in
decreased blood ﬂow. 
Aims and Outline of the Thesis
The aim of the thesis is twofold. The ﬁrst aim is to develop a new i v f
strategy with single embryo transfer to prevent the high number of mul-
tiple pregnancies in i v f treatment. The second aim is to gain more
insight in the role of nk cell subsets in follicular ﬂuid and endometrium
during implantation in i v f treatment in order to improve the pregnancy
rate eventually. 
Single embryo transfer seems the only solution to minimize the mul-
tiple pregnancy rate after i v f drastically. In contrast to earlier studies we
started a randomized controlled trial in which the cost-effectiveness of
two cycles with set were compared with one cycle with det (Chapter
3). To ﬁnd out whether it would be economically worthwhile to prevent
the large number of multiples after i v f treatments, we ﬁrst started a
study in which all medical costs of i v f singleton and twin pregnancies
up to 6 weeks after delivery were calculated (Chapter 2). Another
approach to reduce the number of multiple pregnancies is i v f in the nat-
ural cycle, without ovarian hyperstimulation. Besides a low ongoing
pregnancy rate per cycle (7.2%) (86) this method has a lot of advantages
(low risks, patient-friendly, low cost). This has led to a renewed interest
in natural cycle i v f . However, in case of severe oligozoospermia, icsi in
the natural cycle has never been studied serially and in a systematic way
before. Therefore a pilot study of icsi in the natural cycle was initiated
(Chapter 4). 
It is expected that the live birth rate after set might be lower than
after det , especially when set will be performed in a larger and prog-
nostic less favourable group of patients. Therefore, it is important to
improve the implantation rate of the embryo. It is believed that immuno-
logical processes play an important role during implantation, especially
the interaction between maternal nk cells and hl a- g molecules on
fetal trophoblast cells. When these processes are further understood it
might be possible to modulate the implantation process in order to
enhance the pregnancy rate. It might be possible that detrimental nk cell
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subsets are associated with the cause of idiopathic infertility. We ﬁrst of
all hypothesized that immune cells, especially nk cells, in follicular ﬂuid
might have an inﬂuence on oocyte development and subsequent embryo
quality. Consequently, in chapter 5 we studied the relation between nk
cell subsets in follicular ﬂuid and different causes of infertility. We then
broadened our scope, and addressed the question whether ovarian
hyperstimulation for i v f has a detrimental effect on endometrial recep-
tivity as measured by the differential presence of nk cells subsets in the
endometrium (chapter 6). In i v f , both positive and negative effects of
supraphysiological levels of sex steroid hormones on pregnancy rates
have been reported; in chapter 7, the functional role of nk cells and their
subsets upon interaction with fetal hl a- g on trophoblast cells was fur-
ther explored. 
Finally, in chapter 8 the main ﬁndings of the previous chapters are
summarized and discussed. In addition, the clinical implications are
described and recommendations for future research are made.
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Abstract
st udy obj ecti v e:
Determine the difference in cost between singleton and twin pregnan-
cies after i v f-treatment from pregnancy until six weeks after delivery
from health care perspective.
de sign:
Retrospective cost analysis.
set ting:
i v f department at the University Medical Center Nijmegen (umcn),
the Netherlands.
patien ts:
A representative sample of singleton and twin pregnancies after i v f-
treatment between 1995-2001 at the umcn .
interv ention:
i v f , with or without icsi and with or without cryo-preservation.
m a in ou tcome me a sur e: 
Medical cost per singleton and twin pregnancy after i v f .
r e sults:
In patients with twin pregnancies the incidence of hospital antenatal
care, complicated vaginal deliveries and cesarean sections was higher
and they were associated with more frequent and longer maternal and
neonatal hospital admissions. Maternal and neonatal hospital admis-
sions were the major cost-drivers. The medical cost per twin pregnancy
was found to be more than ﬁve times higher than per singleton pregnan-
cy, 13,469 euro and 2,550 euro respectively.
conclusions: 
The medical cost per twin pregnancy was more than 10,000 euro higher
than per singleton pregnancy. Reduction of the number of twin pregnan-
cies by elective single embryo transfer (set) will save substantial
amounts of money. This might be used for additional i v f-cycles, which
are probably needed to achieve similar success rates with set as with
two embryo transfer.
58
ch a p t er 2
Introduction
Since the introduction of in-vitro fertilization (i v f) 25 years ago, the
number of multiple pregnancies has increased dramatically (1-3). Nowa-
days, most clinics in Europe transfer two embryos per cycle to reduce
chances for high-order multiple pregnancies (4). In the Netherlands a
maximum of two embryos are routinely transferred per cycle. However,
the risk for a multiple pregnancy after i v f-treatment is still 25% (5),
which is a 15 fold increase relative to the risk of 1.6% after natural concep-
tion (6).
Multiple pregnancies have been shown to require more medical care
than singleton pregnancies. Multiple pregnancies are associated with
higher risks for hypertension, pre-eclampsia, intrauterine growth retar-
dation, prematurity, low birth weight and cesarean section (6-8). In addi-
tion, perinatal morbidity and mortality are increased as compared to sin-
gletons (6-8). Moreover, i v f-pregnancies (singletons and multiples) are
at greater risk for obstetric and perinatal complications than sponta-
neously conceived pregnancies (9-12). Due to these effects medical costs
are expected to be higher for multiple pregnancies than for singleton
pregnancies (8;13;14).
In previous studies, age of the woman, number of previous cycles and
quality of embryos available for transfer were identiﬁed as the most
important predictors for multiple birth (15-17). Single Embryo Transfer
(set) in women with good prognosis for pregnancy after i v f-treatment
would be a successful method to reduce the number of twin pregnancies.
However, whether set is cost-effective needs to be determined, since
pregnancy rates probably decrease inversely proportional to the number
of embryos transferred. Even in women with a good prognosis more
cycles might be needed to realize the same success percentage with set
as with two embryos transfer (18). Prevention of twin pregnancies by
set will reduce twin pregnancy related complications and the associat-
ed medical expenses. The question is whether these savings will pay for
the expenses of the extra i v f-cycles required for set . 
The aim of this study was to determine the differences in costs
between singleton and twin pregnancies after i v f-treatment from preg-
nancy until six weeks after delivery from health care perspective.
cost of i v f - singleton a nd t w in pr egna ncie s
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Materials and methods
For this study, cost drivers from pregnancy until six weeks (42 days) after
delivery were determined for singleton and twin pregnancies. Estimates
of volumes were based on data from a representative sample of twin and
singleton pregnancies from the i v f-population at the University Med-
ical Center Nijmegen (umcn). Unit costs were based on real costs
where possible, the remaining unit costs were based on hospital charges.
Total costs per singleton pregnancy and twin pregnancy were calculated
and compared. The protocol was approved by the Medical Ethical
Review Committee of our hospital.
Medical process
Antenatal care during the ﬁrst weeks of pregnancy was routinely per-
formed by a gynecologist at the hospital where the couple received i v f-
treatment. According to the Dutch system of antenatal care, patients
with low risk singleton pregnancies were advised to seek antenatal care
provided by a midwife. If medical complications arose during pregnancy,
antenatal care was taken over by a gynecologist or midwife under super-
vision of a gynecologist at a hospital. Patients with singleton pregnancies
who preferred hospital antenatal care, patients who had medically com-
plicated pregnancies and all patients with twin pregnancies received hos-
pital antenatal care by a gynecologist or midwife under supervision of a
gynecologist at a hospital. 
Delivery for patients with medically uncomplicated pregnancies took
place either at home or at the outpatient department of a hospital. Deliv-
ery for patients with medically complicated pregnancies took place at the
hospital as inpatient. Inpatient deliveries included at least one day of
maternal hospital stay. Cesarean sections were always followed by 3-10
days of hospital stay, depending on maternal and neonatal condition and
on hospital regulations. In addition, due to complications during preg-
nancy or delivery and in the six weeks after delivery, maternal and neona-
tal hospital admissions occurred.
This description led to the following cost-drivers: mode of antenatal
care, mode of delivery and maternal and neonatal hospital admission
days.
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Estimation of volumes
Estimations of volumes were based on data from a representative sample
of twin and singleton pregnancies from a database containing all couples
with a live born singleton or at least one live born twin after i v f treat-
ment (i v f/icsi/cryo-i v f/cryo-icsi) at the umcn between 1995-2001
(n=963 pregnancies, 24% twins). From the database the 172 most recent
twin pregnancies and 168 singleton pregnancies with a similar date of
embryo transfer were selected.
To obtain data not included in the database regarding the course of
pregnancy as well as the occurrence of maternal and neonatal hospital
admissions, all subjects were sent a questionnaire. The questionnaire
contained questions about antenatal care, mode of delivery, days of
maternal hospital admission from pregnancy until six weeks after deliv-
ery and days of neonatal hospital admission during the ﬁrst six weeks
(maximum of 42 days) after birth. In addition, participants were asked
for their consent to verify uncertain or missing data in medical records.
Antenatal care was categorized as either antenatal care by a midwife,
provided outside the hospital or ‘hospital antenatal care’, provided by a
gynecologist or midwife under supervision of a gynecologist at a hospi-
tal. In case of referral during pregnancy from antenatal care by a midwife
to hospital antenatal care, only the latter was charged.
Deliveries were categorized as home delivery, uncomplicated vaginal
delivery (spontaneous birth of singletons), complicated vaginal delivery
(vacuum and forceps extractions and twin deliveries) and cesarean sec-
tion. For twin deliveries in which the ﬁrst child was born by vaginal deliv-
ery and the second by cesarean section, both deliveries were charged sep-
arately. This might cause the sum of twin deliveries to be greater than the
number of twin pregnancies.
No distinction between various hospital departments was made for
maternal hospital admission. Neonatal hospital admission was divided
in admission to a Neonatal Intensive Care Unit (nicu) and non-nicu
departments. Since admission to a nicu is much more expensive than
admission to non-nicu departments, all nicu admissions mentioned
in the questionnaires, including length of stay, were veriﬁed in medical
records to make sure a non-nicu department was not mistaken for a
nicu .
Data on method of conception (i v f/icsi/cryo-i v f/cryo-icsi),
maternal age, birth weight and gestational age were obtained from the
cost of i v f - singleton a nd t w in pr egna ncie s
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existing database. Gestational age for pregnancies after i v f-treatment
was deﬁned as 14 days before the puncture of the oocytes until birth. For
pregnancies after cryo-i v f and cryo-icsi-treatment gestational age was
deﬁned as 17 days before the date of embryo-transfer until birth.
Estimation of unit costs
Unit costs for nicu admission were obtained from real-cost-calcula-
tions of the Dutch National Health Tariffs Authority (ctg) (ctg policy
rule nr. I-612; personal communication). Unit costs for admission to a
non-nicu department and for maternal hospital admission were based
on real-cost-calculations as described by Oostenbrink et al. (19). National
price indexes were used to convert real-costs to 2002 rates. Unit costs of
antenatal care and delivery were based on hospital charges, since real
costs were not available and since they were not expected to be major
cost-drivers. Hospital charges for the year 2003 were obtained from the
ctg (20-22). All unit costs were presented in euro’s.
Statistical Analyses
Data were presented as percentages (number (n)) and means ± standard
deviation (sd) or [range]. The Mann-Whitney-U test was performed on
mean total cost per singleton and twin pregnancy. All analyses were done
in Statistical Package for the Social Sciences (spss) version 10.0 for
Windows. Sensitivity analyses were applied to major cost-drivers of
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Table 1. Characteristics of the study population per pregnancy, unless otherwise indicated.
Singleton pregnancies Twin pregnancies
(n=135) (n=144) 
Mode of conception 
IVF (%) 66 (48.9) 68 (47.2) 
ICSI (%) 63 (46.7) 68 (47.2) 
Cryo-IVF (%) 6 (4.4) 6 (4.2) 
Cryo-ICSI (%) 0 2 (1.4) 
Gender (% male) a 67 (50.0) 132 (46.0) 
Maternal age (years) b 34.5 ± 3.4 33.2 ± 3.6 
Gestational age (weeks) a, b 39.6 ± 1.7 36.5 ± 2.5 
Birth weight (grams) a, b 3,341 ± 540 2,425 ± 586 
a Calculated per newborn.
b Values are means ± SD.
Note: ICSI = intracytoplasmic sperm injection.
which available prices were uncertain. Sensitivity analyses were per-
formed in Microsoft Excel 2000.
Results
Study Population
In total, 279 pregnancies were included in this study (response rate: 82%)
of which 135 were singleton pregnancies and 144 were twin pregnancies.
Table 1 summarizes the characteristics of the study population. There
were no differences in the methods of conception or gender between sin-
gleton and twin pregnancies. Maternal age at delivery, gestational age
and birth weight were all substantially lower in twin pregnancies than in
singleton pregnancies. The number of babies born with a low birth
weight (<2500 gram) or a very low birth weight (<1500 gram) was signif-
icantly higher among twins than among singletons (51% versus 3% and
5.9% versus 1.5%, respectively, p<0.001). The number of preterm births
cost of i v f - singleton a nd t w in pr egna ncie s
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Table 2. Data on antenatal care and delivery per pregnancy
Singleton pregnancies Twin pregnancies
(n=135) (n=144) 
Antenatal care (%) 
Midwife 28 (20.7) 0 
Hospital (gynaecologist/midwife) 107 (79.3) 144 (100.0) 
Delivery (%) 
Vaginal uncomplicated 88 (65.2) a 0 
Vaginal complicated 20 (14.8) 87 (60.4) 
Cesarean section 27 (20.0) 57 (39.6) 
Maternal admission (%) 116 (85.9) 144 (100.0) 
Length of stay b (days) 3.6 (0-50) 10.1 (1-59) 
NICU admission c (%) 3 (2.2) 36 (12.5) 
Length of stay c, b (days) 0.11 (0-11) 1.8 (0-42) d
Non-NICU admission c (%) 39 (28.9) 189 (65.6) 
Length of stay c, b (days) 2.0 (0-33) 8.8 (0-42) d
a Including 13% (N=18) home deliveries.
b Values are means (range).
c Calculated per newborn.
d Six weeks (42 days) was maximum length of follow-up.
Note: NICU = neonatal intensive care unit.
(gestational age <37 weeks) was not signiﬁcantly different between the
singletons and twins (32% and 36%, respectively). This was also the case
for the number of births below 32 weeks of gestational age between sin-
gletons and twins (2.2% and 3.8%, respectively). 
The non-response rate was 16% (n=28) in the twin pregnancy group
and 19% (n=31) in the singleton pregnancy group. The maternal age, ges-
tational age, birth weight and gender were not different between the
responders and non-responders. The methods of conception in the twin
pregnancy group did also not differ between the responders and non-
responders. In the singleton pregnancy group, however, a higher per-
centage of the non-responders became pregnant by cryo-i v f and cryo-
icsi as compared with the responders (29.1% and 4.4%, respectively,
p<0.05). This difference might be based on coincidence due to small
numbers.
Quantities and Costs
Data on antenatal care, delivery and hospital admission days are presen-
ted in Table 2. In the study population all patients with twin pregnancies
and 79% of the patients with singleton pregnancies received hospital
antenatal care. Of this last group, ﬁve percent initially received antenatal
care by a midwife, but was referred during pregnancy. The remaining
21% of patients with singleton pregnancies received antenatal care by a
midwife. Unit cost of total antenatal care by a midwife was 283 euro. Unit
cost of total hospital antenatal care was 88 euro. The unit cost of antena-
tal care was based on charges. Due to the fact that overhead expenses
from an out-patient clinic can be distributed by more gynecologists and
patients than in a midwife practice, the charges for antenatal care by a
gynecologist is much lower. As antenatal care by a midwife occurred
only in singletons, total cost of antenatal care per singleton pregnancy
was substantially higher than per twin pregnancy: (20.7% x 283 euro +
79.3% x 88 euro) = 128 euro versus 88 euro.
As deﬁned before, all vaginal twin deliveries (60%) were regarded as
complicated. Of the singleton pregnancies 65% was an uncomplicated
vaginal delivery, including 13% home deliveries. Singleton vaginal deliv-
eries were in 15% complicated. The cesarean section rate for patients
with twin pregnancies was 40%, in contrast to 20% in singleton pregnan-
cies. Since six twin deliveries were vaginal for the ﬁrst born, but cesarean
section for the second born, a total of 150 deliveries were charged. The
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unit costs of vaginal deliveries were 489 euro for an uncomplicated and
512 euro for a complicated vaginal delivery. Home deliveries were priced
at 309 euro. The unit cost of a cesarean section was 912 euro. Total cost
per twin delivery was (90 x 512 euro + 60 x 912 euro) / 144 = 700 euro and
(13% x 309 euro + 52% x 489 euro + 14.8% x 512 euro + 20% x 912 euro) =
553 euro per singleton delivery.
All patients with twin pregnancies after i v f-treatment were admit-
ted to a hospital for at least one day from pregnancy until six weeks after
delivery, while 86% of the patients with singleton pregnancies was
admitted. The mean duration of hospital stay was 10.1 days (sd = 10.5)
for patients with twin pregnancies and 3.6 days (sd = 6.1) for patients
with singleton pregnancies. The unit cost for a hospital admission day
was 313 euro. Total cost for maternal hospitalization per patient with a
twin pregnancy was 3,147 euro and 1,113 euro per patient with a singleton
pregnancy.
Of the newborns from twin pregnancies 66% was admitted to a hos-
pital after birth, compared to 29% of the newborns from singleton preg-
nancies. Admission to a nicu during the ﬁrst six weeks after birth
occurred in 12% of the newborns from twin pregnancies and in 2% of the
singletons. Newborns from twin pregnancies, on average, stayed longer
at a nicu than those from singleton pregnancies (1.8 days [sd = 6.8] and
0.11 days [sd = 0.98], respectively). Admission to non-nicu depart-
ments during the ﬁrst six weeks after birth occurred in 65% of the new-
borns from twin pregnancies and 29% of the newborns from singleton
pregnancies (including newborns transferred from a nicu). The aver-
age length of stay at these departments for newborns from twin preg-
nancies was substantially higher than for newborns from singleton preg-
nancies (8.8 days [sd = 10.6] and 2.0 days [sd = 5.2], respectively). The
unit cost for admission at a nicu was 1,121 euro per day. The unit cost for
cost of i v f - singleton a nd t w in pr egna ncie s
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Table 3. Cost (in euros) per singleton and twin pregnancy after IVF.
Singleton pregnancy Twin pregnancy Difference 
Antenatal care 128 88 -40 
Delivery costs 553 700 187 
Hospital care mother 1,113 3,147 2,034 
Neonatal care (including NICU) 755 9,534 8,779 
Total costs 2,549 13,469 10,920 
admission at a non-nicu department was 313 euro. Total cost of neona-
tal hospital admission per twin was [(1.8 x 1.121 euro + 8.8 x 313euro)] x 2 =
9,534 euro and (0.11 x 1.121 euro + 2.0 x 313 euro) = 755 euro per singleton.
In Figure 1 cost of the major cost-drivers (A: maternal admissions, B:
nicu-admissions, C: non-nicu-admissions) and the total cost per
pregnancy (D) are presented for singleton and twin pregnancies. In Table
3 the costs of singleton pregnancies, twin pregnancies and the differ-
ences are summarized. Costs were indexed on 2002 rates. Mean total
cost per twin pregnancy was signiﬁcantly higher than per singleton preg-
nancy after i v f (Mann-Whitney-U test: p<0.001), causing a more than
10,000 euro difference in costs.
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Figure 1.
Major cost-drivers and total cost per singleton (triangles) and twin (squares) pregnancy.
Each triangle (singleton) and square (twin) represents the cost of a pregnancy per patient
with respect to A, the maternal admission cost, or the cost of a live born baby with respect to
B, the neonatal intensive care unit (NICU) cost, C, the non-NICU cost, or D, the total cost. The
number of pregnancies or live-born babies were shown as percentile.
Sensitivity Analysis
One-way sensitivity analysis for the cost per neonatal admission day at a
non-nicu department was performed, because for this study no dis-
tinction between various non-nicu departments was made. Since there
will be a difference in costs for admission for observation only, admis-
sion to Medium-Care (mc) and High-Care (hc), the unit cost for non-
nicu admission was varied from 177 euro (minimum cost per admis-
sion day in a regional hospital; 19) to 510 euro (cost per hc admission
day; ctg policy rule I-612; personal communication). This caused the
mean difference between singleton and twin pregnancies to range from
8,803 euro to 13,985 euro.
One-way sensitivity analysis for the cost per maternal admission day
was performed, since for this study no distinction between various hos-
pital departments for maternal hospital admission was made. The unit
cost was varied from 177 euro (minimum price per admission day in
regional hospital; 19) to 458 euro (maximum price per admission day at a
university medical center; 19). This caused the mean difference between
singleton and twin pregnancies to range from 10,036 euro to 11,862 euro.
When these sensitivity analyses were combined, the mean difference
between singleton and twin pregnancies varied from 7,919 euro to
14,928 euro.
Discussion
The results of this study show that the medical costs from induction of
i v f-pregnancy until six weeks after delivery per twin pregnancy were
more than ﬁve times higher than per singleton pregnancy (13,469 euro
and 2,550 euro, respectively). This difference in costs of more than
10,000 euro was mainly caused by an increased number and duration of
maternal and neonatal hospital admissions. Even though nicu days
were by far the most expensive hospital days in this study, due to the
shortage of room at nicu-departments, newborns were referred to
non-nicu-departments as soon as possible, causing non-nicu-depart-
ments to be the major cost-driver. 
Sensitivity analyses for hospital days (the major cost drivers) did not
largely affect the difference in cost between twin and singleton pregnan-
cies. Since all major cost drivers occurred more frequently in twin preg-
cost of i v f - singleton a nd t w in pr egna ncie s
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nancies than in singleton pregnancies, twin pregnancies would have
turned out to be more expensive at any chosen unit cost. 
In this study we focused on the costs of pregnancies with a subse-
quent live born baby. Costs of pregnancies resulting into stillbirth were
not calculated. Five percent (n=12) of all twin pregnancies (n=240) and
2% (n=16) of all singleton pregnancies (n=751) after i v f between 1995
and 2001 resulted into stillbirth. This difference was statistically signiﬁ-
cant (p<0.05), therefore we expect that the twin pregnancies will even be
more expensive as compared to the singleton pregnancies. For this study
we decided to present means (including mean costs) for both normally
distributed and skewed data. It is well known that high medical expenses
occur only in a few pregnancies, causing a skewed distribution of costs.
Logistic transformation would largely diminish the effect of these
expensive pregnancies, thereby leading to a major underestimation of
the costs that could actually be saved by prevention of twin pregnancies.
To illustrate this: geometric means (95% conﬁdence interval [ci]) of the
total costs for twin and singleton pregnancies were 7,247 euro (95% ci :
5,990 euro – 8,769 euro) and 1,618 euro (95% ci : 1,401 euro – 1,867 euro)
respectively (Student t-test: p<0.001). 
Previous studies on costs of singleton and twin pregnancies were
largely hypothetical, not based on data from i v f-pregnancies and/or
included rough estimates of prices (13;14;18). Since Klemetti et al. (10)
found that the outcome for i v f infants was poorer than those for other
infants, we used data from i v f-pregnancies only. In addition, unit costs
were based on real cost prices as much as possible. For some minor cost
drivers of which real cost prices were not available, hospital charges were
used. This might have caused the actual costs to vary slightly.
Comparing the results from our study with previous studies was dif-
ﬁcult, since medical practice, deﬁnitions and prices vary widely between
and even within countries. Furthermore, from some cost-effectiveness
studies, it was not possible to extract data on cost per pregnancy. The
costs per pregnancy found in our study were lower than those found in a
study by Wolner-Hanssen and Rydhstroem (13). However, their study
was performed from a societal perspective and therefore included costs
of sick leave and (medical and societal) costs of handicap. Leaving these
costs out caused the costs per singleton pregnancy to be similar (2,550
euro vs. 2,821 euro). The major discrepancy in cost per twin pregnancy
between their study and ours was found in the cost of neonatal care. This
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difference could partly be explained by the fact that in their study, in con-
trast to the Dutch situation, both children from a twin were admitted to a
nicu for an equally long period, even if only one required nicu treat-
ment. This caused the neonatal care costs in their study to be much high-
er than in this study.
In our study no data on handicaps were included, because only costs
made from pregnancy until six weeks after delivery were counted. Since
handicaps occur more often in children born premature and since twins
are more often born premature than singletons (7;8;23), adding medical
costs for handicaps would have increased the difference in costs between
twin and singleton pregnancies on the longer term (13), indicating that the
10,000 euro difference in cost between twin and singleton pregnancies is
an underestimation of the actual difference in cost on the longer term.
Antenatal care was classiﬁed as antenatal care by a midwife or hospi-
tal antenatal care, but not classiﬁed according to intensity of use. Previ-
ous Finnish studies found women with twin pregnancies after i v f to use
more specialized antenatal care and use this care more intensively (9;10).
Including classiﬁcation of intensity of antenatal care use would cause the
cost of antenatal care per twin pregnancy to increase.
Recall errors due to the fact that some women were pregnant several
years ago, might have occurred in the number and duration of reported
maternal and neonatal hospital admissions. However, since twin and sin-
gleton pregnancies were matched on date of embryo transfer, recall
errors will probably have occurred equally in both groups. Therefore,
recall bias was unlikely to be an issue in the estimation of the difference
in costs between singleton and twin pregnancies.
Although twin pregnancies are associated with a higher complication
rate and associated costs, there might be one ﬁnancial argument in favor
of a twin pregnancy: the birth of a twin might reduce the desire for an
additional pregnancy for some couples. In this selective population of
i v f-couples a twin pregnancy might save the costs of additional i v f-
treatments and costs related to pregnancy and delivery to achieve a sec-
ond pregnancy and subsequent live-born baby. Depending on the costs
of achieving pregnancy by set , two children born from two singleton
pregnancies after set might be more expensive than a twin. However,
we think that, due to costs for handicap on the longer term, even in this
situation twin pregnancies are not likely to be in favor of singleton preg-
nancies in terms of costs.
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This study focussed on costs for twin and singleton pregnancies from
the medical point of view. Savings on the medical budget due to reduc-
tion of the number of twin pregnancies by set might be spent on other
medical treatments. In contrast, savings in other compartments, such as
society (sick leave, travel expenses), are not likely to become available for
medical treatments and were therefore not included in this study (24).
The money that can be saved by reduction of the number of twin preg-
nancies by set might be used for additional i v f-cycles needed to
achieve similar success rates with set as with two embryo transfer. An
effectiveness study for set is needed, to determine whether set is cost-
effective.
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Abstract
backgrou nd:
To reduce the number of multiple pregnancies after i v f we investigated
the effectiveness of two cycles with single embryo transfer (set) and one
cycle with double embryo transfer (det) after i v f and calculated the
cost-effectiveness of both strategies.
methods:
A randomized controlled trial was performed in 107 women, aged < 35
years, in their ﬁrst i v f cycle, with at least one good quality embryo. They
were randomized to the set (n = 54) or det (n = 53) group using a com-
puter-generated random block number table, stratiﬁed for primary or
secondary infertility.
r e sults:
The cumulative live birth rates per woman randomized of two consecu-
tive cycles of set [41%, 95% conﬁdence interval (ci): 27-54] versus one
cycle of det (36%, 95% ci 23-49) were comparable, whereas the multi-
ple pregnancy rate rate was signiﬁcantly higher: 37% (95% ci 15-59) in
the det and 0% in the in the set group (p = 0.002). Combining the
medical costs of the i v f-treatments (where 1.5 more set cycles were
required to achieve each live birth) and of pregnancies up to six weeks
after delivery, the total medical costs of det per live birth were 13,680
euro and 13,438 euro for set .
conclusions:
Two cycles with set are equally effective as one cycle with det , and the
medical costs per live birth up to six weeks after delivery are the same.
However, if lifetime costs for severe handicaps are included, more than
7,000 euro per live birth will be saved after implementing set . Because
of the high probability of multiple pregnancies in this group of i v f-
patients, only set should be performed.
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Introduction
Today multiple pregnancies are considered to be the most serious com-
plication of i v f treatment for both mother and child. In the Netherlands
a maximum of two embryos are routinely transferred per cycle to prevent
higher-order multiple pregnancies. The risk for a twin pregnancy with
this regime, however, is still 20-35% (1), which is a 15-fold increase relative
to the risk of 1.6% after natural conception (1;2).
There is a need to convince both health care workers and the infertile
couples that multiple pregnancies are not a desirable outcome of an i v f-
treatment. The maternal mortality in Europe is twice as high for multiple
pregnancies as compared with singleton pregnancies (3). Multiple preg-
nancies are associated with higher risks to hypertensive disorders,
anaemia and haemorrhage during pregnancy (4). The risk of neonatal
death in twins is even seven times that of singletons (5). In infants from
multiple pregnancies many perinatal complications are attributable to
the fact that they are more likely to be born prematurely and with a lower
birth weight than babies from singleton pregnancies (6). There is an
increased risk of long-term medical and developmental problems, in par-
ticular neurological impairment, in children from multiple pregnancies.
Therefore, there is a higher risk of severe handicap in twins (7). Multiple
pregnancies impose also a steep burden on government expenses and
health services (8-11).
Retrospective studies identiﬁed age, number of embryos available
and quality of embryos as the most important predictors for multiple
birth (12;13).
The only solution to minimize twin pregnancies after i v f is to trans-
fer one embryo per cycle. Up to now only four randomized controlled tri-
als comparing single embryo transfer (set) and double embryo transfer
(det) have been published (14). The study of Gerris et al. was per-
formed in 53 patients less than 34 years of age and had at least two top
quality embryos available. They found an ongoing pregnancy rate of
38.5% in the set group (38.5%) and 74.1% in the det group (14). The
study of Martikainen et al. was performed in 144 patients with at least
four good quality embryos. There was no statistical difference in cumu-
lative live birth rate (fresh and frozen cycles) between the set group
(39%) and the det group (51%) (15). Gardner et al. randomized 48 i v f
patients with at least 10 follicles > 12 mm on day of hcg administration
t wo cycle s set v er sus one cycle det
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to either transfer of one blastocyst or two blastocysts on day 5. There was
no signiﬁcant difference in ongoing pregnancy rate between single blas-
tocyst transfer (61%) and double blastocyst transfer (76%) (16). Finally,
Thurin et al. performed a multi-centre randomized trial in 661 patients
less than 36 years of age having at least two good quality embryos avail-
able. The cumulative ongoing pregnancy rate in the set group (one
fresh set and one frozen set cycle) was 40% versus 44% in the det
group (without a frozen det cycle; p = 0.344) (17). Only an abstract of
this study has been published. While these randomized controlled trials
make an important contribution to the set discussion, the number of
subjects are relatively small, except for the study of Thurin et al., and the
studies were not combined with a cost analysis to determine the cost-
effectiveness of both strategies.
Therefore, we conducted an additional randomized controlled trial,
in which we compared the live birth rate after two consecutive set
cycles with the live birth rate after one det cycle. Freeze-thaw cycles
were not included in this study. We hypothesized that two set cycles
might be needed to compensate for the possibly lower pregnancy rate as
compared with det . This study was performed among patients with a
high risk for multiples (women less than 35 years of age, ﬁrst i v f treat-
ment cycle and at least two embryos of which one of excellent or good
quality). Additionally, we calculated the cost-effectiveness of both strate-
gies to determine the best transfer strategy for efﬁciency decisions. The
set strategy could be more expensive due to the extra set cycles needed
to achieve an equal live birth rate, while the det strategy could generate
more costs because of the complications related to twin pregnancies.
The cost analysis was done by implementing the results of our previous
retrospective study (18), showing that the medical costs of twin pregnan-
cies were more than ﬁve times higher than the costs of singleton preg-
nancies after i v f .
Materials and methods
Study design
The protocol was approved by the Medical Ethical Review Committee
of the University Medical Centre Nijmegen and all couples participating
in the study signed a written informed consent after they had been thor-
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oughly informed regarding the strict study design. The study objective
was to investigate the live birth rate of set after two consecutive treat-
ment cycles with the live birth rate of det after one treatment cycle,
excluding freeze-thaw cycles. Cumulative live birth rate was the primary
outcome measure. Multiple births, live birth rates after only one treat-
ment cycle and clinical pregnancy rates (number of abortions and ectopic
pregnancies) were secondary outcome measures.
Participants
Only patients undergoing their ﬁrst i v f/icsi cycle ever or the ﬁrst cycle
after a successful treatment were included. The age of the women had to
be younger than 35 years (at the time of et) with a basal follicle-stimulat-
ing hormone (fsh) level <10 iu/l (12;13). Patients with a medical reason
for elective set were excluded, e.g. uterine malformation or history of
cervical incompetence. At least two embryos with one excellent (grade 4)
or one good (grade 3) quality embryo had to be available for transfer on
day 3 after oocyte retrieval during the ﬁrst cycle, according to Steer et al.
(19): grade 4: no fragmentation; grade 3: <10% fragmentation; grade 2:
10-50% fragmentation; grade 1: >50% of the embryo is fragmented. The
number of blastomeres was not an inclusion criterion. A total of 494 i v f
patients from the department of Obstetrics and Gynecology at the Uni-
versity Medical Centre in Nijmegen and Gelderse Vallei Hospital in Ede
underwent oocyte retrieval and embryo transfer in the University Med-
ical Centre in Nijmegen and were younger than 35 years (ﬁgure 1). The
pregnant patients were followed up until delivery. Of the 494 i v f
patients, 217 did not agree to participate or were excluded because of the
following reasons: request for det in the supposition that they would
obtain the highest chance of pregnancy after the ﬁrst cycle, request for
set to avoid multiple pregnancy, having concerns about randomisation
as such, and basal fsh level ≥ 10 iu/l . From 162 patients the number or
quality of the available embryos did not meet the inclusion criteria and
eight patients had a medical reason for set . The characteristics of the
patients and their treatment cycles are shown in table I.
Clinical follow-up
A total of 107 patients were randomized to the set (n = 54) or det
group (n = 53) from January 2001, to February 2003. All pregnant
patients were followed up until delivery. The characteristics of the ran-
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domized patients and their ﬁrst treatment cycle were similar between the
set and det group, as well as between the participants and non-partici-
pants. icsi was performed in 28/54 cycles (52%; 95% ci 38-66) of the
set , 21/53 (40%; 95% ci 26-53) of the det and 117/217 (54%; 95% ci 47-
61) of the cycles of the non-participants. These percentages were not sta-
tistically different. The number of patients with at least one good quality
embryo available for transfer was not different between the set and
det group (Table I).
All patients completed the ﬁrst treatment cycle. One patient in the
set group experienced total fertilization failure in the second treatment
cycle. Four patients in the set group did not (yet) undergo their second
treatment cycle. One patient became pregnant spontaneously and one
patient got divorced after the ﬁrst treatment cycle. Two patients still have
to undergo the second cycle. These patients were analyzed as if no preg-
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Assessed for eligibility
 First treatment• 
• 
• 
• 
• • 
Age <35 years
(n=494)
Excluded (n=387)
Not meeting  inclusion
criteria
(i.e. number and quality of
embryos: n=162, medical
reason for SET: n=8)
 Refused to participate and
FSH  ≥ 10 IU/L (n=217)
SET
Allocated to intervention (n=54)
Received allocation (n=54)
DET
Allocated to intervention (n=53)
Received allocation (n=53)
No lost to folow-up 
Analyzed (n=54)
No lost to folow-up 
Analyzed (n=53)
Randomized (n=107)
Figure 1.  Trial proﬁle.
nancy had occurred. In the set group two patients elected to receive two
instead of one embryo at transfer in the second cycle. One of these
patients became pregnant with a singleton. Three patients unintentio-
nally received two embryos during the second set cycle by mistake. Vio-
lation of the protocol after randomization occurred in two cases: in the
set group in one patient no embryo transfer took place because of
severe ovarian hyperstimulation syndrome. The embryos of this cycle
were cryopreserved and one good quality embryo was transferred after
thawing, resulting in an abortion. In the det group one patient was
included despite the fact that this patient already underwent a previous
i v f-treatment cycle with transfer of only one moderate quality embryo.
No pregnancy occurred. In the current cycle two good quality embryos
were transferred resulting in a singleton pregnancy. Because of the inten-
tion-to-treat principle all patients mentioned above were included in the
analyses.
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Table I. Baseline characteristics of the study subjects and the non-participants 
of the ﬁrst cycle
Variable SET (n = 54) DET (n = 53) non-participants 
(n = 217)
Age (years) [mean (SD; range)] 30.2 (3.2; 20-34) 31.2 (2.9; 25-34) 30.6 (3.0; 20-34)
Duration of infertility (months) 7 (17; 6-99) 42 (23; 7-123) 41.2 (23.3; 5.7-139.5) 
[mean (SD; range)]
Primary infertility [n (%)] 40 (74) 38 (72) 162 (72)
Basal FSH level (IU/l) 6.6 (1.5) 6.6 (1.8) NA
Etiology of infertility [n (%)]
Male factor 36 (67) 26 (49) 140 (64)
Tubal 5 (9) 9 (17) 24 (11)
Unexplained 5 (9) 14 (27) 32 (15)
Other female 8 (15) 4 (8) 21 (10)
ICSI [n (%)] 28 (52) 21 (40) 117 (54)
Oocytes
[mean (SD; range)] 13.4 (6.1; 3-29) 12.6 (6.4; 3-26) 11.8 (5.7; 2-43)
Embryos [mean (SD; range)] 8.0 (4.1; 2-18) 7.8 (4.1; 2-18) 7.0 (4.0; 2-24)
≥ 1 good embryo [n (%)] 40 (74) 35 (66) 127 (59)
Cryopreserved [mean (SD; range)] 1.8 (2.0; 0-8) 0.9 (1.8; 0-8)
NA = not available.
Assignment
Randomization to the set or det group was performed using a com-
puter-generated random block number table, stratiﬁed for primary or
secondary infertility, executed by an independent statistician. Allocation
to the randomized group by an opaque, sealed envelope took place just
before embryo transfer by the laboratory personnel to maintain conceal-
ment to the last moment. Both patients and physicians were not blinded
to treatment group.
IVF/ICSI procedure
Pituitary desensitization (long protocol) was achieved using triptoreline
(Decapeptyl®; Ferring, the Netherlands). Ovarian stimulation was
accomplished by recombinant follicle-stimulating hormone (Puregon®;
Organon, Oss, the Netherlands). Thirty-six hours after the injection of
10.000 iu of human chorionic gonadotrophin (hcg) (Pregnyl®; Orga-
non, Oss, the Netherlands) we performed transvaginal oocyte retrieval.
Embryo transfer was performed 3 days after oocyte retrieval.
Luteal support was given through progestogen intravaginal capsules
of 100 mg, at a daily dose of 600 mg (Progestan®; Organon, Oss, the
Netherlands). On day 15 after embryo transfer a pregnancy test was per-
formed, using a commercial urinary kit. Five weeks after embryo trans-
fer clinical pregnancy was conﬁrmed by ultrasonic evidence of an
intrauterine gestational sac and a positive heart beat.
After the retrieval, oocyte-cumulus complexes were prepared, washed
and incubated (37oc , 5% co2 in air) in i v f medium, consisting of human
tubal ﬂuid medium (20) (Bio Whittaker, Verviers, Belgium) supplement-
ed with 10% pasteurized plasma solution (Central Laboritory of Blood-
transfusion, Amsterdam, the Netherlands). Freshly ejaculated semen
was mixed with 5 ml i v f medium, layered onto an 80% Pure-Sperm
(Nidacon International, Gothenberg, Sweden) gradient, centrifuged at
600g for 20 minutes and washed twice with i v f medium. Insemination
was carried out in Falcon dishes by adding about 200,000 motile sper-
matozoa to the oocytes in 2 ml of i v f medium. If icsi was performed,
the oocytes were treated with hyaluronidase solution (Medi-cult, Jyllinge,
Denmark) and denuded with a capillary pipette before injection was per-
formed. icsi was performed according to the method described by Van
Steirteghem and colleagues (21). Only morphologically normal (at 200x
magniﬁcation), motile spermatozoa were injected. After injection or
80
ch a p t er 3
insemination, the oocytes were transferred to 50 ml drops of culture
mineral oil (1 oocyte/droplet), and were judged for the presence of 0, 1, 2
or ≥3 pronucleï (pn). On day 3 after oocyte retrieval, the embryos were
scored for cell number and embryo quality score on a scale from 1 to 4
according to Steer et al. (19).
Excess embryos of good morphological quality (< 10% fragmentation
and at least 7 blastomeres) were cryopreserved using the standard proto-
col with the cryoprotectant 1,2-propanediol (22).
Cost-effectiveness analysis of singleton versus twin pregnancies after IVF
The cost-effectiveness analyses of both embryo transfer strategies were
performed by using the results of a previous study of our group (18) and
by using the direct medical costs of an i v f cycle in the Netherlands
[Dutch National Health Tariffs Authority (ctg)].
In the previous study we determined the medical costs from pregnan-
cy after i v f up to six weeks after delivery, using the following cost-dri-
vers: mode of antenatal care, mode of delivery and maternal and neonatal
hospital admission days (18). Estimations of volumes were based on data
from a representative sample of twin (n = 172) and singleton (n = 168)
pregnancies from a database containing all couples with a live born sin-
gleton or at least one live born twin after i v f treatment at the umcn
between 1995-2001 (n = 963 pregnancies; 24% twins). The medical costs
from the induction of i v f-pregnancy up to six weeks after delivery were
13,469 euro for twin pregnancies and 2,550 euro for singleton pregnan-
cies; p < 0.001) (18).
Furthermore, the direct medical costs of an i v f treatment in the
Netherlands, including hospital charges and medication costs of a long
protocol and a mean starting dose of 200 iu recombinant fsh , have
been researched using 2003 rates [Dutch National Health Tariffs
Authority (ctg)]. The medical costs of freeze-thaw cycles were not
included. This cost analysis was combined with the randomized con-
trolled trial data using the primary outcome measure ‘live birth’ for
effectiveness of treatment. This results in a cost-effectiveness ratio using
a medical perspective of costs per live birth rate.
Statistical analysis
The analyses were based upon the intention-to-treat principle. Cumula-
tive live births were analyzed as primary outcome (ﬁrst plus second fresh
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cycle in set group). Multiple births, live birth rate after just one i v f
cycle in the set group, ongoing pregnancy rate and number of abortions
and extra-uterine pregnancies were analyzed as secondary outcome.
Categorical data were analyzed by the χ2-test. The Student’s t-test for
independent samples was used to test continuous variables between the
set and double embryo transfer group.
Power analysis indicated a requirement of 52 patients in each group to
show a reduction in live birth rate of 20% in the set group after one cycle
(assuming a live birth rate of 50% in the double embryo transfer group
and 30% in the set group after one cycle {[1 - (1 - 0.3)2] x 100 = 51% after
two cycles)} with an α error of 0.10 and a β error of 0.20, tested one-
sided.
P-values ≤ 0.05 were considered signiﬁcant. All analyses were performed
two-sided by spss (Statistics Package for Social Sciences).
Results
Clinical results
The primary outcome, the cumulative live birth rate between the two
strategies, was in the same order of magnitude between two cycles of
set (22/54; 41%, 95% ci 27-54) and the det group (19/53; 36%, 95% ci
23-49) (Table II). So, the difference in live birth rate between two fresh
cycles of set and one fresh cycle of det is 5% (95% ci –10.5-20.5). The
number of twins, as secondary outcome, in the det group was seven (6
twins and 1 dizygotic triplet) out of 19 live births (37%; 95% ci 15- 59) ver-
sus 0 out of 21 in the set group (p = 0.002). One fetus of a twin pregnan-
cy was stillborn at 36 weeks of gestation, cause unknown. The cumula-
tive incidence of miscarriages and ectopic pregnancies was also similar
in the set and det group, respectively 8/54 (15%; 95% ci 5-25) and 6/53
(11%; 95% ci 3-20).
The number of live children born in the det group was 26, including
one dizygotic triplet and one stillborn child. The number of preterm
born babies was not signiﬁcantly higher in the det group than in the
set group, respectively 5/25 (20%; 95% ci 4-36) and 2/22 (9%; 95% ci
–3-21). Nine out of ten babies born before 37 weeks of gestation were
from twin pregnancies. The number of babies with a low birth weight (<
2500 gram) was higher in the det group, entirely attributable to the
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twins, as compared with the set group, respectively 10/26 (38%; 95% ci
19- 58) and 1/22 (5%; 95% ci –4-13, p = 0.002).
Even if we compared just one cycle of set with det , the live birth
rate was not signiﬁcantly different between the two groups, respectively
14/54 (26%; 95% ci 14-38) and 19/53 (36%; 95% ci 23-49; Table ii). The
difference in live birth rate between one cycle of set and det is -10%
(95% ci –24.7-4.7). The percentages of miscarriages and ectopic preg-
nancies were similar in both groups, 6/54 (11%; 95% ci 3-20) after one
cycle in the set and 6/53 (11%; 95% ci 3-20) in the det group.
Health economic results
The cost-effectiveness starts with the calculation of the costs of the i v f-
treatments per live birth. The calculated costs are all expressed per live
birth, although the outcome of a live birth can be one healthy or sick child
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Table II. The cumulative outcome of fresh embryo transfers 
Variable SET (n = 54) DET (n = 53) P
1st cycle 2nd cycle Cumulative
No. of subjects 54 40 54 53 NS
No. of transfers 54 35a 89 53 NS
Clinical pregnancy [n (%)] 20 (37) 10 (25) 30 (56) 25 (47) NS
Miscarriage [n (%)] 6 (11) 2 (5) 8 (15) 5 (9) NS
Ectopic pregnancy [n (%)] 0 0 0 1 (2) NS
Live birth [n (%)] 14 (26) 8 (20) 22 (41) 19 (36) NS
Singleton [n (%) of live births] 14 (100) 8 (100) 22 (100) 12 (63) NS
Twin ([n (%) of live births] 0 0 0 7b (37) 0.002
Perinatal death (n) 0 0 0 1c,d NS
Preterm birth < 37 weeks [n (%)] 2 (14) 0 2e (10) 5d (20) NS
Low birthweight infants 
(<2500 g) [n (%)] 1 (7) 0 1e (5) 10d (40) 0.002
Data given are mean (%).
a In 5 patients no embryo transfer took place: one patient got divorced, one became preg-
nant spontaneously, one experienced total fertilization failure, two still have to undergo
the second cycle. 
b One dizygotic triplet.
c Prenatal death: one fetus from a twin pregnancy died in utero at 36 weeks amenorrhoe.
d Number of live born children in DET group = 26
e Number of live born children in SET group = 22
NS = not signiﬁcant.
or two, even three, healthy and/or sick children. So the mean costs per
live birth are calculated. The medical costs of an i v f-treatment in the
Netherlands are 2,532 euro, including the medication [2003, Dutch
National Health Tariffs Authority (ctg)].
The mean number of i v f-cycles performed per live birth was 4.3 in
the set group [(54 + 40 cycles) / 22 live births] and 2.8 in the det group
(53 cycles / 19 live births). So 1.5 more set cycles were needed per live
birth (4.3/2.8). The medical costs of the i v f-treatment per live birth in
the set group are 10,888 euro (4.3 x 2,532 euro) and 7,090 euro in the
det group (2.8 x 2,532 euro). This results in extra treatment costs per
live birth after set of 3,798 euro (10,888 euro – 7,090 euro). The per-
centage of live born twins was 0% in the set group and 37% in the det
group. Based on the results of a previous study (18) the average medical
costs of an i v f-pregnancy up to six weeks after delivery were 13,469 euro
for twin pregnancies and 2,550 euro for singleton pregnancies. For the
det group this resulted in 6,590 euro per live birth (37% x 13,469 euro +
63% x 2,550 euro), compared with 2,550 euro for set (100% x 2,550
euro). Medical costs of the pregnancies up to 6 weeks after delivery after
set were 4,040 euro (6,590 euro – 2,550 euro) lower than after det .
Combining the medical costs of the i v f-treatments and pregnancies
up to 6 weeks after delivery, the total medical costs of set per live birth
are 13,438 euro (10,888 euro + 2,550 euro) and 13,680 euro (7,090 euro +
6,590 euro) for det .
Discussion
In order to diminish the number of twin pregnancies after i v f substan-
tially, single embryo transfer is considered a serious option for daily i v f-
practice. Before such protocols can be implemented, the effectiveness of
set had to be determined. Our randomized controlled trial assessed the
live birth rate after two consecutive i v f-treatment cycles utilising single
embryo transfer compared with one cycle with double embryo transfer,
in a population with a high risk for multiple births. The cumulative live
birth rate in the set group (22/54; 41%, 95% ci 27-54) was remarkably
similar to the live birth rate in the det group (19/53; 36%, 95% ci 23-49).
The difference in live birth rate between two cycles of set and det is
therefore 5% (95% ci –10.5-20.5). In contrast, six twins and one triplet
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were born out of 19 live births in the det group (37%, 95% ci 15-59) ver-
sus zero twins out of 22 live births in the set group (p = 0.002). Even
after one treatment cycle the live birth rate in the set group (14/54; 26%,
95% ci 14-38) was already close to, and not signiﬁcantly different from
the rate in the det group (19/53; 36%, 95% ci 23-49). The difference in
live birth rate between one cycle of set and det is -10% (95% ci –24.7-
4.7).
The characteristics of the patients and ﬁrst treatment cycle were not
different between the set and det group (Table I), indicating that the
randomization was successful. As the pregnancy rate in the non-
response group (103/276; 37%) was similar to the rate in the det group
(19/53; 36%) selection bias has not likely occurred.
To date, four randomized controlled trials comparing one versus two
embryo transfer have been performed (14;15). Gerris et al. performed
their study in a highly selected population. Patients were included with at
least two top quality embryos (4 or 5 blastomeres on day two, at least 7
blastomeres on day three, <20% fragments and the absence of multinu-
cleated blastomeres). This may explain the high pregnancy rates in their
set (38.5%) and det group (74.1%). At the same time, the number of
twin pregnancies in the non-eligible population was also remarkably
high (35.8%). So, it can be expected that the effect of set in this highly
selected group will have little effect on the overall multiple pregnancy
rate. However, Gerris and colleagues studied in a subsequent retrospec-
tive cohort analysis over a four year period the effect of elective set in a
larger group of patients (n = 1559). They showed that at least one top
embryo with the embryo criteria described above could be transferred in
~70% of all cycles. Over these four years set increased from 13% to 31%,
whereas the ongoing pregnancy rate per retrieval did not change (35.9%
to 31.0%), but the multiple pregnancy rate decreased with almost 50%
(33.6% to 18.6%) (23). Martikainen and colleagues used the following
inclusion criteria for the embryo quality: at least four good quality
embryos available (even sized blastomeres and <20% fragmentation on
day 2), but remarkably almost half of the patients fulﬁlled the inclusion
criteria, so set was applicable to a large group of patients. Gardner et al.
evaluated all blastocysts using a previously described scoring system
(24), but they did not describe inclusion criteria for blastocyst quality in
their randomized controlled trial. Thurin et al. included only patients
with at least two good quality embryos available, but the deﬁnition for
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good quality was not described in their abstract. In our study only one
good quality embryo out of a total of at least two embryos had to be avail-
able with less than 10% fragmentation, irrespective of the number of
blastomeres, so set could be performed in a large group of patients. The
present study makes a contribution to properly designed randomized
controlled trials evaluating the effectiveness of set in a selected i v f
population. In the future performing a meta-analysis could raise the level
of evidence with respect to the effectiveness of set . This study is distin-
guished from the other studies by the fact that we performed two con-
secutive fresh cycles with set versus one cycle with det to determine
how many extra cycles were needed to obtain a similar live birth rate per
strategy.
Another notable difference with the other randomized controlled tri-
als is that we also performed a cost-effectiveness analysis. We used the
medical costs from the induction of i v f-pregnancy up to six weeks after
delivery for singleton and twin pregnancies, determined in a previous
published retrospective study by our group (18). The total costs per live
birth of the two strategies in the present study, including i v f-treatments
and pregnancy up to 6 weeks after delivery, did not differ signiﬁcantly
(set : 13,438 euro, det : 13,680 euro). Gerris et al. just recently showed in
a real-life prospective health economic study that in Belgium set cost
7,126 euro and det 11,039 euro. All medical costs from i v f-treatment,
pregnancy and neonatal period up to 3 months after delivery were
prospectively analyzed in patients of <38 years of age. One cycle of set
with one high quality embryo resulting in a live birth rate of 37.4% was
compared with one cycle of det resulting in a live birth rate of 36.6%. In
the det group embryo quality was not a selection criterion, therefore
both groups were not comparable with respect to chance of pregnancy.
This was not a randomized controlled trial, but based upon patient
choice for set or det , whereas set was exclusively performed if a high
quality embryo was available (11).
In our study however, the long term outcome of the det strategy may
be much more expensive when adding lifetime costs for handicaps. A
French study from 1982 showed that the risk of serious handicap was
6.9-fold higher for a twin child as compared with a singleton child (25).
Based on these ﬁgures, Wolner-Hanssen calculated that the estimated
average cost for care of severely handicapped children was 20,477 euro
for twins and 1,489 euro for singletons (average euro value of sek in
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2004 = 9.219) (9). So, in the det group the lifetime costs for handicaps
will be 8,514 euro (37% x 20,477 euro + 63% x 1,489 euro). In the set
group this amount will be 1,489 euro (100% x 1,489 euro). Finally, com-
bining the costs of i v f-treatments and (singleton and twin) i v f-preg-
nancies up to six weeks after delivery with the costs for severely handi-
capped (singleton and twin) children, det live births will cost 22,194
euro (13,680 euro + 8,514 euro) and set live births 14,927 euro (13,438
euro + 1,489 euro). So, hypothetically when handicaps are included, the
det strategy could be more than 7,000 euro more expensive per live
birth than the set strategy.
An additional advantage of set is the higher number of cryopre-
served embryos, which can contribute to the pregnancy rate per cycle.
The mean number of cryopreserved embryos per ﬁrst treatment cycle
was 1.8 (sd 2.0; range 0-8) in the set group and 0.9 (sd 1.8; range 0-8)
in the det group). Unfortunately, the frozen-thawed embryo transfers
did not contribute to the overall live birth rate in our study. Two Finnish
studies reported an increase of the pregnancy rate due to cryopreserved
embryos in patients treated with elective set of 18% (13) to 26% (26).
Martikainen and colleagues observed an increase in live birth rate from
30% to 39% after frozen-thawed embryo transfers in the set group (15).
It seems worthwhile to put effort in improving the cryopreservation pro-
gramme, which will reduce the number of second cycles with fresh set
and as a consequence result into a considerable costs reduction.
If set is to be implemented, more patient-friendly i v f strategies
might be considered. This will result into a lower number of redundant
embryos, but more importantly, also in reduction of the risk of ovarian
hyperstimulation syndrome. Minimal ovarian stimulation regimens or
even natural cycle i v f can be applied as a low-risk, low-cost and patient-
friendly procedure. Pelinck and colleagues reported an ongoing preg-
nancy rate of 7.2% in a systematic literature review of 1800 natural i v f
cycles (27). Lukassen et al showed a live birth rate of 10.3% per cycle in 29
natural icsi cycles in patients younger than 37 years of age (28). On the
other hand, we have to consider that there will be no or a restricted selec-
tion of embryos available for transfer and it will result in a decrease of the
cryoaugmentation effect. A cost-effectiveness study remains to be done.
The psychological and social impact of multiples on the host family
must also not be underestimated. Mothers of i v f twins experience more
parenting stress as compared with mothers of i v f singletons and natu-
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rally conceived singletons (29;30). Parents of multiples are more likely to
get divorced and mothers of twins suffer more often from fatigue and
depression (31;32). In our study many couples refused to participate
because they desired a twin over a singleton gestation. Ryan et al recently
showed in a prospective analysis that 20% of women with infertility
desired multiples, which was associated with nulliparity and lower fami-
ly income (33). It is the question whether the patients in our study were
aware of the practical, ﬁnancial and emotional impact that the birth of
twins can have on their lives. On the other hand, we did not study
whether there was more emotional stress for the couples in case more
than one cycle was needed to become pregnant of a singleton or to under-
go several i v f cycles to have two singletons instead of one twin. More-
over, insurance policies may play an important role in the acceptation of
single embryo transfer. At the time this study was performed the Dutch
government reimbursed a maximum of three i v f cycles, nowadays the
patient has to pay the ﬁrst out of three i v f cycles. As a consequence,
probably more patients will insist on double embryo transfer, which will
cost the government relatively much more money.
We are aware of the rather small sample size of our study. Retrospec-
tively, to show a signiﬁcant difference of 10% between the live birth rate
of set (26%) and det (36%), 90 patients per group would have been
needed (α error = 0.10 and β error = 0.20). Therefore, it is necessary to
keep monitoring the success rate thoroughly in the future after imple-
menting set in daily practice and through well designed randomized
controlled trials and possible meta-analysis to get more precise estimates
of the success rate.
In conclusion, two cycles with single embryo transfer are equally
effective as one cycle with double embryo transfer, and the medical costs
per live birth up to six weeks after delivery are about the same. This
favours the set strategy because of the dramatic difference in multiple
pregnancy rates. When the lifetime costs for severe handicaps due to
multiple pregnancies are included, almost 7,000 euro per live birth could
be saved after implementing set in this patient group. Therefore, the
det strategy should be abandoned completely in this high-risk group, in
favour of the strategy with 2 cycles with set . This will save the govern-
ment not only a lot of money but most of all the patients and their off-
spring will be saved from a large range of medical and socio-emotional
problems.
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Introduction
The ﬁrst successful pregnancy resulting from i v f occurred during an
unstimulated normal menstrual cycle (1). This approach was soon aban-
doned in favor of controlled ovarian hyperstimulation leading to
improved pregnancy rates. However, ovarian stimulation has many dis-
advantages, including patient burden; risk for various adverse condi-
tions, such as the ovarian hyperstimulation syndrome, multiple pregnan-
cies, and cancer in the long term; ethical dilemmeas, such as storage and
disposal of extra embryos; and high costs (2). 
These disadvantages have prompted many researchers to again in-
vestigate i v f in the natural cycle, especially because i v f technique and
lh monitoring have been improved (2). It has been suggested that i v f
in the natural cycle is best performed in patients with tubal factor infer-
tility, because both male and female gametes should be normal (3). How-
ever, the efﬁcacy of icsi in the natural cycle among patients with severe
oligozoospermia has now been investigated serially and systematically. 
Materials and methods
We performed a pilot study to investigate the efﬁcacy of icsi in 29 nat-
ural cycles of 25 couples. The study was performed at the Department of
Obstetrics and Gynecology of the University Medical Center Nijmegen,
Nijmegen, the Netherlands. Inclusion criteria were female age <37 years,
infertility due to severe male factor with indication for icsi ( total motile
sperm count < 1 x 106), regular menstrual cycle of 26 to 32 days, a baseline
fsh level <10 iu/l , and all couples participating in the study gave writ-
ten informed consent.
Serial transvaginal ultrasonography was performed to monitor folli-
cle growth and endometrial thickness from day 8 or 9, depending on the
length of the cycle. At each visit, serum levels of estradiol and lh were
measured. When the dominant follicle was at least 16 mm in diameter as
measured in two directions and the morning serum lh level was 15 iu/l
or less, ovulation was triggered with 10,000 iu of hcg (Pregnyl®;
Organon, Oss, the Netherlands). Excluded were patients with abnormal
follicular growth, deﬁned as stagnation or decrease in diameter of the
dominant follicle in three consecutive measurements.
icsi in a nat ur a l cycle
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Transvaginal oocyte retrieval was scheduled 34 hours after hcg
administration. If the serum lh value was elevated (>15 iu/l), oocyte
retrieval was performed the next morning. No local or general anaesthe-
sia was given because of the supposed low burden of the quick ovum-
pickup for the patient.
After retrieval, the oocytes were denuded before injection was per-
formed. Freshly ejaculated semen were used for icsi . The morning after
injection, the oocytes were examined for the presence of 0, 1, 2 or ≥3
pronuclei. On day 3 after oocyte retrieval (64 to 72 hours after injection),
embryos were scored for cell number and embryo quality. Embryo trans-
fer was then performed. No luteal support was given since no pituitary
desensitization with gonadotrophin-releasing hormone analogues was
realized.
On day 15 after embryo transfer a pregnancy test was performed. Five
weeks after embryo transfer, clinical pregnancy was conﬁrmed by ultra-
sonographic evidence of an intrauterine gestational sac.
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Table 1. Results of 29 natural ICSI cycles. 
No. of cycles
No. of cycles without
All cycles with elevated elevated LH
(%/cycle) LH level (n) levels (n)
No. of cycles started 29. 10 19
No. of cycles cancelled 3.(10.3) 3 0
Premature ovulation 2.(6.9) 0 2
Oocyte retrieval 24.(82.8) 7 17
successful 17.(58.6) 6 11
not successful 7.(24.1) 1 6
Result of ICSI 14.(48.3) 6 8
Fertilization (2 pronuclei) 14.(48.3) 6 8
Triploidy (3 pronuclei, no ET) 1.(3.4) 1 0 
No fertilization 0. 0 0
Abnormal zygote, no ET 1.(3.4) 1 0
Result of ET 12.(41.4) 4 8
Pregnancy 3.10.3) 0 3
Live birth 3.(10.3) 0 3
Results
Table i shows our ﬁndings. Twenty-ﬁve patients underwent 29 icsi
cycles (4 patients participated in 2 consecutive cycles). The median
female age was 31 ± 3.1 years. The median duration of infertility was 2.1 ±
2.4 years. Three cycles were cancelled, 2 because of abnormal follicular
development and 1 because of an unexpected irregular menstrual cycle of
36 days. Two patients ovulated between the hcg trigger and oocyte
retrieval even though no increased lh value had been detected.
Oocyte retrieval was performed in a total of 24 cycles in which the
mean follicle diameter was 17.2 ± 1.0 mm and the estradiol level was 790 ±
240 pg/l on the day of hcg administration. In 7 cycles, the lh value was
increased on the morning of the last check (Table i). The mean endome-
trial thickness was 8.9 ± 1.5 mm on the day of hcg injection.
Embryo transfer was performed in 12 patients (41.4% per cycle). Three
patients became pregnant and delivered a healthy infant (25% per
embryo transfer). Thus, the live birth rate per started cycle was 10.3% 
(3 of 29 cycles). Quality scores were grade 4 (no fragmentation) in three
embryos, grade 3 (<10% fragmentation) in three embryos, and grade 2
(10% to 20% fragmentation) in two embryos. Three pregnancies resulted
from two grade 4 and one resulted from grade 2 eight-cell embryos.
Discussion
As far as we know, this is the ﬁrst study investigating the efﬁcacy of icsi
only in the natural cycle in a series of patients. Although male factor
infertility is associated with lower fertilization rates in natural-cycle i v f
(4), we found a high fertilization rate in retrieved oocytes after icsi . All
injected oocytes became fertilized, and only one fertilized oocyte did not
develop to a cleavage-stage embryo. Thus, no oocyte was damaged by the
icsi procedure.
A disadvantage of natural-cycle icsi is the high cancellation rate
because of inadequate follicular development or premature lh surges,
despite selection of patients with a regular menstrual cycle and absence
of a female factor of infertility. When cycles with a lh surge are taken
into account (n = 10), the cancellation rate in our study was 44.8% (13 of
29 cycles) (Table i). 
icsi in a nat ur a l cycle
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In contrast to the ﬁndings of Lenton et al. (5), we found no premature
ovulation or immature oocytes (absence of a polar body) in patients with
an increased lh value. Human chorionic gonadotropin was adminis-
tered in ﬁve of these cases and was not administered in two cases,
according to the physician’s judgment. The oocyte retrieval rate per pick-
up was higher in the group with a lh surge than in the group without a
lh surge (85.7% and 64.7%, respectively), although this diference was
not statistically signiﬁcant. However, no pregnancies were obtained in
the six patients with a lh surge. From these data, we cannot draw the
conclusion that it is better to cancel cycles in which a lh surge is mea-
sured. 
An interesting observation was the large variety in embryo quality
(cell number and fragmentation on day 3). It is possible that during the
process of follicular growth, one of the best follicles with a relatively
good quality oocyte is selected by nature to ovulate. A further improve-
ment could be expected by the lack of a negative effect of hyperstimula-
tion on embryo quality, as has been described in murine models (6). In
contrast to these expectations, only 3 of 13 embryos in our study were of
excellent quality on day 3 (> 7 cells and no fragmentation). Two of these
embryos implanted and led to the birth of a healthy infant. The third
implanted embryo had eight cells and was of grade 2 quality. Some
patients had an embryo with moderate quality in the natural cycle but
had excellent quality embryos in a subsequent hyperstimulated cycle, in
which 9 of 18 patients became pregnant. Thus, if natural selection of the
best oocyte occurs during follicular growth, it does not ﬁnd expression
in the quality of the embryos in our study. 
In conclusion, our study shows that icsi in the natural cycle may be a
suitable alternative to icsi in stimulated cycles. The ongoing pregnancy
of 10.3% per started cycle is satisfactory considering the low burden, low
costs and low risks. Moreover, this protocol can be performed on a
monthly basis, because there is no need for the ovaries to recover from
hormonal stimulation. Extrapolation of the 10.3% live birth rate after one
natural cycle yields a calculated cumulative live birth rate after three nat-
ural cycles of 28%. We also found a rate of 32% after one stimulated icsi
treatment in women younger than 37 years in our setting in 2000 (unpub-
lished data). Thus, in the same time span the pregnancy rates are similar.
We believe that natural-cycle icsi may be a suitable alternative to stimu-
lated icsi cycles.
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Abstract
One ﬁfth of all i v f-patients suffer from idiopathic infertility. A low fer-
tilization rate is one of the most characteristic features of i v f in this
group, probably caused by oocyte dysfunction. We speculate that an
altered lymphocyte proﬁle in follicular ﬂuid may affect oocyte function
and thus play a role in idiopathic infertility. Therefore, we compared lev-
els of lymphocyte populations present in follicular ﬂuid (f f) of eleven
patients with idiopathic infertility (study group) with 29 patients in the
control group i.e. severe male factor infertility (n=17) or tubal factor
infertility (n=12). Triple color ﬂow cytometry was used to discriminate
between T cells and nk cell subpopulations. In the idiopathic infertility
group a shift from T cells to nk cells was observed in f f as compared to
the control group, mainly caused by a signiﬁcant higher level of nk cells,
20.3% and 13.6% (p<0.05), respectively. This high level of nk cells was
due to a rise of the cd16+cd56dim nk cell subset. In peripheral blood the
nk cell levels showed a similar, although not signiﬁcant trend (p=0.08).
As the cd16+cd56dim nk cell subpopulation is known for its cytotoxic
properties, this subpopulation may negatively affect folliculogenesis and
oocyte maturation, which is reﬂected by a diminished fertilization rate in
the idiopathic infertility group. An altered lymphocyte proﬁle in follicu-
lar ﬂuid could therefore inﬂuence fertility in these patients.
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Introduction
In about one ﬁfth of the patients who start In-vitro Fertilization (i v f)
the cause of their fertility problem is unknown (1). Patients with unex-
plained infertility form a heterogeneous population whose etiology
remains elusive, despite profound infertility investigations of both part-
ners. It is known that the fertilization rate of oocytes from patients with
unexplained infertility is lower as compared to oocytes from patients
suffering from tubal factor infertility, resulting more frequently in total
fertilization failure in the ﬁrst group (2-4). Fertilization failure can be
caused by unsuspected sperm dysfunction and/or oocyte dysfunction
(5;6).
In the ovary immunological factors play an important role in follicu-
logenesis and corpus luteum development (7;8). Follicular ﬂuid (f f) pro-
vides the environment in which oocyte maturation occurs. Follicular
ﬂuid may therefore inﬂuence the quality of the oocyte, and thus be linked
to fertilization and early embryonic development. Until now in follicular
ﬂuid the presence and function of many cytokines have been determined
(9-14). However, there is only limited information from dated studies
evaluating the immune cells present in f f responsible for the production
of those cytokines (15-20). These studies have demonstrated the pres-
ence of the following leukocyte populations in f f of women undergoing
i v f treatment: monocytes-macrophages, B cells, T cells and natural
killer (nk) cells. 
It is known that nk cells play an important role in human reproduction.
Two phenotypically and functionally distinct nk cell subsets can be dis-
tinguished by cd56 surface density expression. The cd16+cd56dim nk
cells have cytotoxic properties and cd16-cd56bright nk cells produce
mainly immunoregulatory cytokines (21). The nk cell population in the
uterus predominantly comprises of cd16-cd56bright nk cells, which are
supposed to be crucial at the time of implantation by controlling tro-
phoblast invasion (22;23).
The main population (90%) of peripheral blood nk cells is
cd16+cd56dim. Implantation failure in i v f and idiopathic infertility in
i v f patients was associated with a high level of cd16+cd56dim nk cells
(24;25).
We hypothesize that a disturbance in the local cellular immune sys-
tem of the follicle might cause aberrant oocyte development which can
the proportion of follicul a r f luid
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reveal a possible explanation for the ‘idiopathic’ cause of infertility in
this group of patients. We determined the levels of T and nk cell subsets
by ﬂowcytometric analysis in separately collected follicular ﬂuids of
patients with idiopathic infertility and compared these levels to f f of a
control group consisting of couples with severe male and tubal factor
infertility. 
Materials and methods
Patients
After obtaining an informed consent according to the Medical Ethical
Review Committee of the University Medical Center Nijmegen, 63 fol-
licular ﬂuid samples were collected from 40 women undergoing i v f .
From these 40 patients, 11 patients were categorized in the study group
(idiopathic infertility) and 29 patients in the control group i.e. male fac-
tor infertility (n=17) or tubal factor infertility (n=12). 
Couples were diagnosed as having idiopathic infertility if no abnor-
mality was found during the full infertility investigation and they had
been suffering from idiopathic subfertility for at least 3 years, in spite of
several intrauterine inseminations. Severe male factor infertility with
indication for intracytoplasmic sperm injection (icsi) was diagnosed if
at least two semen samples yielded less than 0.5 million progressively
motile spermatozoa after processing by 80% Puresperm‚ (Nidacon
International, Götenborg, Sweden) gradient centrifugation. Tubal factor
infertility was deﬁned as bilateral or unilateral tubal occlusion in combi-
nation with infertility for at least two years. In these patients no hydro-
salpinges were diagnosed by ultrasound.
IVF-procedure
Pituitary down-regulation (long protocol) was achieved using a gnr h
analogue (Decapeptyl®; Ferring, the Netherlands). Multiple follicle
growth was achieved using recombinant fsh (Puregon®; Organon, Oss,
the Netherlands). Thirty-six hours after hcg injection (Pregnyl®; Orga-
non, Oss, the Netherlands) we performed transvaginal oocyte retrieval. 
For this study the ﬂuids of the two largest follicles in each ovary were
collected and assessed as follows: the ﬂuid of the ﬁrst follicle was collect-
ed in a tube. The needle was removed and ﬂushed with Phosphate
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Buffered Saline (pbs) plus heparine and penicilline, to maximize oocyte
retrieval. This ﬂush medium was collected into another tube in order to
prevent contamination with the previous punctured follicle. Then the
needle was re-injected to puncture the second largest follicle. This ﬂuid
was collected separately as well. The same procedure took place in the
other ovary. Because of the patient’s burden of multiple vaginal wall
punctures it was not considered ethical to collect more than four f f ’s
separately per patient. 
Leukocyte isolation 
Follicular ﬂuid was centrifuged at 1400 rpm for 5 minutes. After discard-
ing the supernatant the remaining cells were washed in r pmi-1640 sup-
plemented with 10% human serum, sodium pyruvate and 1% penicillin-
streptomycin (gibco , Grand Island, n y). After centrifugation, the cells
were resuspended in 2 ml lysis buffer (nh4cl , k-edta) to remove ery-
throcytes and incubated on ice for 5 minutes. The cells were washed
again after adding 13 ml of Phosphate Buffered Saline (pbs). Cells were
resuspended in ﬂuorescence activated cell sorting (facs) buffer (pbs
containing 0.5% bovine serum albumin (bsa)) and the leukocytes were
counted. Leukocytes were present at a mean concentration of 90x103
cells/ml in f f . There was no signiﬁcant difference in the numbers of
leukocytes isolated from f f of the patient group (mean ± sd ; 0.42x106 ±
0.41 x106 leukocytes) and the control group (0.25x106 ± 0.21 x106 leuko-
cytes).
During oocyte retrieval also a peripheral blood sample of each patient
was taken. Peripheral blood mononuclear cells (pbmc) were isolated
from these samples by Ficoll-Hypaque density centrifugation (Lympho-
prep, Nycomed, Oslo, Norway). The leukocyte fraction was washed
twice in pbs and counted. 
Flow cytometric labeling and analysis
Cells were phenotypically analyzed by a one-step triple labeling proce-
dure. 5x104 cells were stained directly using a combination of cd3-f i tc/
cd45-pe (Dako, Glostrup, Denmark)/cd56-Cy5 (Coulter Immunotech,
Marseille, France), and cd16-f i tc (Dako, Glostrup, Denmark)/cd3-
pe/cd56-Cy5. 
The follicular lymphocytes were analyzed blinded with regard to the
origin of the samples. Analysis was as follows: a gate was set around the
f f nkdim cell s incr e a sed in idiopathic inf ertili t y
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Figure 1. (A) Dot plot showing forward and site scatter of mononuclear cells present in FF. A
gate was set around the living lymphocytes for analysis of the T, NK and NK-T cells. 
(B) Fluorescence histogram of the CD56 expression level (CD56dim, CD56bright) of CD45+ leuko-
cytes in FF of a patient with male factor infertility determined by ﬂow cytometry. 
(C) FACS plot showing CD45+ leukocytes double-stained for CD16 and CD56. A gate was set
around the CD3- population to exclude NK-T cells. The (CD3-)CD16+CD56dim (M) and (CD3-)
CD16-CD56bright NK cell (N) subpopulations are indicated. Data from one representative FF of
the same patient as in Fig. 1A are shown.
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live lymphocyte population, as indicated by Propidium Iodide (pi , 5
mg/ml) staining, in a forward and side scatter dot plot (Fig. 1a). Backgat-
ing on cd3 and cd56 conﬁrmed that practically all lymphocytes were
located in the gate. The percentage of nk , nkt and T cells were mea-
sured, as well as the intensity of ﬂuorescence. 
The cd45 marker was used to identify the total leukocyte population
in the gate, T cells were deﬁned as cd3+ cells, nk cells as cd56+cd3-
cells and nkt cells as cd3+cd56+ cells. Two distinct subsets of nk cells
were identiﬁed by cell surface density of cd56 and the presence of cd16
antigen, i.e. cd16-cd56bright and cd16+cd56dim (Fig. 1b and c). Isotype
matched antibodies were used to deﬁne marker settings (Dako,
Glostrup, Denmark and Immunotech, Marseille, France).
The samples were run on a Coulter Epics x l Flowcytometer (Beck-
man Coulter, Fullerton, ca , usa). Analysis of the data was performed
using Coulter Epics Expo 32 software (Beckman Coulter, Fullerton, ca ,
usa).
f f nkdim cell s incr e a sed in idiopathic inf ertili t y
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Statistical methods
nk , nkt and T cell numbers were expressed as a percentage of the num-
ber of cd45+ cells. Multiple follicles were sampled from a single patient.
The variation in lymphocyte levels obtained from a single patient was
signiﬁcantly smaller than the variation observed between patients,
allowing us to average lymphocyte levels of each follicle obtained from
one patient. The t-test for independent samples was used, after a log-
transformation if appropriate, to test for statistical signiﬁcant differ-
ences in mean values between the idiopathic infertility group and the
control group. Paired student’s t-test was used to compare means
between f f and peripheral blood within patients. The dichotomized
data were analyzed using the χ2-test. P-values ≤ 0.05 were considered sig-
niﬁcant. All analyses were performed two-sided. Statistics Package for
Social Sciences was used.
Results
Distinct lymphocyte levels are observed in FF versus peripheral blood
Signiﬁcant differences in lymphocyte levels were found between follicu-
lar ﬂuid and peripheral blood per patient in the control group. The per-
centage of T cells was lower in f f than in peripheral blood, while the per-
centages of cd16-cd56bright nk cells, nkt cells and the remaining
mononuclear cells, i.e. particularly B-lymphocytes and monocytes
(cd45+cd3-cd56-) were signiﬁcantly higher in f f as compared to
peripheral blood (Table 1). Thus, we show that the cellular composition
of peripheral blood and follicular ﬂuid is different, despite possible con-
tamination of f f with ovarian blood lymphocytes. 
A high FF level of CD16+CD56dim NK cells is observed in idiopathic infertility 
From the 40 patients, with a median number of 2 f f per patient, 
11 patients were categorized in the study group (n=22 f f) and 29 in 
the control group (n=41 f f). There was no signiﬁcant difference (p-value
< 0.05) between the study group and the control group with respect to
age, the level of fsh on cycle day 3 and history of previous conception
(Table 2).
In both groups an equal dosage of gnr h analogue and hcg was used
and also the duration of the treatment was equal. The total amount
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recombinant fsh used for multiple follicle growth was 2,590 iu in the
study group and 2,435 iu in the control group. This was not signiﬁcantly
different. 
In the study group 68 % of the oocytes fertilized successfully, while
one patient experienced total fertilization failure. In the control group
successful fertilization took place of 63% of the oocytes. The number of
patients experiencing total fertilization failure in this group was two. 
fcm analysis of follicular ﬂuid revealed a shift from T cells to nk cells
in the idiopathic infertility group as compared to the control group,
exempliﬁed by a signiﬁcantly higher level of nk cells, 20.3% and 13.6%,
respectively (p<0.05, Table 1, Fig. 2). This increase of nk cells was due to
a signiﬁcant relative rise of the cd16+cd56dim nk cell, but not the cd16-
cd56bright nk cell subset. The level of cd3+cd56+ nkt cells and
remaining mononuclear cells, like monocytes and B-lymphocytes, in f f
from the study group was not different from the control group. 
f f nkdim cell s incr e a sed in idiopathic inf ertili t y
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Table 1. Levels of lymphocyte populations in FF and peripheral blood 
Cells FF Peripheral blood
Idiopathic Control Idiopathic Control
(n = 11) (n = 29) (n = 11) (n = 29)
NK cells 20.3 (7.8)a 13.6 (8.1) 18.3 (8.2)b 13.2 (6.4)
(CD45+CD3-CD56+)
CD16+CD56dimNKc 18.9 (7.4)a 13.0 (7.8) 17.0 (8.0) 11.8 (6.2)
CD16-CD56brightNKc 1.5 (0.8) 1.9 (1.8) 1.3 (0.8) 1.3 (0.8)d
T cells 67.2 (10.5) 71.6 (10.5) 72.4 (10.2) 76.0 (8.5)d
(CD45+CD3+CD56-)
NKT cells 3.8 (2.4) 4.1 (4.1) 2.7 (1.6) 3.2 (3.1)d
(CD45+CD3+CD56+)
B-cells, Monocytes 8.8 (4.3) 10.7 (4.4) 6.6 (3.6) 7.7 (4.8)d
etc. (CD45+CD3-CD56-)
Values represent mean (SD) percentage of lymphocytes.
a Signiﬁcant difference (p<0.05) in FF between idiopathic infertility and control group. 
b Signiﬁcant difference (p<0.05) in peripheral blood between idiopathic infertility and 
control group.
c In the control group the levels of the NK cell subsets in FF and PBMC are determined in only
24 patients.
d Signiﬁcant difference (p<0.05) in control group between FF and peripheral blood.
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Table 2 Patient characteristics 
Idiopathic infertility Control group 
Number of patients (n) 11 29
Agea (year) 34.6 ± 4.1 34.0 ± 4.5
FSHa,b (IU/L) 6.8 ± 1.4 7.1 ± 2.5
Primary infertility (%) 58 50
a Values represent mean ± SD.
b on cycle day 3.
P<0.05 P<0.05
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Figure 2. Graphical representation of the relationships between cause of infertility and lym-
phocyte levels in FF and peripheral blood (PBMC). The individually determined NK cell (CD3-
CD56+) level was expressed as percentage of CD45+ cells in patients with idiopathic infertility
(n=11) and in a control group (n=29). The horizontal line shows the mean value. Braces indi-
cate signiﬁcant differences in levels of lymphocyte populations between the idiopathic and
control group and/or between FF and PBMC. 
Also, in peripheral blood of women suffering from idiopathic infer-
tility there was a signiﬁcantly higher level of nk cells observed as 
compared to the control group, 18.3% and 13.2%, respectively (p<0.05,
Table 1, Fig. 2). A trend was observed towards an increase of the
cd16+cd56dim nk cell subset (p=0.08). No difference was observed
between the idiopathic infertility and control group for the nkt cell level
and the level of the remaining mononuclear cells (Table 1).
Discussion
Follicular ﬂuid provides the most suitable microenvironment for the
oocyte and is very likely a key factor in determining growth and develop-
ment of this particular oocyte. Therefore, a disturbance in the cellular
immunity of follicular ﬂuid might affect the oocyte. Our data show that
in follicular ﬂuid from patients suffering from idiopathic infertility a sig-
niﬁcant higher percentage of nk cells was present as compared to folli-
cular ﬂuids from a control group. This higher level of nk cells was exem-
pliﬁed by a relative increase of the cd16+cd56dim nk cell subpopula-
tion. The excess of cd16+cd56dim nk cells in follicular ﬂuid could reveal
a cause for oocyte ‘dysfunction’ and therefore for the idiopathic infertili-
ty in this group.
It is believed that the nk cell subpopulations, cd16+cd56dim and
cd16-cd56bright, represent functionally and phenotypically distinct
subsets of nk cells with unique immunoregulatory roles in vivo.
cd16+cd56dim nk cells have cytotoxic and antibody-dependent cellular
cytotoxic properties, while cd16-cd56bright nk cells mainly produce
immunoregulatory cytokines (21). The cd16-cd56bright nk cell popula-
tion appears in relatively high number at the fetal-maternal interface of
the decidua in the uterus and is strongly associated with successful
implantation and placental maturation (23). The cd16+cd56dim nk cell
subpopulation is negatively associated with reproductive events. Fukui et
al. (24) reported higher cytotoxicity and cd16+cd56dim nk cell count in
endometrial tissue of i v f patients experiencing an abortion compared
to an ongoing pregnancy. As it is clear that nk cells play an important
role in the uterus, it can be expected that nk cells are also playing a role
in the ovary, i.e. follicle, inﬂuencing oocyte quality. Next to the study
described in this paper, only one other study investigated the correlation
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between cause of infertility and nk cell levels in follicular ﬂuid (19). In
contrast to our results, they found no correlation. 
In peripheral blood a high proportion of cd16+cd56dim nk cell pop-
ulation is negatively associated with reproduction, such as implantation
failure during i v f , multiple i v f failures in idiopathic infertile women
and recurrent spontaneous abortion (26-28). In line with the results of
these reports, we found in peripheral blood of patients with idiopathic
infertility a signiﬁcant higher percentage of nk cells. Again, the level of
cd16+cd56dim nk cells (17.0%) in this group was higher, albeit not sig-
niﬁcantly, as compared to the control group (11.8%, P=0.08). So, also on
systemic level we observed an altered lymphocyte proﬁle in idiopathic
infertility, but these differences were less outspoken. A generalized alter-
ation in the cellular immunity of patients with idiopathic infertility could
also lead to poor fertilization rates or perhaps poor implantation rates.
We found no signiﬁcant difference in the absolute number of leukocytes
in follicular ﬂuid between the patient group and the control group (mean
± sd is 0.42x106 ± 0.41 x106 and 0.25x106 ± 0.21 x106 leukocytes, respec-
tively) when counted by light microscopy using a counting chamber.
This suggests that there is not just a relative increase in nk cells but also
an increase in the absolute number of cd16+cd56+ nk cells in the folli-
cles of idiopathic patients. Yovel et al. (29), have shown that during the
periovulatory phase of the menstrual cycle there is an increase in the
number of nk cells in peripheral blood. Further studies using quantita-
tive ﬂowcytometric analysis with beads for standardization (as used by
Yovel et al.(29)) will have to conﬁrm the increase in the absolute number
of nk cells in the follicles of patients suffering from idiopathic infertility.
We observed a quantitative difference in the levels of various lympho-
cyte populations between f f and peripheral blood, although the possi-
bility that a part of the lymphocytes we found in f f are derived from
blood of the local circulation of that particular follicle can not be exclu-
ded. Piccinni and co-workers (30) reported also a qualitative, tissue-spe-
ciﬁc difference in functionality between lymphocytes present in the
cumulus cells of a follicle, producing a different cytokine amount and
proﬁle, as compared to peripheral blood lymphocytes. The observed dif-
ferences raise the question whether the lymphocytes present in follicular
ﬂuid originate from a distinct population or are recruited from the
peripheral blood circulation. It might be that these peripheral lympho-
cytes home to the follicle where they may undergo tissue-speciﬁc differ-
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entiation. It is known that nk cells express a variety of adhesion mole-
cules and chemokine receptors such as ccr2 and ccr5 (31) while follic-
ular ﬂuid is known to contain different chemoattracants such as il-8 and
mcp1 (32;33). In addition cytokines present in follicular ﬂuid may play a
role in activation or differentiation of lymphocyte subsets. It has for
example been shown that the presence of il-12 in follicular ﬂuid, a
cytokine that is capable of activating nk cells, is associated with a nega-
tive outcome in i v f treatment (32). 
A low fertilization rate and subsequent high number of total fertiliza-
tion failures is one of the most speciﬁc features of i v f treatment of
patients with unexplained infertility (3;34) and is a manifestation of
abnormal gamete interaction. In our clinic the frequency of total fertil-
ization failure in patients with idiopathic infertility was 16% compared
to 5.5% in the control group (p<0.0001). Similar data have been reported
by others (3;4;35;36). Oocyte dysfunction was suggested to account for
total fertilization failure in the idiopathic infertility group by Gabrielsen
et al. (37). Hull and colleagues (6) demonstrated, by using donor semen,
that in the unexplained infertility group both subtle sperm dysfunction
as well as impaired function of the oocyte is responsible for the poor fer-
tilization rate in this patient group. Concerning our study, it can be spec-
ulated that the altered lymphocyte proﬁle, i.e. a high level of
(cd16+cd56dim) nk cells, observed in follicular ﬂuid of patients suffer-
ing from idiopathic infertility could be responsible for impaired oocyte
maturation and fertilization. However, the functional role of these cells
was not determined, because adequate numbers of cells could not be
recovered.
In conclusion, the proportion of cd16+cd56dim nk cells in follicular
ﬂuid of women suffering from idiopathic infertility is signiﬁcantly high-
er than in controls. Whether idiopathic infertility is itself a cause or con-
sequence of the altered immune cell composition of follicular ﬂuid
remains unclear and needs to be explored. 
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Abstract 
The effects of hormone stimulation for i v f treatment on endometrial
receptivity remain controversial. Since cd56bright nk cells in the endo-
metrium positively contribute to implantation and decidualization, while
cd56dim nk cells are negatively associated with reproduction, shifts in
the balance between those cells will affect receptivity. Therefore, we
compared the leukocyte composition in the endometrium of i v f women
(n=20) with non-pregnant women (n=18) in a natural cycle, as a para-
meter for endometrial quality. Biopsies were obtained seven days after
ovulation. Histological dating of the endometrium showed no increased
endometrial advancement after i v f treatment as compared to the 
control group. Flow cytometric analysis of leukocyte subsets showed that
hormonal stimulation positively affected the cd56bright/ cd56dim ratio
in the endometrium by a relative decrease in the cytotoxic cd56dimcd16+
nk cell numbers. The relative number of T cells remained unaffected,
while the number of non-T and non-nk cells (i.e B-cells and macro-
phages) was higher in the i v f group. These effects were restricted to the
endometrium and not observed in peripheral blood. Within the
cd56bright population we could identify a distinct subset of nk cells
(cd56superbright) that was unique for the endometrium. We conclude 
that hormonal stimulation for i v f treatment positively affects the
cd56bright/ cd56dim ratio of the endometrium during the window of
implantation and does not affect endometrial advancement. 
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Introduction
Ovarian stimulation for i v f treatment results in supraphysiological con-
centrations of sex steroids during the follicular and luteal phase of the
menstrual cycle. The effect on endometrial receptivity remains contro-
versial. Both positive and negative effects on pregnancy rates after i v f
have been reported (1-4). 
To date there are limited means to deﬁne endometrium quality. One
parameter is the histological maturation of the endometrium in relation
to the menstrual date. It has been stated that extreme endometrial
advancement (> 2 days) results in lower pregnancy rates (5-7). Of interest
with regard to i v f is that high levels of progesterone were found to be
associated with advanced endometrial histology (8-10), dated by criteria
of Noyes et al. (11).
Based on recent insights in nk cell function, the leukocyte composi-
tion in the endometrium could well be considered an alternative parame-
ter for endometrial quality. During the menstrual cycle uterine nk cells
increase dramatically in number after ovulation and reach a peak in the
late secretory phase. In pregnancy their numbers remain high during
early gestation, around 70% of the stromal leukocytes, and they come
into close contact with invading extravillous trophoblast cells (5;10;12).
The localization and the large numbers of nk cells found in the decidua
during pregnancy suggest an important role in the decidualization (13).
The uterine nk cells (unk) that are imputed to play an important role
in implantation have a phenotype that differs from most peripheral
blood nk cells. These so called cd56bright nk cells express the nk cell
marker cd56 at high levels and lack the marker cd16. These nk cells
have low cytotoxic activity but are potent producers of a variety of
immunoregulatory cytokines and angiogenic growth factors contribu-
ting to endometrial angiogenesis (14-16). In contrast, most peripheral
blood nk cells, but also a small part of the uterine nk cell fraction, is of
the cd56dimcd16+ phenotype with high cytolytic activity and low
cytokine production(15). This cytotoxic cd56dim nk cell population is
negatively associated with pregnancy outcome (17-20).
Activation of nk cells is tightly regulated by a set of activating and
inhibitory receptors on the cell surface. These receptors interact with
hl a molecules expressed on the invading trophoblast (such as hl a- c ,
hl a-e and hl a- g) and thereby affect cytokine production and cytoly-
u t er ine nk cell popul ation a nd hor mone t r e at men t
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tic activity of maternal unk cells (21-24). It is believed that each individ-
ual nk cell and the nk cell subsets expresses a unique combination of
natural killer cell receptors depending on their functional role.
During the menstrual cycle as well as throughout pregnancy the
leukocyte numbers vary, therefore an interaction with sex steroids is sug-
gested, although it is not clear yet whether this is a direct or an indirect
mechanism. DeLoia et al. have shown that the total number of lympho-
cytes in endometrium as well as in peripheral blood, particularly the nk
cells, increases under inﬂuence of supraphysiological estrogen levels (25).
To determine the inﬂuence of ovarian stimulation on shifts in
endometrial leukocyte populations, and in particular the nk cell subsets,
we compared leukocyte populations in the endometrium of i v f patients
with naturally cycling women during the window of implantation. By
analyzing shifts in the beneﬁcial cd56bright nk cells and the harmful
cd56dim nk cells, we want to answer the question whether hormonal
stimulation during i v f treatment improves or deteriorates the quality of
the endometrium.
Materials and methods
Patients
In the study group (i v f group), endometrial tissue was obtained from 20
women participating in an i v f/icsi program. These 20 women had no
embryo transfer (et). et was omitted due to total fertilization failure (9
with male factor infertility, 7 with idiopathic infertility, 3 with tubal fac-
tor infertility, 1 with polycystic ovary syndrome). In 1 case no embryos
were transferred due to severe ovarian hyperstimulation syndrome. In 16
patients i v f was carried out and 4 patients were treated by intracyto-
plasmic sperm injection (icsi).
In the control group endometrial biopsies were obtained in a natural
cycle from 18 non-pregnant women. These women had a regular cycle.
They had a partner with severe male infertility and were recruited from
the waiting list for icsi . One woman was a healthy volunteer with no
history of subfertility. Characteristics of both groups are summarized in
Table i . 
All women gave informed consent according to the Medical Ethical
Review Committee of the University Medical Center Nijmegen.
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IVF procedure
Pituitary down-regulation (long protocol) was achieved using a gnr h
analogue (Decapeptyl®; Ferring, the Netherlands). Multiple follicular
stimulation was realized by recombinant follicle-stimulating hormone
(Puregon®; Organon, Oss, the Netherlands). Thirty-six hours after hcg
injection (Pregnyl®; Organon, Oss, the Netherlands) we performed
transvaginal oocyte retrieval under systemic analgesia (10 mg oxazepam
orally and 1mg alfentanyl, i.v.). The retrieved oocytes were inseminated
or icsi was performed according to the method described by Van
Steirteghem and colleagues (26). The morning following injection or
insemination fertilization of the oocytes was judged. The luteal phase
was supported by three doses of progesterone (200 mg; Progestan®;
Nourypharma, Oss, the Netherlands) intravaginally daily from the day
of oocyte retrieval until the day of the endometrial biopsy. 
Endometrial biopsy
In the i v f group endometrial tissue was obtained by a microcurettage
using a Pipelle de Cornier (Prodimed, Neuilly-en-Thelle, France) six
days after oocyte retrieval. In the control group an endometrial biopsy
was taken seven days after the endogenous luteinising-hormone (lh)
surge was detected, tested daily, with a urinary semi-quantative mono-
clonal-antibody based kit (Clearplan, Unipath Ltd., Bedford, United
Kingdom). Median weight of the biopsies was not signiﬁcantly different
between the i v f group (1.1 g) and the control group (0.7 gram).
Of the ﬁrst three i v f patients and two controls all the collected mate-
u t er ine nk cell popul ation a nd hor mone t r e at men t
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Table I. Patient characteristics
Variable IVF patients (n = 20) Control group (n = 18) 
Age (years) 32.7 (3.1) 32.1 (3.0)
FSH (IU/l) 7.2 (4.6-15.7) 6.7 (4.7-8)
Estradiol (pmol/l) 3700 (940-8400) 560 (300-1200)a
Progesterone (nmol/l) 170 (54-650) 37 (22-74)b
Nulligravida (%) 55 83
Nullipara (%) 60 88
Age is given as means ± SD; FSH, estradiol and progesterone are given as median (range).
a P<0.05.
b P<0.05.
rial was used immediately for isolation of uterine mononuclear cells. In
the following 17 biopsies in the i v f group and 16 biopsies in the control
group a part of the tissue was ﬁxed by formaldehyde and used for histo-
logical examination. Endometrial histology was analyzed by Noyes crite-
ria (11) by a single observer who was blinded to the treatment group. In
the i v f group the day of oocyte retrieval was considered the day of ovu-
lation (day 0), while in the control group day 0 was deﬁned 24 hours after
the lh surge. The endometrium was considered out of phase if there was
a discrepancy of three days or more between the observed and expected
endometrial maturation, as this was the published margin of error
described by the Noyes criteria (11). Glandular-stromal dissociation 
was observed in one i v f-patient. Peripheral blood samples were drawn
immediately before the endometrial biopsy was taken to assess lym-
phocyte populations and determination of estradiol and progesterone
levels.
Isolation of uterine mononuclear cells 
Endometrial tissue was suspended in a very small volume of r pmi-1640
with glutamax supplemented with pyruvate containing 100 u/ml peni-
cillin, 100 mg/ml streptomycine (all from Gibco, Paisley, uk) and10%
heat inactivated pooled human serum and then disrupted very carefully
by mincing between two scalpels. This was performed very thoroughly
until the suspension only contained fragments of maximally 0.5 mm.
The cell suspension was then ﬁltered through a 70 µm sieve while gently
pushing with the back of a plunger. Living mononuclear cells were isola-
ted from the cell suspension by density centrifugation (Lymphoprep,
Nycomed, Oslo, Norway) yielding a median of 1.0x106 mononuclear
cells per biopsy in the i v f group and 0.5x106 in the control group (p=ns).
Median weight of the biopsies was not signiﬁcantly different between
the i v f group (1.1 g) and the control group (0.7 gram). pbmc were isolat-
ed from blood samples by density centrifugation (Lymphoprep,
Nycomed, Oslo, Norway).
Monoclonal antibodies and ﬂow cytometry 
Cells were phenotypically analyzed by a direct one-step triple labeling
procedure. The following monoclonal antibodies were used: cd3 (clone
uch t1) conjugated with ﬂuorescein isothiocyanate (f i tc) or phyco-
erythrin (pe), cd16 (clone dj130c) conjugated with f i tc , cd45 (clone
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t29/33) conjugated with pe all from Dako (Glostrup, Denmark), cd56
(clone nk h1) conjugated with pe -cytochrome 5 (cy5), cd158a (clone
eb6) conjugated with pe , 158b (clone gl183) conjugated with pe ,
nkg2a/cd94 (clone z199) conjugated with pe all from Coulter
Immunotech (Marseille, France). The ilt-2 antibody was a kind gift
from Dr. López-Botet (Madrid, Spain) and was stained indirectly using 
a ga m-pe antibody. The samples were run on a Coulter Epics x l Flow-
cytometer (Beckman Coulter, Fullerton, ca , usa), and 10,000 events
were collected based on live leukocyte gating as indicated by propidium
iodide (pi , 5 mg/ml) in a forward and side scatter dot plot. Backgating 
on cd3 and cd56 conﬁrmed that practically all lymphocytes were 
located in the gate. Isotype matched antibodies were used to deﬁne
marker settings. Analysis of the data was performed using Coulter Epics
Expo 32 software (Beckman Coulter, Fullerton, ca , usa). cd45 was
used as common leukocyte marker and T cells were identiﬁed as
cd3+cd56-cells, nk cells as cd56+cd3- cells and nkt cells as
cd3+cd56+ cells. 
Immunohistochemistry
Formalin-ﬁxed and parafﬁn-embedded endometrial biopsies were used.
From 17 i v f patients and 16 controls a four-micrometer thick parafﬁn
section was stained using the monoclonal antibody cd45r b , clone
pd7/26 (Dako, Denmark). The tissue sections were stained with the
recently developed and highly sensitive, speciﬁc and ready to use Pow-
erVision kit (ImmunoLogic, the Netherlands) in a dilution 1:800 in pbs .
cd45+ leukocytes were scored by counting 5 randomly selected micro-
scope ﬁelds at a magniﬁcation of x400. The average number of cells per
x400 ﬁeld is reported. The slides were scored by three investigators
blinded to the identity of the samples. 
Statistical analysis
nk , nkt , T cell, cd45+cd3-cd56- cell numbers and the nk subsets
were expressed as a percentage of the number of cd45+ cells. The
Mann-Whitney-U test was used to test for statistical differences in mean
percentages of leukocyte populations and fsh value between the i v f
and the control group. The t-test for independent samples was used, after
log-transformation if appropriate, to test for statistical signiﬁcant differ-
ences of mean values of age, estradiol and progesterone levels between
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the i v f and control group. All tests were two-tailed with a conﬁdence
interval of 95% (p<0.05). All tests were performed using the Statistical
Package for Social Sciences.
Results
IVF treatment does not result in endometrial advancement
According to expectation, the median levels of estradiol and proges-
terone in peripheral blood were signiﬁcantly higher in the i v f group as
compared to the control group (3700 pmol/L and 170 nmol/L versus 560
pmol/L and 37 nmol/L, respectively (p<0.0001). There was no difference
in age, obstetrical history and basal fsh level between the i v f and con-
trol group (Table i).
Endometrial histology can be used as a measure of endometrial quali-
ty since extreme endometrial advancement (3 days or more) results in
lower pregnancy rates. To determine whether hormone treatment affec-
ted endometrial advancement, biopsies were scored according to the cri-
teria of Noyes (11). There was no signiﬁcant difference in number of
patients with endometrial advancement between the i v f group and the
control group (37 % and 19%, respectively, Figure 1). Thus, hormone
treatment did not affect endometrial advancement. 
Hormone treatment shifts the balance away from the cytotoxic
cd56dimcd16+ population
Another way to deﬁne endometrial quality could be by deﬁning the
leukocyte composition of the endometrium and more particular nk cell
ratios. During implantation cd56bright nk cells are imputed to play an
important role while cd56dim nk cells are mostly negatively associated
with reproduction. Therefore, we determined absolute numbers of
leukocytes in endometrial biopsies and more importantly, we assessed
leukocyte subpopulations by ﬂowcytometric analysis as a measure of the
total population of leukocytes (i.e. cd45+). 
cd45 staining of parafﬁn sections of endometrial biopsies showed
that hormone treatment resulted in higher leukocyte levels (Figure 2).
The average number of leukocytes in the i v f group was 5.7 per x400
ﬁeld compared to 2.7 in the control group (p<0.05).
We found that the proportion of the uterine cd56dimcd16+ nk cells
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was signiﬁcantly lower in i v f patients as compared to the controls (6.9%
and 13.7%, respectively, p<0.01, Table ii , Figure 3). The proportion 
of cd56brightnk cells (cd56+/cd16-) was not different between 
i v f patients and controls in the uterus (28.8% and 33.5% respectively,
Figure 3). These data indicate a shift in the ratio towards the beneﬁcial
cd56bright nk cells and away from the harmful cd56dim nk cells. 
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Figure 1. Endometrial maturation. The data are illustrated as a frequency distribution of the
endometrial glandular dating expressed as observed (Noyes’ criteria) minus expected (calcu-
lated from day of ovulation) endometrial maturation in days per patient in the IVF group and
the control group.
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Figure 2. The endometrium of hormone-treated women contains a higher number of leuko-
cytes. The absolute number of CD45+ cells per x400 ﬁeld was scored per patient by counting
ﬁve randomly selected microscope ﬁelds at a magniﬁcation of x400. The average number of
cells per x400 ﬁeld is reported.
Table II. Levels of lymphocyte populations in endometrium and peripheral blood 
Endometrium Peripheral blood
Cells (%) IVF Control IVF Control
(n = 20) (n = 18) (n = 15) (n = 16)
T cells 33.4 36.1 73.3 69.1
(CD45+CD3+CD56-)
NKT cells 3.3 5.1 4.0 3.7
(CD45+CD3+CD56+)
NK cells
CD16+CD56dimNK 6.9 13.7a 12.3 13.1
CD16-CD56brightNK 28.8 33.5 1.3 0.9
CD45+CD3-CD56- 27.6 11.6b 9.1 13.2
All values are given as mean percentage ± SD.
a p<0.01, in endometrium.
b p<0.001, in endometrium.
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Figure 3. The proportion of cytotoxic CD56dim NK cells is lower in the endometrium of hor-
mone-treated women. NK cell populations in endometrium in all patients (upper panel) and
in patients in the mid-secretory phase (lower panel) derived from hormone-treated women
(IVF patients) compared to control women. Cells were analyzed by ﬂow cytometry, gating on
the living lymphocytes. Data are expressed as percentage of the whole leukocyte population
(i.e. CD45+). CD56dim = CD16+/CD56+; CD56bright = CD16-/CD56++. * P < 0.05. ** P < 0.01. All
tests were performed by the Mann-Whitney-U-test.
The relative number of uterine T cells remained unaffected by ovarian
stimulation (31.7% and 36.1%, respectively). The level of cd45-cd3-
cd56- cells, i.e. mainly monocytes and few B-cells was signiﬁcantly
higher in the endometrium of i v f patients as compared to the control
group (27,6% and 11.6%, p<0.001, Table ii). 
Similar results were obtained when the analyses were limited to
patients that were shown to be in the mid-secretory phase, seven in the
i v f group and 10 in the control group (Figure 1). The percentage
cd56brightnk cells was signiﬁcantly lower in the i v f-group as com-
pared to the control group (6.5% and 15.1%, p<0.01, Figure 3) while the
percentage monocytes was increased (23% and 11%, p<0.005). No differ-
ences were observed in proportion of cd56brightnk cells (21% and 28%),
T cells (35% and 40%) and nkt-cells (3.5% and 5.1%) between i v f
patients and controls, respectively. 
Since the i v f group contained patients with different causes of infer-
tility we also performed a subgroup analyses to exclude that the observed
nk shift was a result of a disturbed endometrial function in a subgroup
of patients. Similar results, i.e. lower levels of cd56dim nk cells, were
obtained when analysing i v f patients with male factor versus controls
infertility (p<0.02) and patients with idiopathic infertility versus con-
trols (p<0.02).
In peripheral blood there is no shift in the cd56dim/cd56bright ratio 
Next we determined whether hormone treatment induced a systemic
shift in the cd56dim/cd56bright ratio or whether this was a purely local
phenomenon i.e restricted to the endometrium. Therefore, the leukocyte
composition of peripheral blood of i v f patients and control women was
compared. 
First, as expected, in these women the leukocyte composition of
peripheral blood was shown to be different from the endometrium. In
peripheral blood the nk cell number was relatively low as compared to
the T cell number (approximately 14% and 70%, respectively) and most
of the nk cells were of the cd56dim phenotype (90%).
Second, when comparing peripheral blood samples of i v f patients
and controls, no differences in the proportion of cd56dim or cd56bright
nk cells were observed (Figure 4 and Table ii). Neither were there differ-
ences in T cell numbers, nor in number of cd45+cd3-cd56- cells. Thus,
the effect of hormone treatment on the shift in the cd56dim/ cd56bright
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ratio appears limited to the endometrium and is not observed in periph-
eral blood. 
Endometrium contains a unique cd56superbright population
When analyzing the uterine nk cell populations, we observed a double
ﬂuorescence peak of cd56 expression within the cd56bright nk cell
population. One subset had a similar expression of cd56 as peripheral
blood cd56bright nk cells and the second one had a clearly higher expres-
sion of the marker cd56 (Figure 5). Based upon this ﬁnding, we deﬁned
three distinct nk cell populations in the uterus, i.e. cd56dim, cd56bright
and cd56superbright. The cd56superbrightcd16- was unique for the uterus
and was not found in peripheral blood (Figure 5). 
To further characterize whether these uterine cd56superbrightcd16-
nk cells differed from uterine cd56bright nk cells, we determined the
expression of various nk cell receptors that are involved in interactions
with hl a molecules on trophoblast cells, namely cd158a and cd158b
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Figure 4. In peripheral blood there is no shift in the CD56dim/CD56bright ratio. NK cell popula-
tions in peripheral blood derived from hormone-treated women (IVF patients) compared to
control women. Cells were analyzed by ﬂow cytometry, gating on the living lymphocytes.
Data are expressed as percentage of the whole leukocyte population (i.e. CD45+). CD56dim =
CD16+/CD56+; CD56bright = CD16-/CD56++.
that bind to hl a- cw, ilt-2 that binds to hl a- g and nkg2a that binds
to hl a-e . The data show, that the cd56superbright cells do indeed differ
from cd56bright nk cells with respect to nk cell receptor expression
(Figure 6). A signiﬁcantly higher number of cd56superbright nk cells
express cd158a, cd158b, ilt2 and nkg2a as compared to cd56bright
nk cells (Figure 7, p<0.05). Also, the level of expression of nkg2a was
signiﬁcantly higher in the cd56superbright nk cell population as com-
pared to cd56dim and cd56bright nk cells. There was a trend towards a
higher level of cd158a, cd158b and ilt2 expression in the cd56super-
bright nk cells as compared to the cd56bright nk cells (Figure 7).
In conclusion, many cd56superbright nk cells express nk cell recep-
tors and practically all cells of this subset are nkg2a positive. These cells
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Figure 5. The endometrium contains a population of CD56superbright cells that is not present in
peripheral blood. CD56dim is deﬁned as CD16+/CD56+; CD56bright is CD16-/CD56++and
CD56superbright is CD16-/CD56+++. UMC = uterine mononuclear cells; PBMC = peripheral blood
mononuclear cells. 
were only found in the endometrium and not in peripheral blood. In con-
trast, only few uterine cd56bright nk cells express the nk cell receptors
cd158a, -b and ilt2, although the majority of cells (80%) are nkg2a
positive. This pattern is comparable to peripheral blood cd56bright nk
cells. 
There was no signiﬁcant difference in cd56bright nk cell number
between the i v f and control group (14.8% and 19.7%, respectively). This
also applies for the number of cd56superbright nk cells between the i v f
and control group (13.8% and 13.8%, Figure 8). 
Discussion
A critical event at the onset of a pregnancy is the implantation of the
embryo in the uterus. At that time there is believed to be an active dia-
logue between fetal trophoblast cells and uterine lymphocytes that are
present in the endometrium. During i v f-treatment a patient is exposed
to supraphysiological levels of sex steroid hormones either directly by
administration (progesterone) or indirectly due to multiple follicle
growth (estradiol and progesterone). In the current study, we deter-
mined whether treatment with exogenous hormones affected the com-
position of the lymphocyte populations in the endometrium during the
window of implantation. We paid special attention to the uterine nk cell
subset, since it is thought that nk cells play an important role in human
reproduction (27). Our data show that ovarian stimulation leads to a shift
in the ratio of cd56dim/ cd56brightcd16- nk cells, i.e. a relative decrease
in the cytotoxic cd56dim/cd16+ nk cell population. 
From literature it is known, that the cd56dimcd16+ nk cell subset is
negatively associated with reproductive events (17-20;28). Fukui et al. (17)
reported higher cytotoxicity and cd56dimcd16+ nk cell count in
endometrial tissue of i v f patients experiencing implantation failure or
an abortion compared to an ongoing pregnancy. In contrast, the
cd56brightcd16- nk cell population is associated with successful
implantation and placental maturation (13) and is supposed to be crucial
at the time of implantation by controlling trophoblast invasion and the
production of immunoregulatory cytokines (24;29). An important func-
tion of the invading trophoblast cells is vascular transformation of the
spiral arteries to provide an adequate blood supply to the fetus and pla-
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Figure 6. CD56superbright NK cells differ from CD56bright NK cells with respect to number and
expression levels of NK cell receptors. Uterine and peripheral blood mononuclear cells were
stained with CD56-PC5 and CD3-FITC in combination with CD158a, CD158b, ILT2 or NKG2A
labelled with phycoerythrin. Double staining of CD56 and the different NK cell receptor is
shown for a single representative example. CD56+, CD56++ and CD56+++ represent CD56dim NK
cells, CD56bright NK cells and CD56superbright NK cells respectively.
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centa. Our data suggest that hormone treatment shifts the balance
towards the cd56bright cells and away from the cytotoxic cd56dim nk
population and would thus positively affect endometrial quality.
The shift in nk cell subpopulations does not appear to be due to dif-
ferences in endometrial maturation between hormone-treated women
and control women. First, we found no signiﬁcant difference in histolo-
gical dating between those two groups. Second, when the analyses were
limited to women that were in the mid-secretory phase, similar results
were obtained, i.e. a decrease in the proportion of cd56dim nk cells.
We discovered even a third subset of nk cells in the endometrium at
the time that it is receptive for implantation, which has not been
described previously. We showed that, based upon the nk cell marker
cd56 and nk cell receptor expression, the cd56bright population could
be subdivided into two different populations. The so-called cd56super-
bright cells, which are cd16 negative, were detected only in the
endometrium and not in peripheral blood. Furthermore, in contrast to
both uterine and peripheral cd56bright nk cells, a large proportion of
cd56superbright nk cells express nk cell receptors for hl a- c and -g
molecules that are present on the invading trophoblasts. Practically all
cd56superbright express nkg2a at high levels. This latter receptor binds
hl a-e , a non-classical class Ib molecule. These features of cd56super-
bright nk cells suggest different functional properties as compared with
cd56bright cells. Preliminary data that we obtained from a single speci-
men of decidua of a 13-week pregnant woman with a cervix carcinoma
indicate that the cd56superbright nk cell population can also be found in
the decidua. Maybe it is this cd56superbright subset of the cd56bright nk
cells that is responsible for the favorable effects on reproduction as
described above. 
It has been shown by us as well as others that the absolute number of
leukocytes in the endometrium increases under the inﬂuence of sex
steroids (25). This would suggest that the shift in the cd56dim
/cd56bright ratio is caused by speciﬁc recruitment of the less cytolytic nk
cell population. So far the mechanisms behind this speciﬁc recruitment
of leukocyte subsets remains uncertain. Estrogen receptors have been
detected on nk cells (30), although there is some controversy about this
(31). Alternatively, chemokine receptor expression on cd16- cells (32)
and on cd56bright cells and monocytes (Drake et al, 2003) might be
involved in speciﬁc homing to invading extravillous trophoblast cells.
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Figure 7. CD56superbright NK cells differ from CD56bright NK cells with respect to number and
expression levels of NK cell receptors. Upper panel (four graphs) represents the percentage of
NK cells expressing a particular receptor expressed as percentage of the total population of
that particular NK cell (CD56dim, CD56bright or CD56superbright). Lower panel (four graphs) rep-
resents expression level per NK receptor positive cell (expressed as mean ﬂuorescence intensi-
ty). The line represents the mean value. CD56dim is deﬁned as CD16+/CD56+, CD56bright is
CD16-/CD56++ and CD56superbright is CD16-/CD56+++. Gating for the CD56superbright population
was based upon maximal Cy5 signal found in the peripheral blood NK cell population.
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Differential expression of chemokine receptors by human cd56bright
and cd56dim nk cells indeed suggests that these subsets may home to
different microenvironments in vivo (33). 
A feature of endometrial quality is the receptivity determined by his-
tological dating of endometrial tissue by criteria of Noyes et al. (11). Biop-
sies, in natural as well as in ovarian stimulated cycles, which are out of
phase by three days or more, are associated with a reduction in clinical
pregnancy rates (5;7;34). In contrast to others (8;9;35), we did not ﬁnd
signiﬁcantly more cases of endometrial advancement in the i v f group as
compared with the control group, although we are aware of the small
numbers of biopsies investigated. So, we suppose that in our study the
supraphysiological sex steroid concentrations have no deleterious
impact upon implantation.
In summary, we conclude that hormonal stimulation for i v f treat-
ment positively affects the cd56bright/ cd56dim ratio of the endometri-
um during the window of implantation by a relative decrease in the cyto-
toxic cd56dimcd16+ nk cell number. Further studies are needed to
investigate the relationship between nk cell subset composition of
endometrium and pregnancy rates after ovarian stimulation in order to
improve stimulation protocols in assisted reproductive technology. 
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Figure 8. CD56superbright NK cell levels do not differ between hormone-treated women and
controls. Cells were analyzed by ﬂow cytometry, gating on the living lymphocytes. Data are
expressed as percentage of the whole leukocyte population (i.e. CD45+). CD56bright = CD16-
/CD56++ and CD56superbright = CD16-/CD56+++. Gating for the CD56superbright population was
based upon maximal Cy5 signal found in the peripheral blood NK cell population.
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Abstract
The expression of hl a- g by invading trophoblasts suggests a role for
this molecule in embryo implantation. Putative targets for hl a- g are
the uterine nk cells (unk) that are abundantly present at the time of
implantation. Since nk cells are potent producers of a variety of
cytokines, interaction with hl a- g may result in the production of
cytokines involved in trophoblast differentiation or tissue remodelling.
In the present study we investigated the effect of membrane-bound
hl a- g (mhl a- g) on the uterine mononuclear cell population (umc)
as a whole and on unk cells in particular by measuring proliferation and
cytokine production (if n-γ / v egf/ lif/ il-3). Uterine cells were isola-
ted from endometrium of non-pregnant woman at the time that the
endometrium is thought to be receptive to implantation, and then co-
cultured with hl a-class i -/hl a-class ii+ 721.221 b-lcl cells transfec-
ted with mhl a- g . hl a- g suppressed the alloproliferative response of
unfractionated umc to 721.221 cells. Also, if n-γ and il-3 production
was strongly reduced. In contrast, puriﬁed unk cells were stimulated by
mhl a- g . Proliferation as well as if n-γ production was increased after
co-culture with mhl a- g transfected 721.221 cells. hl a- g stimulated
v egf production by umc as well as puriﬁed unk cells. lif-levels were
below the detection level of our elisa . In conclusion, our data show that
mhl a- g stimulates proliferation and cytokine production by nk cells,
while downmodulating the response of unfractionated umc . 
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Introduction
Implantation of the embryo in the uterus is a critical event in human
pregnancy. During this event, foetal trophoblast cells attach to and
invade the maternal decidua, altering the tissue in such a way that an
appropriate blood ﬂow to the placenta can develop. A typical characteris-
tic of the invading trophoblasts is the expression of the non-classical
mhc molecule hl a- g , besides hl a- c and hl a-e (1;2). 
hl a- g , in contrast to the classical hl a class ii molecules, has a
restricted tissue distribution and low polymorphism. Expression is lim-
ited to thymic epithelial cells and to the foetal-maternal interface, where
it is expressed by invasive trophoblast cells. Also, it is found to be present
in amniotic ﬂuid. Recent data suggest that hl a- g expression is also
induced in peripheral organs/tissues under certain pathological condi-
tions (3;4). Seven splice variants of hl a- g exist, four membrane-bound
forms and three soluble forms. Although there still is debate on the
expression and function of the different isoforms, it is well established
that the full-length membrane bound and soluble forms, hl a- g1 and 
-g5 respectively, are expressed, stable and functionally active (5-7). So far,
three different receptors have been identiﬁed that can putatively interact
with hl a- g , i.e., ilt2 (8;9), ilt4 (8) and k ir2dl4 (10;11). These
receptors are present on the different leukocyte populations that are pre-
sent in the endometrium, i.e. nk cells (k ir2dl4 and ilt2), subsets of 
T cells (ilt2), B-cells (ilt2 and ilt4) and monomyelocytic cells (ilt2
and ilt4). 
There is in vitro evidence that hl a- g has an immunomodulatory
effect on peripheral lymphocytes. The membrane-bound form has been
shown to protect cells from lysis by nk cells (12), it inhibits the allo-pro-
liferative response in a mixed lymphocyte culture (13;14) and affects
cytokine production (15). 
In the endometrium the main population of leukocytes present are
the nk cells. Their number gradually increases during the menstrual
cycle, peaking at the time of implantation. When pregnancy occurs, the
nk cells remain in the decidua and come into close contact with the
invading trophoblast. Their abundant presence at the time of implanta-
tion and the expression of receptors for hl a- g suggest a role for nk
cells by modulating implantation by interaction with hl a- g , present on
the invading trophoblast.
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Two functions of hl a- g in modulating uterine nk cells have been
postulated. First, they might protect trophoblasts from nk cell mediated
lysis (12). More recent data however suggest that this protection appears
to be largely independent of hl a class i expression (2;16). Therefore, the
second option is more likely, which is to modulate production of
cytokines and angiogenic factors by uterine nk cells in order to alter tro-
phoblast invasion and differentiation or tissue remodeling (17). This
would suggest a more ﬁnely tuned modulatory function for hl a- g
rather than a strictly inhibitory.
Cytokines that are produced by nk cells and/or T cells and that might
play a role in implantation are if n-γ, vascular endothelial growth factor
(v egf), interleukin 3 (il-3) and leukaemia inhibitory factor (lif). Dur-
ing implantation if n-γ may play a dual role. It has been shown that a
localized production of if n-γ by uterine nk cells is necessary for vascu-
lar modiﬁcation and decidual integrity and thereby contributes to nor-
malcy of pregnancy in mice (18). A more generalized if n-γ response
however is likely detrimental, since this was found to be associated with
pregnancy disorders (19;20). v egf is an important growth factor in-
volved in angiogenesis by affecting endothelial cells (21) and was shown
to be present in endometrium as well as in the decidua during gestation
(22;23). Leukaemia inhibitory factor (lif) has been shown to be an
essential cytokine for implantation in mice (24). In humans lif has been
shown to be produced by unk cells as well T cells (25). il-3 has been
shown to affect trophoblast implantation and development in vitro (26).
In the present study we investigated the effect of membrane-bound
hl a- g on production of these various cytokines and proliferation of the
uterine mononuclear cell population as a whole, and on uterine nk cells
in particular. Since we were interested in cytokine production at the time
of implantation, uterine cells were isolated from the endometrium of
non-pregnant woman during the phase that the endometrium is recep-
tive for implantation, i.e. seven days after the lh surge. 
Materials and methods
Patients
Endometrial tissue was obtained from healthy non-pregnant women or
women participating in an i v f program who experienced total fertiliza-
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tion failure by a microcurettage using a pipelle de cornier (Prodimed,
Reilly-en-Thelle, France) at day seven after the lh surge in a natural
cycle or six days after oocyte retrieval in case of i v f treatment. All 13
women (8 i v f and 5 control) gave informed consent according to the
Medical Ethical Review Committee of the University Medical Center
Nijmegen.
Isolation of uterine mononuclear cells and uterine NK cells
Endometrial tissue (median weight 1 g, 0.2 - 1.2 g) was mechanically dis-
rupted by mincing between two scalpels and then ﬁltered through a
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Figure 1. Flow cytometric analysis of natural killer (NK) cells (CD56) and T cells (CD3) in the 
uterine mononuclear cell fraction directly after isolation from the endometrium biopsy (A)
and after NK cell puriﬁcation (B). Analysis was performed on the living CD45+ cell population.
sieve. Mononuclear cells were isolated from the cell suspension by densi-
ty centrifugation (Lymphoprep, Nycomed, Oslo, Norway) yielding a
median of 1.5x106 mononuclear cells per biopsy (ranging from 0.5 to 3.4
x106). The cellular composition was analyzed by ﬂow cytometry. 
Uterine nk cells were puriﬁed from the umc population by negative
selection (a cocktail of anti-cd3, cd4, cd19 and cd33 antibodies) using
magnetic cell sorting (m acs) according to the manufacturers protocol
(Miltenyi Biotech, Bergisch Gladbach, Germany). Purity of the nk cell
fraction was tested by ﬂow cytometry and varied between 80% and 95%.
In all cases the percentage of T cells was below 2%. One representative
example is shown in Figure 1. 
Flow cytometry
1x105 cells were stained directly using a combination of cd3-
f i tc/cd45-pe/cd56-cy5 or cd16-f i tc/cd3-pe/cd56-cy5. Except
cd56-cy5 (Coulter Immunotech, Marseille, France) all antibodies were
purchased from Dako (Glostrup, Denmark). The samples were run on a
Coulter Epics x l Flowcytometer (Beckman Coulter, Fullerton, ca), and
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Figure 2. Expression of membrane-bound HLA-G in 721.221 cells was conﬁrmed by ﬂow
cytometry using the HLA-G speciﬁc monoclonal antibody MEM-G/9 and 56B. HLA-G speciﬁcity
of the 56B was conﬁrmed by staining HLA-B44 transfected 721.221 cells and HLA-E transfec-
ted 721.221 cells. The grey line represents the isotype control, the dark line represents MEM-
G/9 or 56B staining.
10,000 events were collected based on live lymphocyte cell gating as indi-
cated by Propidium Iodide (pi , 5 mg/ml) staining. Isotype matched anti-
bodies, usually below background staining, were used to deﬁne marker
settings. Analysis of the data was performed using Coulter Epics Expo
32 software (Beckman Coulter, Fullerton, ca , usa).
Monoclonal antibodies and cell lines
The hl a- g speciﬁc antibody 56b was generated by immunization of
Balb/c mice with a peptide corresponding to amino acids 138 to 158 of the
α2 domain of hl a- g (27). hl a- g speciﬁcity was shown by Western
blot and ﬂow cytometry. Flow cytometric analysis of 721.221 cells trans-
fected with hl a- g , hl a-b44 or hl a-e conﬁrmed hl a- g speciﬁcity
and showed no cross-reactivity with hl a-e (Figure 2). Similar results
were obtained with K562 cells transfected with full-length hl a- g or
hl a-e (kindly provided by Prof.Dr. E.H. Weiss, Munich, Germany, data
not shown). The hl a- g speciﬁc antibody mem- g/9 was obtained from
Exbio (Prague, Czech Republic). The hl a-e speciﬁc antibody dt9 was
a kind gift from Dr. V. Braud (Valbonne, France). 
The hl a-a ,-b ,-c and -g deﬁcient B-cell line 721.221 was obtained
from the American Type Culture Collection (atcc , Rockville, md).
721.221 cells were stable transfected by electroporation with the full-
length transcript of hl a- g1 inserted in the pngv1-vector. hl a- g
expression was conﬁrmed by ﬂow cytometry using the hl a- g speciﬁc
monoclonal antibody mem- g/9 or 56b as shown in ﬁgure 2. hl a-b44
transfected 721.221 cells were a kind gift from Dr. H. Dolstra (Nijmegen,
the Netherlands). hl a- g1(eneg)721.221 cells were a kind gift from Dr.M.
López-Botet (Madrid, Spain). These cells have been transfected with an
hl a- g1 cdna that has a mutated signal sequence that does not allow
binding to hl a-e and thus prevents co-expression of hl a-e (28). hl a-
e 721.221 cells contains the hl a-e*0101 gene and the hl a-b8 signal
sequence and were a kind gift from Dr. V. Braud (Valbonne, France).
Cells were continuously kept in culture in r pmi-1640 with glutamax
supplemented with pyruvate containing 100 U/ml penicillin, 100 mg/ml
streptomycin (all from Gibco, Paisley, uk),10% heat inactivated foetal
calf’s serum (fcs) and geneticin (1µg/ml, Gibco, Paisley, UK). Cells were
washed extensively before use in the co-cultures and hl a- g or -b44
expression was checked for by fcm analysis using the monoclonal anti-
body w6/32. 
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Co-cultures 
umc or uterine nk cells were plated at 5x104 cells/well in triplicate in 96-
wells U-bottom microtiter plates (Greiner, Frickenhausen, Germany) in
the presence of irradiated (100 Gy) 721.221 cells or hl a- g transfected
721.221 cells (5x104 cells/well) or hl a-b44 transfected or hl a- g1(eneg)
transfected 721.221. As a control cells were plated in culture medium
alone (r pmi-1640 with glutamax supplemented with pyruvate contain-
ing 100 U/ml penicillin, 100 mg/ml streptomycine (all from Gibco, Pais-
ley, uk) and10% heat inactivated pooled human serum). In case of block-
ing hl a- g , the anti-hl a- g Moab 56B was added to the wells at a con-
centration of 5 µg/ml. An isotype matched irrelevant Moab was used as
negative control. Analysis of the kinetics showed a peak in proliferation
and if n-γ production around day 5. Therefore, after 5 days incubation at
37°c in a humidiﬁed atmosphere containing 5% co2, supernatant was
harvested for cytokine measurements and subsequently 0.5 µCi
[3H]TdR was added to each well. The plates were harvested the follow-
ing day (day 6) using a Micromate 196 harvesting device (Canberra,
Meriden, ct , usa) and counted in the Packard Matrix 96 Direct Beta
counter (Canberra). The results are presented as the mean ± sd from
triplicate wells. 
Enzyme-linked immunosorbent assay (elisa)
Cytokines were measured in cell culture supernatants. if n-γ (Pelikine
Compact human elisa kit, cl b , Amsterdam, the Netherlands), il-3,
v egf (both from Biosource International, Camarillo, usa ,) and lif
(r& d systems, Minneapolis, usa) were measured by sandwich elisa .
The v egf elisa only detects the v egf-165 form and not pigf . The
assays were performed according to the supplier’s manual. The results
were measured photometrically at 450nm using an elisa plate reader
(Titertek Multiskan mcc/340). v egf data were corrected for back-
ground production of v egf by irradiated 721.221 cells or 721.221 cells
transfected with mhl a- g . Data are mean of a triplicate.
Statistical analysis
Differences between groups were analyzed for signiﬁcance (p<0.05) by a
two-sided students t-test or, in case of three sample groups, by a one-way
anova.
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Figure 3. Proliferative response of uterine mononuclear cells (UMC) after co-culture with irra-
diated 721.221 cells or 721.221 cells transfected with membrane-bound HLA-G (A), HLA-
G(Eneg) (B) or HLA-B44 (C). Results show the mean of triplicates and are expressed as mean ±
SD and are a single representative experiment out of four separate experiments.
Results
Membrane-bound HLA-G stimulates proliferation of uterine NK cells
To study the effect of membrane-bound hl a- g on the proliferation of
uterine lymphocytes and in particular uterine nk cells, 721.221 cells
transfected with hl a- g1 were used as stimulator cells in a mixed lym-
phocyte culture. 721.221 cells are hl a-a and -b negative, but hl a class
ii positive and can thus function as allogeneic stimulator cells. The data
show that expression of mhl a- g suppressed the allo-induced prolifera-
tion of umc consisting of nk cells, T cells, B-cells and monocytes/
macrophages (Figure 3a, p<0.0001). In four independent experiments
this inhibition varied from 46 up to 100% as compared to cultures with
non-transfected 721.221 cells. The inhibitory effect of hl a- g could at
least partly be reversed by the addition of the anti-hl a- g monoclonal
antibody 56B to the cultures (Figure 3a). Since the 721.221-hl a- g trans-
fected cells express both hl a- g and hl a-e at the cell surface, we fur-
ther conﬁrmed hl a- g speciﬁcity of the effect by using the hl a-
g(Eneg) 721.221 cell-line. This cell-line was negative for hl a-e expres-
sion as was shown by staining with hl a-e speciﬁc antibody dt9 (data
not shown). Again, proliferation of umc was inhibited by the hl a- g
expressing cells up to 80% in four independent experiments (Figure 3b,
p<0.005), clearly showing that the inhibition was induced by hl a- g .
Furthermore, the inhibitory effect appeared not broadly class i spe-
ciﬁc, since the response to hl a-b44 transfected 721.221 cells was not
strongly inhibited (Figure 3c), although in different experiments the
strength of the response was variable. 
In contrast to the overall inhibitory effect observed for the unfrac-
tionated population, mhl a- g stimulated proliferation of puriﬁed ute-
rine nk cells (Figure 4a, p<0.005). While puriﬁed uterine nk cells hard-
ly proliferate on stimulation with untransfected 721.221 cells, expression
of mhl a- g resulted in enhanced proliferation of this population. Again
a similar effect was observed when the hl a- g(eneg) 721.221 cells were
used ( Figure 4b, p<0.05). 
Membrane bound HLA-G stimulates IFN-γ production by uterine NK cells
Next, we addressed the question of whether mhl a- g can affect
cytokine production by umc or puriﬁed unk cells. Supernatants of co-
cultures set up with umc or puriﬁed uterine nk cells and mhl a- g
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transfected 721.221 cells were analyzed by sandwich-elisa for if n-γ
levels. Membrane-bound hl a- g signiﬁcantly inhibited the 721.221 in-
duced if n-γ production of umc (Figure 5a, p<0.05, percentage inhibi-
tion ranging from 27 to 100 % in four different experiments). Co-culture
with hl a-b44 transfected 721.221 cells also lead to a slight reduction in
if n-γ production, although this was never as outspoken as for hl a- g .
Notably and in line with the proliferation data, when puriﬁed uterine nk
cells were used, an increase in if n-γ was observed (Figure 5b, p<0.05).
For both umc and puriﬁed unk cells, similar data were obtained when
using the hl a- g(eneg) 721.221 cells (data not shown).
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Figure 4. Proliferative response of puriﬁed uterine natural killer cells after co-culture with
irradiated 721.221 cells or 721.221 cells transfected with membrane-bound HLA-G (A) or HLA-
G(Eneg) (B). Results show the mean of triplicates expressed as mean ± SD and are a single 
representative experiment out of three (HLA-G) or two [HLA-G(Eneg)] separate experiments. 
Membrane bound HLA-G stimulates VEGF production 
Besides if n-γ, the effect of mhl a- g was also evaluated for three other
cytokines that potentially play a role in implantation and placentation
and are produced by T cells and/or nk cells, i.e. v egf , il-3, and lif . 
Regarding v egf , our data show that umc (Figure 6a, p<0.005) as
well as puriﬁed uterine nk cells (Figure 6b, p<0.05) produce increased
levels of v egf upon co-culture with mhl a- g transfected 721.221 cells
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Figure 5. Interferon-γ concentrations in the culture medium of uterine mononuclear cells
(UMC) (A) or puriﬁed uterine natural killer (uNK) cells (B) after co-culture with irradiated
721.221 cells or 721.221 cells transfected with membrane-bound HLA-G or HLA-B44. The data
shown are the results from a single representative experiment out of four (UMC) or three
(uNK) separate experiments.
as compared to the untransfected 721.221 cells. Co-culture with hl a-
b44 transfected 721.221 cells did not signiﬁcantly affect v egf produc-
tion (Figure 6a).
In response to untransfected 721.221 cells umc produced only very
low levels of il-3 (Figure 7). Co-culture with mhl a- g transfected
721.221 cells in all cases lead to a further decrease in il-3 production
although the reduction in levels did not reach statistical signiﬁcance (Fig-
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Figure 6. Vascular endothelial growth factor (VEGF) concentrations in the culture medium of
uterine mononuclear cells (UMC) (A) or puriﬁed uterine natural killer (uNK) cells (B) after co-
culture with irradiated 721.221 cells or 721.221 cells transfected with membrane-bound HLA-
G or HLA-B44. The data shown are the results from a single experiment representative of
three (UMC and uNK ) separate experiments.
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ure 7a, p = 0.07). No il-3 was found in co-cultures with puriﬁed uterine
nk cells (Figure 7b). Again, similar data were obtained when using the
hl a- g(eneg) 721.221 transfectants (p<0.05, data not shown) and no sig-
niﬁcant decrease was observed in co-cultures with hl a-b44 transfec-
ted 721.221 cells (Figure 7a). 
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Figure 7. Interleukin-3 (IL-3) concentrations in the culture medium of uterine mononuclear
cells (UMC) (A) or puriﬁed uterine natural killer (uNK) cells (B) after co-culture with irradiated
721.221 cells or 721.221 cells transfected with membrane-bound HLA-G or HLA-B44. The data
shown are the results from a representative experiment out of four separate experiments. *
Below threshold.
With respect to lif , neither umc nor puriﬁed uterine nk cells pro-
duced detectable levels of lif upon stimulation with 721.221 cells or
hl a- g transfected 721.221 cells. 
Discussion
In this study, we have shown that membrane-bound hl a- g promotes
proliferation and if n-γ production of puriﬁed uterine nk cells derived
from non-pregnant endometrium at the mid-luteal phase (day lh +7).
Thus, our data reveal for the ﬁrst time that mhl a- g can indeed stimu-
late speciﬁc functions of uterine nk cells that may positively contribute
to implantation and decidualization. Studies on uterine lymphocytes so
far only pointed towards a role for mhl a- g in protection of the semial-
logeneic foetus from an attack by maternal nk and T cells. This was
achieved by inhibition of nk cell cytotoxicity (12) and downmodulation
of Th1 type cytokine production (29;30). Upregulation of the Th2
response by mhl a- g was found in peripheral lymphocytes, but was not
observed for uterine lymphocytes (29). 
The increased if n-γ production by uterine nk cells challenges the
Th1/Th2 paradigm as proposed by Wegman et al. (1993), stating that
Th1-like cytokines are detrimental for successful pregnancy (19). In line
with our data, several other groups have already shown the presence of
both if n-γ encoding mr na (31;32) and if n-γ protein (33) in unk cells
derived from pregnant women. Furthermore, receptors for if n-γ are
present on all ﬁrst trimester cytotrophoblast populations, macrophages
and vascular endothelial cells in the human decidua (33). In mice it has
been shown that if n-γ produced by unk cells promotes the initiation of
uterine vascular modiﬁcation and decidual integrity and thereby con-
tributes to the normalcy of pregnancy (18;34). The ﬁnding that unk cells
produce if n-γ in response to mhl a- g lends support to the idea that
if n-γ may play a role during the ﬁrst stages of human pregnancy when
hl a- g expressing invading trophoblasts come in contact with uterine
nk cells. The role of if n-γ may be very localized, effective within a
restricted time frame and dependent on the expression levels, or as
Chaouat stated with respect to the involvement of cytokines in pregnan-
cy “sequential windows and extreme complexity mixed with very precise
timing and tuning” (35). A candidate receptor on uterine nk cells
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responsible for the upregulation of if n-γ production is k ir2dl4
(10;11). Triggering of this hl a- g binding receptor on resting nk cells
has been shown to induce an increased if n-γ production without affect-
ing lytic function (36). 
Because of the extremely limited material we were not able to study
the effect of 721.221 hl a- g transfectants on puriﬁed uterine T cells.
However, it should be appreciated that in case of unfractionated umc ,
the proliferation measured, is the net result of the proliferation of T cells
and nk-cells. Using peripheral blood mononuclear cells it has been
shown that the strong proliferative response of cd4+ T cells to 721.221
cells is inhibited by mhl a- g (14). Puriﬁed uterine nk cells show only
limited proliferation. In case of umc the stimulatory effect of mhl a- g
on uterine nk cells is probably masked by the strong inhibition of a vi-
gorous uterine T cell response on the allogeneic hl a class ii+ 721.221
cells. This remains to be conﬁrmed by using uterine T cells. 
The exact mechanism by which hl a- g induces proliferation of ute-
rine nk cells remains speculative. So far two receptors have been identi-
ﬁed that can bind to hl a- g and that are present on (uterine) nk cells,
i.e. ilt2 and k ir2dl4 . It remains to be determined whether the effect is
induced directly via either of these receptors or that a yet unknown
receptor plays a role in this effect. Furthermore, autocrine production of
cytokines that affect nk cell proliferation may play a role. Decidual nk
cells proliferate strongly on il-15 and this cytokine can be produced by
these cells themselves (37). Another important cytokine that plays a role
in the induction of nk cell maturation, proliferation and if n-γ produc-
tion is il-21 (38;39). However, it is not clear yet whether uterine nk cells
can produce il-21. 
Interestingly unfractionated umc , including T cells, were inhibited in
their if n-γ production when co-cultured with mhl a- g transfected
721.221 cells. Apparently a generalized if n-γ response in the uterus
should be avoided and hl a- g protects against a too strong response.
This down modulation of if n-γ production by mhl a- g has also been
found by others when using unfractionated uterine leukocytes derived
from pregnant endometrium (29) as well as peripheral blood mononu-
clear cells (13-15). This indicates that the effects observed for membrane-
bound hl a- g are not solely due to intrinsic properties of uterine lym-
phocytes but also extend to peripheral lymphocytes and lymphocytes
that have already been into contact with foetal cells. Be that as it may, it
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cannot be excluded that differences exist at the single cell level or in the
modulation of other cytokines than the few we have measured.
In our study we utilized mononuclear cells derived from non-preg-
nant endometrium at the time that it is receptive for implantation. Most
other studies on the interaction between hl a- g and uterine cells have
used cells from decidual tissue from elective abortions (2;12;29;30). It has
already been shown that decidual nk cells express different activation
markers and adhesion molecules as compared to those from non-preg-
nant endometrium (40). Consequently, it is well conceivable that also the
functional capacities of cells derived from non-pregnant endometrium
differ since they have not yet been into contact with the invading tro-
phoblasts or have been affected by the altered hormone and cytokine lev-
els that occur during pregnancy. 
hl a- g speciﬁcity was shown by addition of anti-hl a- g monoclon-
al antibody to the co-culture of umc and hl a- g transfected 721.221
cells, leading to reduction of the inhibitory effect of mhl a- g . To further
exclude an effect of hl a-e we also used the hl a- g(eneg) transfected
721.221 cells. Furthermore, the ﬁnding that proliferation and cytokine
production of umc was not inhibited by hl a-b44 expression on 721.221
cells indicates that the affect is not a broad characteristic of (classical)
class ii molecules. Nevertheless, this does not rule out the possibility
that hl a-e plays a role in the uterus in modulation of the response. The
leader peptide of hl a- g is capable of binding to hl a-e , leading to sta-
bilization and surface expression of hl a-e in hl a- g transfected
721.221 cells. Although the receptor for hl a-e (cd94/nkg2) is present
on practically all uterine nk cells, recent data indicated that hl a-e
expressed on K562 cells does not affect if n-γ production of decidual nk
cells (30). Very little is known so far on the effect of hl a-e on T cells,
although it has been shown that hl a-e can be recognized through the
ab T cell receptor (41). The fact that the hl a- g speciﬁc monoclonal anti-
body could not fully restore the response may indicate a role for hl a-e
in the effect on T cells. The hl a- g transfected 721.221 cells mimic the in
vivo situation in the sense that also on trophoblast cells hl a- g and
hl a-e are expressed simultaneously (2). It is most likely that the combi-
nation of hl a- g and hl a-e loaded with hl a- g derived nonamer pep-
tide, provides the unique signals for modulating local uterine immune
responses.
In conclusion, our data suggest an active role for mhl a- g in modu-
mhl a- g acti vat e s if n-γ production by nk cell s
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lating uterine nk cells that are present in the endometrium at the time
that it is receptive for implantation. This indicates that mhl a- g is
instrumental in active ﬁne-tuning of the local immune response in order
to promote successful implantation. 
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General Discussion 
and 
Summary8

Multiple pregnancies are considered to be the most serious complication
of i v f . A substantially higher incidence of both maternal and perinatal
morbidity and mortality as compared to i v f singleton pregnancies is
reported (1). That is why multiple pregnancies require more medical care
than singleton pregnancies. Moreover, i v f-pregnancies in itself (single-
tons and multiples) are at greater risk for obstetric and perinatal compli-
cations than spontaneously conceived pregnancies (2-7). In this thesis we
studied the effect of single embryo transfer compared with double
embryo transfer. Furthermore, we investigated the medical costs of i v f
singleton- and twin-pregnancies. We also investigated the results of sin-
gle embryo transfer in a natural icsi treatment cycle (without any hor-
monal stimulation). Because the success of single embryo transfer
depends on the implantation rate of the embryo, we studied other,
immunological factors that might be important to increase the chance of
implantation.
Part I: Clinical Aspects
In the introduction of this thesis (chapter 1) we presented in Part I some
background information on the medical, social and economical prob-
lems related to multiple pregnancies after i v f . A literature update on
various solutions to decrease the number of multiple births due to i v f
are given (set , natural cycle i v f , selective embryo reduction). When
set might be put into practice in order to decrease the number of i v f-
twins and higher order multiple births, the pregnancy rate could drop
slightly as well. The implantation phase seems to be a crucial step in
establishing a pregnancy. Our goal was to gain more insight in the
immunological processes during implantation, because the fetus is con-
sidered to be a semi-allograft that has to be accepted by the maternal
immune system in order to survive. In Part II we described the role of the
immune system in various anatomical sites of the female reproductive
tract (ovary, endometrium, decidua). We explained why we believe that
the interaction between maternal nk cells and their subsets on the one
hand and the hl a-molecules on fetal trophoblast cells on the other hand
play an important role in implantation. Finally, we gave information
about the existing evidence of immunological involvement in several
pregnancy disorders (i v f-failure, preeclampsia, endometriosis, recur-
rent abortion).
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In chapter 2 we calculated the difference in costs between singleton
and twin i v f-pregnancies from early pregnancy until six weeks after
delivery. This was done in a retrospective cost analysis from a health care
perspective. The medical cost per twin pregnancy were found to be more
than ﬁve times higher than per singleton pregnancy, 13,469 euro and
2,550 euro respectively. In the present thesis, we focused on costs for
twin and singleton pregnancies from a medical point of view. The reason
is that savings on the medical budget due to reduction of the number of
twin pregnancies by set might be spent on other medical treatments,
for example i v f treatments. Savings in other compartments, sick leave,
travel expenses etc., are not likely to become available for medical treat-
ments (8) and were therefore not included in this study.
It is difﬁcult to extrapolate economic consequences of health care
conditions from one region or country to another. Costs related to sin-
gleton and twin pregnancies after i v f depend on i v f results, duration
of hospitalization, Caesarean section rate, need for neonatal intensive
care, costs for hospital care, costs for treatment of handicapped children.
These variables may differ from country to country and from year to
year.
Obviously, there is an urgent need to improve i v f outcome by reduc-
ing the number of multiples. In the Netherlands, as in most North Euro-
pean countries, the transfer of two embryos is now considered as a stan-
dard policy, therefore higher order multiple pregnancies (triplets and
more) following i v f are an exceptional phenomenon, namely 20 triplets
(0.5%) in 2003 (www.nvog.nl). The twin pregnancy rate in our country,
however, still was 22% in 2003 (www.nvog.nl). The only way to reduce
this number of twin pregnancies tremendously is to increase the per-
centage of single embryo transfer.
We performed a randomized controlled trial to investigate the effec-
tiveness of two i v f-cycles with single embryo transfer (set) and one
cycle with double embryo transfer (det) (chapter 3). We also calculated
the cost-effectiveness of both strategies using the results from chapter 2.
As we expected the live birth rate after set to be lower than after det
we compared two consecutive set cycles with only one det cycle. The
randomized controlled trial was performed in 107 women, aged < 35
years, in their ﬁrst i v f cycle, with at least one good quality embryo. They
were randomized to the set (n = 54) or det (n =53) group using a com-
puter-generated random block number table, stratiﬁed for primary or
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secondary infertility. The cumulative live birth rates per woman ran-
domized of two consecutive cycles of set (41%, 95% conﬁdence interval
(ci): 27-54) versus one cycle of det (36%, 95% ci 23-49) were compara-
ble. The multiple pregnancy rate, however, was signiﬁcantly higher: 37%
(95% ci 15-59) in the det and 0% in the in the set group (p = 0.002).
Combining the medical costs of the i v f-treatments (where 1.5 more set
cycles were required to achieve each live birth) and of pregnancies up to
six weeks after delivery (see chapter 2) the total medical costs per live
birth were 13,680 euro for det and 13,438 euro for set . So, two cycles
with set are equally effective as one cycle with det , and the medical
costs per live birth up to six weeks after delivery are the same. However, if
lifetime costs for severe handicaps are included, more than 7,000 euro
per live birth will be saved after implementing set .
There are a few health economic studies evaluating set versus det
(9-11), but no cost-effectiveness analysis has been published yet where
the effectiveness of set and det is based on a randomized controlled
trial as in our study. Wolner-Hanssen et al. performed a cost-analysis
from a societal perspective and therefore they also included costs of sick
leave and (medical and societal) lifetime costs of handicap. They used
estimates of hypothetical ﬁgures. They found that the total costs for the
det strategy were 4 times higher than for the set strategy (10). De Sut-
ter and colleagues developed a decision-analytic model to compare set
with det . Pregnancy rates from both randomized and observational
studies were included in this model. They concluded that the set cost
per child born was the same as with det (11). Gerris et al. performed a
real-life prospective health economic study of set versus det . All med-
ical costs from i v f-treatment, pregnancy and neonatal period up to 3
months after delivery were prospectively analysed in patients of <38 years
of age. This was not a randomized controlled trial, but based upon patient
choice for set or det , whereas set was exclusively performed if a high
quality embryo was available. They showed that the cost of set was
7,126 euro and the cost of det 11,039 euro per liveborn delivery. In the
det group embryo quality was not a selection criterion, therefore both
groups were not comparable with respect to chance of pregnancy (9).
Bergh et al. just recently reviewed the results of single embryo trans-
fer (12). The results from seven relevant observational studies indicate
that similar pregnancy and delivery rates are achieved with set and
det . In these studies patients with a good prognosis recieved set while
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poor prognosis patients received det (9;13-17). Up to now only four ran-
domized controlled trials comparing single embryo transfer (set) and
double embryo transfer (det) have been published (18-21). These stud-
ies all compared the effectiveness of just one set cycle with one det
cycle. These trials found no signiﬁcant difference in pregnancy rate
between set and det . Martikainen et al. and Thurin et al. determined
the cumulative live birth rate that included the live birth rate after frozen
embryo cycles. It is however odd that they did not include the frozen
embryo cycles in the det group. Moreover, the frozen cycle live birth
rate in the set group was very high (16.4%). When comparing the
results of only one fresh-embryo cycle the live birth rate in the set group
was signiﬁcantly lower than in the det group, 27.6% and 42.9% respec-
tively. Martikainen and colleagues observed an increase in live birth rate
from 30% to 39% after frozen embryo transfers in the set group and
from 40% to 51% in the det group (19). Van Montfoort et al., Academic
Hospital Maastricht, just recently performed an observational study to
the ongoing pregnancy rate after set (n = 55, ﬁrst cycle) and det (n =
235, ﬁrst cycle) in patients younger than 38 years with at least one top
quality embryo in the ﬁrst three treatment i v f cycles. The cumulative
pregnancy rate after the ﬁrst cycle (fresh and frozen cycles in both
groups) in the set group (45%) was signiﬁcantly higher than in the det
group (34%). Without the contribution of frozen embryo cycles (det) to
the pregnancy rate (12% in the set and 1% in the det group) the fresh
embryo ongoing pregnancy rate was the same (33% in both groups). The
twin pregnancy rate in the det group was 33% (22).
These results stress the importance of a good cryopreservation pro-
gramme with low costs to increase the live birth rate of one i v f treat-
ment cycle, especially in case of single embryo transfer. This will reduce
the number of second stimulated i v f cycles and it is expected that this
will result into a considerable cost reduction. In the Netherlands the
overall contribution of frozen cycles to the live birth rate of fresh cycles is
only 1.8%. In 11% of all started i v f treatment cycles transfer of frozen
embryos could take place (www.nvog.nl). These results are lower than
other European countries (23). Two Finnish studies reported a remark-
able increase of the pregnancy rate due to frozen embryos in patients
treated with elective set of 18% (15) to 26% (24).
In conclusion, the det strategy should be abandoned completely in a
high-risk group for multiple pregnancies, in favour of the strategy with 2
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cycles with set . Embryo freezing programmes must be optimized in the
Netherlands in order to maximize the cumulative live birth rate of set
per started i v f cycle. The reduction of multiple pregnancies will not
only save the government a lot of money but most of all the patients and
their offspring may be spared from a large range of medical and socio-
emotional problems.
Alternative IVF protocols
When set will be implemented in daily practice to reduce the multiple
pregnancy rate, it seems logical that less embryos have to be available for
transfer. Furthermore, hormonal stimulation is not without risks like the
Ovarian Hyperstimulation Syndrome (ohss). For these reasons, new
mild ovarian stimulation protocols or even i v f in the natural cycle might
be (re)considered, although we have to bear in mind that in natural cycle
i v f selection of the best quality embryo and the beneﬁt of frozen cycles
will be omitted.
In chapter 4 we investigated the efﬁcacy of icsi in 29 natural cycles
of 25 couples at the department of Obstetrics and Gynaecology of the
University Medical Center Nijmegen. To our knowledge this was the
ﬁrst serial and systemic investigation of the efﬁcacy of icsi in the natural
cycle. The inclusion criteria were: female age <37 years, infertility due to
severe male factor with indication for icsi (a total motile sperm count <
1 x 106), regular menstrual cycle between 26-32 days, a baseline follicle-
stimulating hormone (fsh) value of <10 iu/l and no female fertility
problem diagnosed. Oocyte retrieval was performed in a total of 24
cycles. The oocyte recovery rate per cycle was 58.6% (17/29). In three
cases the icsi procedure could not be performed (in one case due to
ejaculatory failure and in two cases due to morphological abnormal
oocytes). Finally, icsi was performed in 14 patients. All the injected
oocytes fertilized. In twelve patients embryo transfer was performed
(41.4% per cycle). Three patients got pregnant and delivered a healthy
child (25% per embryo transfer). Thus, the live birth rate per started cycle
was 10.3% (3/29).
The ongoing pregnancy rate of 10.3% per started cycle is satisfactory
considering the low burden, low costs and low risks. Moreover, this pro-
tocol can be performed on a monthly basis, because there is no need for
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the ovaries to recover from hormonal stimulation. Extrapolation of the
10.3% live birth rate after one natural cycle results into 28% cumulative
live birth rate after three natural cycles. This is comparable with 32% live
birth rate after one stimulated icsi treatment in women younger than 37
years of age in our setting in 2000 (data not published). So, in the same
time span the pregnancy rates are comparable. In our opinion natural
cycle icsi can be an alternative for stimulated icsi cycles in women
younger than 37 years of age and with a regular menstrual cycle.
Although natural cycle i v f and icsi is a patient-friendly, low-risk
and low-cost procedure, the major drawback seems to be the high cancel-
lation rate. Pelinck et al. described in a systematic review on the effective-
ness of natural cycle i v f a cancellation rate before oocyte retrieval of
28.9%. Embryo transfer was performed in only 45.5% of the 1800 cycles.
The ongoing pregnancy rate was 7.2% per cycle and 15.8% per embryo
transfer (25). The same group investigated at the University Hospital
Groningen the efﬁcacy of a modiﬁed approach of natural cycle i v f (26).
In this study a gnr h-antagonist was used to prevent a lh-surge, thus
minimizing the cancellation rate. They aimed at monofollicular growth
to reduce the risk of multiple pregnancies and ovarian hyperstimulation
syndrome. The gnr h-antagonist was started and given daily at a follicle
size of 14 mm, together with 150 IU recombinant fsh (rfsh) to prevent
aberrant follicle growth. In total 50 patients underwent 119 cycles, with a
maximum of three cycles. The cancellation rate before oocyte retrieval
was 12.6% (15/119) and in only 43.7% of the cycles embryo transfer was
performed (52/119). The ongoing pregnancy rate per cycle was 14.3%.
The cumulative ongoing pregnancy rate after three cycles was 34%.
Although the cumulative pregnancy rate per cycle is good, the cancella-
tion rate is still rather high. Also the cost-effectiveness should be mea-
sured. It seems worthwhile to study the cumulative pregnancy rate after
a maximum of nine cycles of unmodiﬁed natural cycle i v f/ icsi with the
so called modiﬁed natural cycle i v f/ icsi to compare both approaches.
Mild stimulation protocols might anticipate the problem of a high
cancellation rate, while less redundant oocytes and embryos will be pro-
duced. Hohmann et al. compared a mild ovarian stimulation protocol
(150 iu rfsh on cycle day 5 + gnr h antagonist from follicle size of 14
mm) with the standard long gnr h agonist protocol with a ﬁxed dose of
150 iu rfsh . In this study a maximum of two embryos were transferred.
The mean number of embryos obtained after the mild stimulation proto-
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col was three, whereas the standard long gnr h agonist protocol yielded
four embryos. Despite the fact that more cycles were cancelled before
oocyte retrieval in the mild stimulation protocol (37%) as compared with
the standard long gnr h agonist protocol (16%), the ongoing pregnancy
rate per cycle were similar (16%, 8/49 and 18%, 8/45, respectively) (27).
The twin pregnancy rate was 38% in both groups. However, a shorter
stimulation period and a 27% reduction in exogenous rfsh dose were
observed in the mild stimulation protocol. A returning problem of the
natural and mild stimulation i v f protocols is the high cancellation rate.
Hojgaard et al. evaluated the patient attitude towards mild stimulation
protocols (clomiphene citrate), including natural cycle i v f , and the stan-
dard long protocol for i v f . They conclude that the majority of patients
seem to accept the drawbacks of mild stimulation protocols in terms of
cycle cancellation and accordingly the necessity of more treatment cycles
against the advantages of such protocols in terms of few side-effects,
simplicity and short duration (28). In chapter 4 we noticed the same pos-
itive attitude of our patients towards natural cycle icsi .
Extrapolation of SET strategy to national level in the Netherlands
It is interesting to extrapolate the cost-effectiveness of the set strategy
to the entire population at local level (Nijmegen) and even on national
level. The overall live birth rate, the multiple pregnancy rate and the med-
ical costs (including lifetime costs for handicapped singleton and twin
children) after the implementation of set are important parameters to
determine.
The medical costs can be divided into mean costs of one i v f treat-
ment cycle (2,532 euro, chapter 3), mean costs of i v f pregnancy up to 6
weeks postpartum per singleton live birth (2,550 euro, chapter 2) and
per twin live birth (13,469 euro, chapter 2) and mean lifetime costs of
severe handicapped children per singleton (1,489 euro, chapter 3) and
twin live birth (20,477 euro, chapter 3).
To extrapolate the results of our set-transfer strategy to the entire
i v f/icsi population in our clinic we estimated the effect of set during
one cycle in the total i v f population in the year 2001 and 2002 (n=1788).
Of all ﬁrst treatment cycles (n=789) 41 percent met our inclusion criteria
for set (326/789). In this group with a high risk on multiples 37% got
pregnant with a twin pregnancy rate of 36%. The remaining patients
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were excluded for set and received det (age > 34 years, , poor quality
embryos) or set because of the fact that only one embryo was available.
In this group with a low risk on multiples the pregnancy rate was 14% of
which 12.5% twin pregnancies. The overall pregnancy rate was 23% and
the twinning rate 27%. If all the couples that met the inclusion criteria
would have had set , with a live birth rate of 26% (see chapter 3), the
overall pregnancy rate would have dropped from 23% to 19%. The overall
twin pregnancy rate would have dropped from 27% to 5%. So, a dramatic
fall in twin pregnancies can be accomplished at the cost of a small drop in
the overall pregnancy rate after implementing single cycle set in
patients undergoing their ﬁrst treatment cycle, who are less than 35 years
of age, and had at least one excellent or good quality embryo during
transfer. If the results of frozen i v f cycles were included in this analysis,
this ﬁnal conclusion would have been even more pronounced .
The next step is the calculation of total costs before and after the
implementation of set in the ﬁrst cycle in our clinic. The total costs are
the costs of the i v f cycles (n x ci v f -cycle) plus the costs of the i v f preg-
nancies up to 6 weeks postpartum together with the lifetime costs of
handicapped children, per singleton live birth (Cpreg-sing + Chand-sing) and
per twin live birth (Cpreg-twin + Chand-twin).
Using the formulas shown in appendix a, the total costs for 789 ﬁrst
i v f cycles before the implementation of set in Nijmegen are the costs of
i v f cycles (2.0 million euro) plus the costs of i v f-pregnancies up to 6
weeks postpartum together with lifetime costs for handicapped children
(2.2 million euro), which amounts to a total of 4.2 million euro.
The total costs for 789 ﬁrst i v f cycles after the implementation of
set in Nijmegen are the costs of i v f cycles (2.0 million euro) plus the
costs of i v f-pregnancies up to 6 weeks postpartum together with life-
time costs for handicapped children (0.8 million euro), which amounts
to a total of 2.8 million euro (appendix a).
Thus, in our i v f clinic the implementation of set in the ﬁrst i v f
cycle could save us 1.4 million euro per 789 ﬁrst cycles in a twin prone
population at the cost of a small drop in the overall pregnancy rate (from
23% to 19%). This means a reduction of 33% of the total costs.
If we make the assumption that 1.5 more set cycles are needed to
have the same live birth rate as 1 det cycle (chapter 3), the formula of
total costs after implementation of set will be changed. The costs of i v f
cycles will become 1.2 times higher; 1.5 x n x P se t + n x P de t. The costs
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for the set group will become 1.5 times higher than for the det group
(appendix b). The total costs after implementing set will then become
3.4 million euro (i.e. the costs of i v f cycles (2.4 million euro) plus the
costs of i v f-pregnancies up to 6 weeks postpartum together with life-
time costs for handicapped children (1.0 million euro)) (appendix b). So,
when 1.5 more set cycles will be performed to bring the pregnancy rate
after set into the same level as after det , 0.8 million euro could be
saved. This results in a 19% reduction of total costs.
In 2001 and 2002 our i v f clinic started 1788 i v f/icsi treatment
cycles, which is 6.2 % of the total number of cycles in the Netherlands
(1788/28742) (www.nvog.nl). To estimate the savings after implementa-
tion of set in the ﬁrst cycle in all clinics in the Netherlands the amounts
have to be multiplied by 1/0.062. This means that on national level rough-
ly 22.6 million euro (1/0.062 x 1.4 million euro) can be saved in two years
when set would be implemented for the ﬁrst i v f cycle. In case 1.5 more
set cycles will be performed to equalize the pregnancy rate, roughly 13
million euro (1/0.062 x 0.8 million euro) can be saved in two years after
implementation of set .
Consequences of the abolition of reimbursement 
of IVF treatments
In the past in the Netherlands up to three i v f treatment cycles were
reimbursed. Since January 2004 the government has abolished this regu-
lation. Nowadays patients have to pay the ﬁrst out of three i v f cycles
themselves. When infertility patients have effected a supplementary
insurance for infertility treatment the ﬁrst i v f cycle will be (partly)
reimbursed. This governmental decision might have detrimental health
consequences. In general fertility-specialists do not transfer more than
two embryos on medical grounds. However, it can be expected that the
trend to transfer less than two embryos will stop under pressure from
couples who have to pay the ﬁrst cycle themselves. This explanation is
supported by the literature. Decreasing reimbursement strategies result
in higher numbers of embryos per transfer (29-31). Multiple pregnancies
make det less cost-effective than set , especially in couples with a good
prognosis, and therefore this measure will lead to higher costs instead of
the intended lower costs. Moreover, inadequate or absent health cover-
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age for i v f will also provide unequal access and care to some couples
with infertility.
It would be better if this governmental measure, to exclude the ﬁrst
i v f cycle from reimbursement, will be replaced by a more cost-effective
measure. At short notice, the “Umbrella” study, ﬁnanced by zon-m w ,
will combine the results of the 5 Dutch studies on the efﬁciency (effec-
tiveness and cost-analysis) of different i v f strategies (Pre-implantation
Genetic Screening, set , natural cycle i v f/icsi and mild i v f stimula-
tion protocols) with intent to decrease the number of multiple pregnan-
cies. These studies have been performed in the following i v f centra;
Groningen, Maastricht, Rotterdam, Utrecht and Nijmegen. In the end,
concrete recommendations should follow from these results that are
intended for fertility specialists, infertility patients, insurance companies
and last but not least the minister of health. Hopefully, the Umbrella study
will lead to a better and more efﬁcient strategy for infertility treatment.
Based on the calculation that nationwide implementation of set in
the ﬁrst cycle of couples with a good prognosis will save 22.6 million euro
in two years, we propose to change the reimbursement regulation in a
sense that the ﬁrst three i v f-cycles are reimbursed completely, provided
that set is performed during the ﬁrst cycle of couples with a good prog-
nosis. We did not calculate the consequences of alternative scenarios, but
it can be speculated that for instance the complete reimbursement of a
total of six i v f/icsi treatment cycles per couple with set will be more
cost-effective than the present regulation. It is important to state that
frozen embryo transfer(s) are part of the original cycle and should be
reimbursed as well, since the use of frozen embryos is an important con-
dition for a successful set program.
Furthermore, we seriously have to consider the implementation of
natural or mildly stimulated i v f/icsi set cycles (with or without
gnr h antagonists and low dose rfsh) as these cycles are patient-friend-
ly, low-risk and probably low-cost cycles and can be performed on a
monthly basis. One conventional set cycle might be replaced by three
natural or mildly stimulated i v f/icsi cycles, considering the higher
cancellation rate and lower pregnancy rate.
Finally, it is important to realize that the exclusion of the ﬁrst cycle for
reimbursement has to change. All three cycles should be reimbursed.
The high initial costs are too high for lower-class couples and thus lead to
unequal access to reproductive care. Moreover, the high costs of the ﬁrst
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cycle will stop the trend to set and thus will lead to undesirable high
rates of multiples.
Future research
Two cyles with single embryo transfer seems equally effective as one
cycle with double embryo transfer in an i v f population prone to twin
pregnancies and the medical costs per live birth up to six weeks after
delivery are the same. More than Euro 7,000 per live birth will be saved
after implementing set , if lifetime costs for severe handicaps are includ-
ed. To make set even more cost-effective and therefore better accepted
by the patient, as well as the fertility specialist and the government, the
live birth rate has to be improved. Fundamental research can contribute
to more knowledge about the implantation process of the embryo into
the decidua, which remains a difﬁcult step in the achievement of a preg-
nancy after i v f (part II of this thesis). Another way to improve the preg-
nancy rate is to enhance the results of cryopreservation programmes to
increase the cumulative live birth rate per started cycle. Since only one
embryo will be transferred after set more embryos are available for this
procedure. The costs of the cryopreservation procedure and the transfer
of frozen embryos is less than one stimulated i v f cycle. A third manner
to improve the pregnancy rate after i v f is the search for better parame-
ters for embryo quality that are highly correlated to subsequent pregnan-
cy. We could, for example, focus on substances in follicular ﬂuid like
immune cells (chapter 5). Pre-implantation Genetic Screening is also a
promising technique to select genetically normal embryos with a high
implantation potential.
It would also be interesting to investigate the efﬁciency of set in a
broader group of i v f patients, less prone to twin pregnancies. How efﬁ-
cient is set in a third or fourth i v f cycle, in older women, with low qual-
ity embryos?
Furthermore, we have to gain more insight in the preference of infer-
tility patients to set or det in order to facilitate the implementation of
set by a better acceptance in this group of patients. Murray and col-
leagues showed already that additional information about the risks of
twins did not change couples’ attitude towards set , but maintaining
existing pregnancy rates and offering a ﬁxed charge for all embryo trans-
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fers resulting from one started cycle may encourage more couples to con-
sider set (32).
Finally, what will be the hindering factors when set would be imple-
mented in daily practice and what are the best strategies to overcome
these obstacles. As mentioned before, the ﬁrst obstacle could be the
desire for a twin over a singleton pregnancy by infertile couples. A sec-
ond major obstacle for both patients and fertility specialists is thought to
be the restricted reimbursement of only the second and third i v f/icsi
treatment cycle. Both may prefer cycles with det instead of set ,
because of an increased total chance for pregnancy. Implementation of
set cannot be overcome by legislation adaptation only. Olofsson et al.
just recently showed that in Sweden after a legislation update that states
set fundamentally, the set rate got stuck on 61% (33).
Part II: Immunological Aspects
NK cells and pregnancy
We were interested in reducing the multiple pregnancy rate after i v f ,
without decreasing the pregnancy rate as such. As shown in this thesis
single embryo transfer can decrease the number of multiple pregnancies
substantially, with only a slight drop in pregnancy rate. To make imple-
mentation of single embryo transfer not only better accepted, but also
applicable to a broader group of patients, the overall pregnancy rate of an
i v f clinic has to be high. In our view pregnancy rates can be increased if
the implantation of the embryo into the decidua takes place under opti-
mal conditions. So, we set out to gain more insight into the immunologi-
cal interaction between the fetus and the mother at the time of implanta-
tion. We focused on natural killer (nk) cells, because they play an impor-
tant role in human implantation. A characteristic feature of human
endometrium and decidua during reproductive life is the presence of a
large population of natural killer cells. In pregnancy up to 70% of decid-
ual leukocytes are nk cells. They accumulate at the implantation site
where they are found in close proximity to invading trophoblast. After
about the twentieth week of gestation, trophoblast invasion is complete,
and at this time the number of uterine nk cells is thought to decline.
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Large numbers of nk cells are not a feature of other solid tissues. Anoth-
er remarkable feature of uterine nk cells is the expression of speciﬁc nk
cell receptors on their surface which interact with hl a molecules
expressed on the invading trophoblast cells (hl a- cw, hl a-e and hl a-
g). It is suggested that interaction between hl a- g (fetal) and uterine
nk cells (maternal) induces a combination of positive and negative sig-
nals that regulate cytokine production, proliferation and cytolysis in
order to make successful placentation possible (34-37). Thus, it is imper-
ative to gain more insight in the precise role of unk cells in implantation
in normal as well as pathologic pregnancies. It is well possible that nk
cells also play a role in reproductive processes during stages preceding
implantation, for example in oocyte maturation. Both follicular ﬂuid and
uterine nk cells might be valuable parameters for the quality of oocytes
and/or endometrium.
In i v f treatment, hormonal stimulation of the ovaries is used to
induce multiple follicular growth. This ovarian hyperstimulation results
in supraphysiological concentrations of sex steroids (estradiol and prog-
esterone) that might have a deleterious effect on endometrial receptivity.
In fact, both positive and negative effects of ovarian hyperstimulation on
pregnancy rates after i v f have been reported (38-41). Hormones do have
an effect on the number and possibly the function of leukocytes, as the
number of leukocytes ﬂuctuate substantially during the menstrual cycle
and throughout pregnancy. Moreover, estrogen receptors have been
detected on nk cells (42), although this was not conﬁrmed by Stewart et
al. (43).
We investigated the repercussion of hormonal hyperstimulation on
the nk cell composition of endometrium from i v f patients compared
with the endometrium of naturally cycling women during the window of
implantation (chapter 6). We found that hormonal stimulation positive-
ly affected the cd56bright/ cd56dim ratio of the endometrium caused by a
relative decrease in the cytotoxic cd56dimcd16+ nk cell number. This
nk cell subset has mainly cytotoxic properties and is thought to be detri-
mental for implantation, whereas the cd56brightcd16- nk cell popula-
tion is associated with successful implantation and placental maturation
(34). So, we suggest that supraphysiological levels of sex steroids after
i v f treatment do not impair endometrium receptivity, indeed it might
even be beneﬁcial. This idea is endorsed by the fact that histologically no
endometrial advancement was shown in the i v f group.
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We discovered a third subset of nk cells in the endometrium at the
time that it is receptive for implantation, which has not been described
previously. We showed that, based upon the nk cell marker cd56, the
cd56bright population could be subdivided into two different popula-
tions. The so-called cd56superbright cells, which are cd16 negative, are
unique in the sense that they were detected only in the endometrium and
not in peripheral blood. Based upon this ﬁnding, we deﬁned three dis-
tinct nk cell populations in the uterus, i.e. cd56dim, cd56bright and
cd56superbright. Furthermore, in contrast to both uterine and peripheral
cd56bright nk cells, a large proportion of cd56superbright nk cells
expressed nk cell receptors for hl a- cw and -g molecules. Practically
all cd56superbright expressed nkg2a at high levels. This latter receptor is
reported to bind hl a-e . These features of cd56superbright nk cells sug-
gest different functional properties as compared with cd56bright cells.
Maybe it is this cd56superbright subset of the cd56bright nk cells that is
responsible for the favorable effects on reproduction as described above.
The results of this study might be a ﬁrst step for further investiga-
tions to use the number and function of nk cell subsets as a parameter
for endometrium quality by linking these data to subsequent outcome of
pregnancy. This may support improvement of stimulation protocols in
assisted reproductive technology.
Next to the implantation phase, nk cells may also be of importance
in the very early stages of reproduction. It is known that leukocytes are
present in follicular ﬂuid (f f). nk cells in f f might well be involved in
oocyte development and maturation. We hypothesized that follicular
ﬂuid provides the environment in which oocyte maturation occurs and
therefore may inﬂuence the quality of the oocyte. The composition of the
ﬂuid may thus be linked to fertilization and early embryonic develop-
ment and disturbed cellular immunity in follicular ﬂuid might be the
cause of aberrant oocyte development.
Aberrant oocyte development can provide a possible explanation for
the ‘idiopathic’ cause of infertility, because the fertilization rate of these
oocytes is lower as compared to oocytes from patients suffering from
tubal factor infertility (44-46). To investigate this hypothesis we deter-
mined the levels of nk and T cell subsets by ﬂowcytometric analysis in
separately collected follicular ﬂuids of patients with idiopathic infertility
and compared these levels to f f of a control group consisting of couples
with severe male and tubal factor infertility (chapter 5). We found that
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the proportion of f f cd56dimcd16+nk cells in women suffering from
idiopathic infertility was signiﬁcantly higher than in controls. The excess
of cd56dimcd16+nk cells in follicular ﬂuid could reveal a cause for
oocyte ‘dysfunction’ and therefore for the idiopathic infertility in this
group, because the cd56dimcd16+nk cell subset is generally considered
to be cytotoxic and is negatively associated with reproductive events.
It would be interesting to correlate nk cell subset levels and function
in f f to subsequent quality of embryos and their implantation capacity.
Monofollicular growth in case of natural cycle i v f and icsi offers an
excellent opportunity to study the correlation between cellular immune
cells in f f and pregnancy rate, although the inﬂuence of hormonal stim-
ulation cannot be measured. When data is gathered on a large scale, sub-
group analysis can be performed to investigate for instance the inﬂuence
of smoking or the use of painkillers on leukocyte composition of the folli-
cles.
An intriguing question is where the f f leukocytes come from. Do
they originate from a distinct population or are they recruited from the
peripheral blood circulation and undergo tissue-speciﬁc differentiation?
Piccinni and co-workers (47) reported a qualitative, tissue-speciﬁc dif-
ference in functionality between lymphocytes present in the cumulus
cells of a follicle as compared to peripheral blood lymphocytes. These
lymphocytes produce a different proﬁle and amount of cytokines. It will
be interesting to determine cytokines and chemokines in f f that could
attract nk cells to the follicle. This will enable us to investigate nk cell
trafﬁc and possibly inﬂuence these processes to enhance oocyte quality
and subsequent pregnancy rate after i v f .
Function of uterine NK cells
nk cells appear instrumental in successful decidualization. Their func-
tion is modulated through interaction with hl a-molecules expressed on
invading trophoblast cells. We paid particular attention to hl a- g ,
because hl a- g has a restricted tissue distribution and low polymor-
phism. In the placenta, hl a- g is expressed by the extra-villous (inva-
sive) trophoblast cells at the fetal-maternal interface. Also, it is found to
be present in amniotic ﬂuid. Initially, it was thought that hl a- g had a
strictly inhibitory function in order to protect the semi-allogenic fetus
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from an attack from the maternal immune system. Nowadays, it
becomes clear that the most likely function of hl a- g is to induce the
production of cytokines and angiogenic factors by uterine nk cells to
alter trophoblast invasion and differentiation in order to supply an
appropriate blood ﬂow to the placenta (48). This would suggest a more
ﬁnely tuned modulatory function for hl a- g rather than a strictly
inhibitory role.
In chapter 7 we investigated the effect of membrane-bound hl a- g
(mhl a- g) on production of various cytokines related to implantation,
i.e if n-γ, Vascular Endothelial Growth Factor (v egf), Interleukin 3
(il3) and Leukaemia Inhibitory Factor (lif) (49-52). We also investiga-
ted mhl a- g induced proliferation of the uterine mononuclear cell
(umc) population as a whole, and uterine nk cells in particular from
endometrium of non-pregnant woman during the phase that the
endometrium is receptive for implantation.
We have shown that mhl a- g stimulated speciﬁc functions of unk
cells, like proliferation and cytokine production. Notably, the same func-
tions were suppressed in T cells. Studies on uterine lymphocytes so far
only pointed towards an inhibitory role for mhl a- g in protection of the
semiallogeneic foetus by maternal nk and T cells. This was achieved by
inhibition of nk cell cytotoxicity (53) and downmodulation of Th1 type
cytokine production (36;37). Upregulation of the Th2 response by
mhl a- g was found in peripheral lymphocytes, but was not observed
for uterine lymphocytes (36). Our results indicate that a delicate balance
exists between active processes to promote proper implantation, while
at the same time inhibitory processes must protect the fetus from a gen-
eralized attack by the maternal immune system.
In our study the mononuclear cells were derived from non-pregnant
endometrium at the time that it is receptive for implantation. These
endometrial cells have not yet been in contact with fetal trophoblast cells
and/or have not yet been affected by the altered hormone and cytokine
levels that occur during pregnancy. Therefore this tissue is most appro-
priate to study the interaction of nk cells with hl a- g , because it has
been shown that decidual nk cells express different activation markers
and adhesion molecules as compared to those from non-pregnant
endometrium (54). It is well conceivable that also the functional capaci-
ties of cells derived from non-pregnant endometrium differ from deci-
dual tissue from pregnant women. Most other research groups, however,
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used decidual tissue from elective abortions to study the interaction
between hl a- g and uterine cells (34;36;37;53).
In conclusion, our data suggest an active role for mhl a- g in modu-
lating uterine nk cells that are present in the endometrium at the time
that it is receptive for implantation. This indicates that mhl a- g is
instrumental in active ﬁne-tuning of the local immune response in order
to promote successful implantation. Besides hl a- g , two other hl a-
molecules are present on trophoblast cells, namely hl a-e and hl a-
cw. hl a-e , like hl a- g , is also a non-classical class I molecule with lim-
ited polymorphism. Previous studies using hl a- g transfectants are
hampered by the co-expression of hl a-e . The cell-surface expression of
hl a-e is dependent on its binding of signal peptides cleaved from other
class I molecules, such as hl a- g . Signal nonamer peptides from both
hl a- g and hl a- cw have been shown to bind to hl a-e (55-57). The
receptor cd94/nkg2a recognizes hl a-e on extra-villous trophoblast.
It can well be assumed that hl a-e has a different function as com-
pared to hl a- g , notably its receptor on nk cells shows a different
expression pattern than hl a- g receptors. A signiﬁcantly higher num-
ber of cd56superbright nk cells as compared to cd56bright nk cells
express cd94/nkg2a and also the level of expression is higher in this
group as compared to cd56bright nk cells (chapter 6). It is most likely
that the combination of hl a- g and hl a-e loaded with hl a- g derived
nonamer peptide, provides the unique signals for modulating local ute-
rine immune responses to facilitate implantation.
Clinical Implications
Immunotherapy for pregnancy failure
Recent reports in the media and on the internet have exposed women to a
bafﬂing array of conﬂicting information about tests for nk cells and
“cures” for infertility and miscarriage. These authors assume that mal-
function of nk cells causes pregnancy failure and are offering blood
tests to measure the number and activity of peripheral blood nk cells. As
a consequence of these test results these women are exposed to
immunotherapy such as steroids, intravenous immunoglobulins, pater-
nal or donor cell immunization and cytokine blocking agents (58). This is
a dangerous development, because there is not enough scientiﬁc know-
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ledge yet of the speciﬁc underlying immunological pathophysiology of
pregnancy failure. Therefore, immunotherapy could have its effect the
wrong way. Moreover, there is no scientiﬁc evidence of the beneﬁcial
effect of these therapies on pregnancy failure. Up to now, most of these
tests aim at the number and activity of peripheral blood leukocytes, espe-
cially the nk cells. It is becoming more clearly now that the uterine nk
cells play a crucial role in implantation and that these cells are phenotypi-
cally and functionally different from peripheral nk cells and should be
regarded as a separate lyphoid subset. Evidence is accumulating that the
function of uterine nk cells must nót be inhibited but exactly activated.
Uterine nk cells probably have an essential, beneﬁcial effect on tro-
phoblast by secreting cytokines that alter the depth of placental invasion.
Therefore, current immunotherapies that suppress nk cell activity in a
general way could have a detrimental effect on pregnancy.
Many clinical trials that investigate the effects of immunotherapy on
pregnancy outcome show an inadequate sample size, poor deﬁnition of
heterogeneity and lack proper stratiﬁcation to minimize the effects of
heterogeneity. Another weak point is that most trials also lack veriﬁca-
tion of the expected alteration in immunophysiology in the recipients
(59). Daya and colleagues performed a meta-analysis to determine
whether intravenous immunoglobulin (i v ig) improved the chances of
successful pregnancy in women with recurrent miscarriage by using
individual patient data from efﬁcacy trials. They found no signiﬁcant
improvement in successful pregnancy or live birth rate with i v ig (60).
Furthermore, a systemic Cochrane review also states that various
immunological treatments in women with recurrent miscarriage provide
no signiﬁcant beneﬁcial effect over placebo in preventing further miscar-
riages (61).
In reproductive medicine it is very important to evaluate treatments
carefully before implementation in daily practice. Theoretically, it might
be possible to intervene with selection of nature and maintain pregnan-
cies with for instance chromosome abnormalities.
In our opinion, it remains of utmost importance to perform extensive
fundamental research to understand the process of implantation, before
immunotherapies will be applied to infertility patients. Today, it is too
early and risky to perform immunotherapy in daily i v f practice.
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Future research
hl a- cw is the third hl a molecule present on fetal trophoblast cells.
hl a- cw, in contrast to hl a- g and hl a-e , is a polymorphic classical
mhc class I molecule. The paternal allele is expressed on the extra-vil-
lous trophoblast cell surface and may be important for allorecognition of
trophoblast. hl a- cw shows ubiquitous expression in the human body.
Up to now, little is known about the precise role of hl a- cw in implanta-
tion. Hiby et al. have proposed a new theory about the role of hl a- cw
in the pathogenesis of preeclampsia (62).
Preeclampsia is a serious disorder of human pregnancy in which the
placenta receives an inadequate supply of blood due to failure of tro-
phoblast invasion. The maternal systemic illness is thought to be a late
manifestation of the placental ischaemia that is secondary to the reduced
utero-placental blood ﬂow (63). In genetic studies as well as in popula-
tion-based studies a contribution of both paternal and maternal factors
and genotype is apparent (64). The increased risk of preeclampsia in ﬁrst
pregnancies and after changing partners suggests that immune recogni-
tion is involved (65). Strikingly, there is also a greatly increased risk in
women who have received donated oocytes in an i v f program (66). In
this case the fetus will share neither maternal nor paternal genes.
Hiby and colleagues implicate that hl a- cw on fetal trophoblast and
Killer cell Immunoglobulin-like Receptors (k ir) on uterine nk cells
play an important immunological role in preeclampsia. hl a- cw, as tro-
phoblast ligand, is known to have extensive polymorphism in contrast to
hl a- g and hl a-e . On the other hand, the k ir family of nk cell recep-
tors is also polymorphic. Therefore hl a- cw and k ir are important for
allorecognition and are probably relevant for the development of
preeclampsia. k ir haplotypes can be divided into two groups. The A
haplotypes are mainly characterized by the presence of inhibitory recep-
tors, while the B haplotypes presents mainly activating receptors. The
hl a- cw allotypes can be grouped into hl a1 (weak inhibition upon
interaction with k ir) and hl a- c2 (strong inhibition upon interaction
with k ir). Hiby et al. found preeclampsia to be more prevalent in
women who are homozygous for A k ir haplotype (AA) than women
who are either heterozygous (AB) or homozygous for group B haplo-
types (BB). They also found that the increased prevalence of preeclamp-
sia in AA k ir women was entirely due to pregnancies where the fetus
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genotype was either homozygous C2 or heterozygous C1C2. So, it is
hypothesized that an absence of activating k ir favors preeclampsia,
because too much inhibition of unk cells will lead to poor trophoblast
invasion into the uterine arteries. These results indicate a possibly
important role for fetal hl a- cw on trophoblast cells in implantation
through interaction with maternal k ir on unk cells.
In the light of these results it is difﬁcult to explain why a ﬁrst pregnan-
cy protects against the development of preeclampsia or at least causes a
milder form of the disease in subsequent pregnancies with the same
partner. Although nk cells do not exhibit memory, it is speculated that in
subsequent pregnancies with the same AA-C2 combination a weaker
inhibition would occur via the nk receptor k ir2dl1 . This can be
achieved by a reduced expression level of k ir2dl1 on nk cells in subse-
quent pregnancies or by a decreased presence of k ir2dl1 positive cells
at the implantation site.
Once more the regulation of the development of the placenta seems
an active process, rather than suppression of the maternal immune sys-
tem against her semi-allogeneic fetus.
Furthermore, we would like to draw attention to regulatory T cells.
Evidence is accumulating that, next to nk cells, regulatory T cells in the
decidua and peripheral blood may also play an important role in protect-
ing the fetus from alloreactive immune responses against paternal anti-
gens at the maternal-fetal interface. Immunosuppressive regulatory T
cells (Treg) are already known to be crucial in the induction and mainte-
nance of transplantation tolerance (67;68). Regulatory T cells are a spe-
cialized population of T cells that suppress T cell responses. The absolute
number of circulating maternal Treg cells and decidual Treg cells,
deﬁned as cd4+cd25+ cells, increases progressively at each stage in
human pregnancy starting from the ﬁrst trimester (69-71). Increased
numbers of systemic Treg cells and altered function might explain why
some autoimmune syndromes, such as rheumatoid arthritis, go into
remission during pregnancy (72).
Sasaki et al. demonstrated that the proportion of decidual Treg cells
was signiﬁcantly lower in samples from patients suffering from sponta-
neous abortions (71). In murine pregnancy it has been shown that trans-
fer of maternal T cells depleted of Treg cells resulted in uniform failure of
allogeneic pregnancies, whereas this manupilation did not affect the out-
come of matings involving genetically identical male and female mice
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(syngeneic pregnancies). The ability to suppress maternal immunity to
fetal alloantigens was dependent on expansion of the maternal Treg
pool. This response was not driven by fetal alloantigens, because expan-
sion also occurred in females mated with syngeneic males (73). Hormon-
al changes during pregnancy might provide an explanation for enhanced
maternal Treg development during gestation as was shown by Polanczyk
and colleagues. They demonstrated that estradiol treatment induces a
similar increase in number and function of Treg cells as does pregnancy.
Expansion of Treg number and function during pregnancy may be
responsible not only for preventing rejection of the fetus, but also for
protecting the mother from developing (relapses) of autoimmunne dis-
eases (74).
Regulatory T cells may play an important role in reproduction, espe-
cially during implantation. It will be interesting to investigate whether
these cells interact with nk cell function. Do Treg cells inﬂuence the
process of implantation directly or indirectly possibly via nk cells? Do
they express speciﬁc receptors for hl a- g , hl a-e and hl a- cw on tro-
phoblast cells?
Implantation and development of the human fetus is for the greater
part a mystery. In the ﬁeld of local immunity at the implantation site
much remains to discover. In this thesis the role of uterine nk cells and
hl a- g in implantation was further explored. Future research on the
interaction of nk cells and hl a- g with other immune cells and process-
es, like Treg cells and the complex of hl a- cw with uterine nk cell
receptors, might contribute to unravel the mystery of human implanta-
tion. When we gain more insight into the immunological processes of
implantation it might be possible to increase the pregnancy rate, while
reducing the multiple pregnancy rate in i v f by implementing single
embryo transfer.
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Appendix: calculation of costs
va r i a ble s:
n = number of i v f treatment cycles (n = 789)
Ctot = costs i v f-cycle + costs i v f-pregnancy up to 6 weeks post-
partum + lifetime costs handicapped children
Ci v f-cycle = costs i v f-cycle (2,532 euro)
Cpreg-twin = costs i v f twin pregnancy up to 6 weeks post partum 
(13,469 euro)
Cpreg-sing = costs i v f singleton pregnancy up to 6 weeks post partum 
(2,550 euro)
Chand-twin = lifetime costs of handicapped twin per twin birth (20,477 euro)
Chand-sing = lifetime costs of handicapped singleton per singleton birth
(1,489 euro)
Ppreg = overall pregnancy rate (before implementing set) (23%)
Ptwin = overall twin pregnancy rate (before implementing set) (27%)
Pset = chance to be included for set (41%)
Pdet = chance to be included for det (1- Pset ) (59%)
Ppreg-set = pregnancy rate after set (ﬁrst cycle) (26%)
Ppreg-det = pregnancy rate after det (14%)
Ptwin-det = twin pregnancy rate after det (12.5%)
Appendix a:
Before implementation of set (Nijmegen):
Ctot = n x Ci v f-cycle + n x Ppreg x Ptwin x (Cpreg-twin + Chand-twin) +
n x Ppreg x (1 - Ptwin) x (Cpreg-sing + Chand-sing)
After implementation of set (Nijmegen):
Ctot = n x Ci v f-cycle + n x P set x Ppreg-set x (Cpreg-sing + Chand-sing) +
n x P det x Ppreg-det x Ptwin-det x (Cpreg-twin + Chand-twin) +
n x P det x Ppreg-det x (1-Ptwin-det) x (Cpreg-sing + Chand-sing)
Appendix b:
In case 1.5 more set cycles will be performed to equalize the pregnancy rate to
det in the same population. The costs of i v f cycles will become 1.2 times
higher; 1.5 x n x P set + n x P det. The costs for the set group will become 1.5
times higher than for the det group.
Ctot = 1.2 x n x Ci v f-cycle + 1.5 x n x P set x Ppreg-set x (Cpreg-sing + Chand-sing) +
n x P det x Ppreg-det x Ptwin-det x (Cpreg-twin + Chand-twin) +
n x P det x Ppreg-det x (1-Ptwin-det) x (Cpreg-sing + Chand-sing)
note: In the det group the costs of i v f pregnancy up to six weeks after delivery
together with the lifetime costs for handicapped children are measured for
both singleton and twin pregnancies.
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Samenvatting
Het optreden van meerlingzwangerschappen is de meest ernstige com-
plicatie van i v f behandelingen. De incidentie van maternale en perina-
tale morbiditeit en mortaliteit is signiﬁcant hoger dan van éénlingzwan-
gerschappen. Daarom hebben de patiënten die zwanger zijn van een
meerling en de meerlingen zelf meer medische zorg nodig. In hoofdstuk
1 wordt in deel I achtergrond informatie gegeven over de medische, so-
ciale en economische problemen die gerelateerd zijn aan meerling-
zwangerschappen na i v f . Tevens wordt een aantal behandelingsstrate-
gieën beschreven welke het aantal meerlingen na i v f verminderen: het
terugplaatsen van één embryo (single embryo transfer (set)), i v f in de
natuurlijke cyclus en selectieve embryo reductie. set lijkt een goede
optie om een daling van het aantal meerlingen te bewerkstelligen, echter
het zwangerschapspercentage zal naar verwachting door deze strategie
ook enigszins dalen. Om de acceptatie van de implementatie van set te
verhogen is het daarom noodzakelijk om de zwangerschapskans na i v f
te verbeteren, met als doel de zwangerschapskans na set op hetzelfde
niveau te brengen als de kans na transfer van twee embryo’s (double
embryo transfer (det)). De implantatie van een embryo is een cruciale
stap in de totstandkoming van een succesvolle zwangerschap. Om de
zwangerschapskans na i v f te verbeteren is het daarom belangrijk om
meer fundamenteel onderzoek te verrichten naar processen die een rol
spelen bij de implantatie. In dit kader is het interessant om immunologi-
sche processen die tijdens de implantatie plaatsvinden te bestuderen.
Niet alleen is de foetus een semi-allograft die geaccepteerd moet worden
door het maternale immuun systeem (50% van de genen is van paternale
oorsprong en dus ‘vreemd’) ook spelen cellen van het immuunsysteem
een rol bij de rijping en groei van de placenta en foetus.
In deel II van de introductie wordt daarom de rol van het immuun sys-
teem van de vrouwelijke voortplantings organen (ovaria, uterus) be-
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schreven. De natural killer (nk) cellen blijken een belangrijke rol te spe-
len tijdens de implantatie. Ten eerste vormen de nk cellen de meerder-
heid van de witte bloedcel (leukocyten) populatie in het endometrium.
Het percentage nk cellen neemt tijdens de menstruele cyclus snel toe en
bereikt een piek in de luteale fase rondom de periode van innesteling. Tij-
dens het eerste trimester van de zwangerschap stijgt het aantal nk cellen
verder tot wel 70% van alle leukocyten die aanwezig zijn in de decidua.
Een tweede opmerkelijk feit is dat nk cellen accumuleren rondom de
plaats van innesteling, zij worden dicht in de nabijheid van invasieve
trophoblast cellen waargenomen. Een belangrijk aanknopingspunt voor
verder onderzoek is dat nk cellen receptoren bevatten voor hl a-mole-
culen (hl a- g , hl a-e , hl a- cw) die aanwezig zijn op invasieve trop-
hoblast cellen van de foetus. Er is steeds meer wetenschappelijk bewijs
dat de interactie tussen de maternale nk cellen en invasieve trophoblast
cellen van de foetus een cruciale stap is in het realiseren van een goede
innesteling. Extravilleuze trophoblast cellen vervangen de spierwand
van de spiraalarteriën, waardoor verwijding en ontwinding van deze
arteriën optreedt. Daardoor kan een betere maternale bloeddoorstro-
ming plaatsvinden naar de intervilleuze ruimte van de placenta. De
meest gangbare hypothese is dat de (diepte van) remodellering van de
spiraalarteriën door extravilleuze trophoblast cellen mogelijk wordt
gemaakt door geactiveerde nk cellen.
Deel I
Single embryo transfer lijkt de beste strategie om het grote aantal meer-
lingen ten gevolge van i v f behandelingen drastisch te verminderen. Er
zullen echter meer behandelingen met set nodig zijn om, in vergelijking
met det , dezelfde zwangerschapskans te behalen. Aan de andere kant
zullen er ook kosten bespaard worden door afname van maternale en
perinatale complicaties veroorzaakt door meerlingzwangerschappen.
Wij waren geïnteresseerd in de vraag hoeveel extra set cycli nodig zijn
om een evengrote zwangerschapskans te behalen als bij 1 det cyclus en
hoe groot de uiteindelijke kostenbesparing zou zijn na invoering van
set . Om die vragen te kunnen beantwoorden is in hoofdstuk 2 bere-
kend hoe duur een i v f tweeling zwangerschap is ten opzichte van een
i v f éénling zwangerschap bezien vanuit medisch perspectief. De
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belangrijkste ‘cost drivers’ tijdens de zwangerschap tot en met zes weken
na de bevalling bleken de prenatale controles (1e of 2e lijns), de wijze van
bevallen, ziekenhuis opname tijdens de zwangerschap en ziekenhuis
opname van het kind(eren) (nicu en non-nicu opnames). De frequen-
tie van voorkomen van deze ‘cost drivers’ werd bepaald bij 172 tweeling
en 168 éénling zwangerschappen na i v f in het umc St. Radboud. De
kosten van deze ‘cost drivers’ werden berekend op basis van werkelijke
kosten, indien mogelijk, of ziekenhuis tarieven. De medische kosten van
een i v f tweeling zwangerschap bleken meer dan 5 keer zo hoog als die
van een i v f éénling zwangerschap, respectievelijk 13.469 euro en 2.550
euro.
Vervolgens wordt in hoofdstuk 3 de effectiviteit van single embryo
transfer berekend. In een gerandomiseerde studie werd het aantal levend
geborenen na 2 set cycli vergeleken met het aantal levend geborenen na 1
det cyclus. In totaal werden 107 i v f patiënten jonger dan 35 jaar, eerste
behandeling en met tenminste één kwalitatief goed embryo, na stratiﬁca-
tie voor primaire of secundaire infertiliteit, gerandomiseerd. Het percen-
tage levend geborenen na 2 opeenvolgende set cycli was 41%. Dit per-
centage was vergelijkbaar met het aantal levend geborenen na 1 det
cyclus (36%), terwijl het aantal meerlingen in deze laatste groep signiﬁ-
cant hoger was: 37% in de det groep en 0% in de set groep (p = 0.002).
Per levend geborene werden 1.5 x meer set cycli dan det cycli uitge-
voerd. Wanneer de medische kosten van de extra i v f behandelingen en
de kosten van i v f éénling en tweeling zwangerschappen tot en met zes
weken postpartum bij elkaar werden opgeteld dan kostte de set strate-
gie 13.438 euro en de det strategie 13.680 euro per levend geborene.
Echter, wanneer de levenslange kosten van ernstig gehandicapte kinde-
ren wordt meeberekend dan zal meer dan 7.000 euro bespaard worden
door invoering van de set strategie.
In hoofdstuk 8 wordt bediscussieerd wat het theoretische effect zou
zijn van de implementatie van set bij patiënten met een gunstige zwan-
gerschapsprognose op de gehele i v f populatie van het umc St. Rad-
boud in het jaar 2000 en 2001. Na extrapolatie van de gegevens van de
set-studie zou de overall zwangerschapskans slechts minimaal dalen
van 23% naar 19%, terwijl de kans op een tweeling sterk zou afnemen van
27% naar 5%. Op landelijk niveau zou bijna 13 miljoen euro in 2 jaar tijd
bespaard kunnen worden na invoering van set , met een even hoge
zwangerschapskans als bij det .
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Indien in de toekomst op steeds grotere schaal 1 embryo zal worden
teruggeplaatst, dan moet ook serieus worden nagedacht over mildere
ovariële hyperstimulatie schema’s of zelfs géén hormonale stimulatie.
Tot nu toe zijn er alleen studies verricht naar de effectiviteit van i v f in de
natuurlijke cyclus, maar nog niet naar icsi in de natuurlijke cyclus bij
een serie paren waarvan de man extreem slechte zaadkwaliteit heeft.
Terwijl juist in deze laatste groep er bij de vrouw geen sprake is van een
aanwijsbare fertiliteitsstoornis en daardoor een hoge implantatiekans
verwacht wordt. i v f/icsi in de natuurlijke cyclus is een patiënt vriende-
lijke, relatief veilige en goedkope behandelingsstrategie. Bovendien kan
deze vorm van behandeling op maandelijkse basis plaatsvinden, dit in
tegenstelling tot een conventionele i v f behandeling welke 3 maanden in
beslag neemt, omdat de eigen cyclus onderdrukt moet worden en de ova-
ria na stimulatie weer ‘tot rust’ moeten komen. Het nadeel van i v f/icsi
in de natuurlijke cyclus is de lagere zwangerschapskans per gestarte
cyclus door een grote kans op canceling van de cyclus vanwege het ont-
breken van een eicel of embryo. In hoofdstuk 4 worden de resultaten van
een pilotstudie naar de effectiviteit van icsi in de natuurlijke cyclus bij
25 patiënten in 29 cycli beschreven. De inclusiecriteria waren extreem
slechte zaadkwaliteit, leeftijd van de vrouw jonger dan 37 jaar, regulaire
menstruele cyclus en geen aanwijsbare vruchtbaarheidsstoornis bij de
vrouw. Het percentage verkregen eicellen na punctie was 58.6%. Alle met
een zaadcel geïnjecteerde eicellen werden bevrucht. Bij 41.4% van de
patiënten werd een embryo teruggeplaatst. Drie patiënten werden zwan-
ger en bevielen van een gezonde éénling; dit is 10.3% per gestarte cyclus
en 25% per embryo transfer. icsi in de natuurlijke cyclus is een goed
alternatief voor icsi in de gestimuleerde cyclus, indien de cumulatieve
zwangerschapskans van 3 natuurlijke cycli wordt vergeleken met 1 gesti-
muleerde cyclus.
Deel II
Het is bekend dat uteriene nk cellen van groot belang zijn voor goede
innesteling van een embryo. Echter, nk cellen spelen mogelijk ook al een
belangrijke rol in eerdere stadia van de voortplanting, vóór de implanta-
tie. Wellicht oefenen leukocyten die aanwezig zijn in follikel vloeistof
reeds invloed uit op de rijping en ontwikkeling van de oöcyten en de
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embryo’s die daaruit ontstaan. In hoofdstuk 5 is onderzocht of de leuko-
cyten samenstelling, met de focus op nk cellen, van follikel vloeistof 
van patiënten met een onbekende oorzaak van hun fertiliteitsstoornis
anders is dan een controle groep bestaande uit patiënten met slechte
zaadkwaliteit of tuba pathologie. Met behulp van ﬂow cytometrie wer-
den de aantallen T cellen, nkt cellen, nk cellen en subsets van nk cellen
bepaald. Het belangrijkste resultaat van deze studie was dat in de groep
met een idiopathische fertiliteitsstoornis er signiﬁcant meer nkdim
(cd56+cd16+) cellen werden gevonden dan in de controle groep. nkdim
cellen hebben overwegend cytotoxische eigenschappen en zijn negatief
geassocieerd met verscheidene reproductieve stoornissen, zoals habitu-
ele abortus. Deze overmaat van nkdim cellen in follikel vloeistof zou
oöcyt dysfunctie kunnen veroorzaken en dus mogelijk een verklaring
kunnen zijn voor de ‘onbekende’ oorzaak van de fertiliteitsstoornis in
deze groep patiënten.
In hoofdstuk 6 is onderzocht of de leukocyten samenstelling van
endometrium tijdens de implantatie fase verandert onder invloed van
hormonale stimulatie van de ovaria. Ovariële hyperstimulatie veroor-
zaakt namelijk suprafysiologische concentraties van oestradiol en proge-
steron in het bloed. In de literatuur worden onderzoeken gerapporteerd
die zowel gunstige als ongunstige effecten op de receptiviteit van het
endometrium beschrijven. Zoals beschreven in hoofdstuk 6 werd van
20 i v f patiënten (tijdens hormonale stimulatie) een endometriumbiopt
(pipelle) genomen en werd de leukocyten samenstelling hiervan vergele-
ken met 18 biopten van vrouwen in de natuurlijke cyclus. Histologische
datering wees uit dat de endometriumbiopten na i v f niet vaker uit fase
waren dan de biopten in de controle groep. Flow cytometrische analyse
van de leukocyten subsets liet een verhoogde ratio van uteriene nkbright /
nkdim cellen zien, veroorzaakt door een relatief verminderd aantal
nkdim cellen ten opzichte van de controle groep. Een tweede opvallende
bevinding van dit onderzoek was dat er een derde nk cel subset werd
ontdekt; de nksuperbright (cd56+++cd16-) cellen. Deze celpopulatie werd
exclusief in het endometrium en niet in perifeer bloed gevonden. De spe-
ciﬁeke functie van deze nksuperbright subset moet nog verder onderzocht
worden. Aangezien nkbright cellen van het endometrium een positieve
invloed hebben op de implantatie en nkdim cellen negatief geassocieerd
worden met reproductieve processen, wordt verondersteld dat hormo-
nale stimulatie een gunstig effect kan hebben op de receptiviteit van het
endometrium.
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In hoofdstuk 7 is onderzocht wat het effect is van de interactie tussen
uterine nk cellen en hl a moleculen die aanwezig zijn op invaderende
trophoblast cellen, nl. hl a- g en hl a-e . Een potentiële rol van uteriene
nk cellen is de modulatie van implantatie door interactie met deze hl a-
moleculen. In het onderzoek beschreven in hoofdstuk 7 werden leuko-
cyten geïsoleerd uit endometrium biopten van 13 fertiele vrouwen tijdens
de implantatie fase. Deze leukocyten werden geïncubeerd met cellijnen
getransfecteerd met hl a- g . Het bleek dat hl a- g de proliferatie en
cytokine productie van uteriene nk cellen stimuleert. Terwijl er juist
remming optrad van de proliferatie en productie van if n-γ en il-3 van
de gehéle leukocyten populatie, voornamelijk bestaande uit T cellen.
v egf werd zowel door uteriene nk cellen als door de gehele leukocyten
populatie uit het endometrium geproduceerd na interactie met hl a- g .
Uit deze bevindingen zou voorzichtig geconcludeerd kunnen worden dat
hl a- g een te sterke gegeneraliseerde respons van het maternale
immuun systeem op de innesteling van de semi-allogene foetus onder-
drukt, maar dat de speciﬁeke functie van de uteriene nk cellen wel geac-
tiveerd moet worden om goede invasie van trophoblast cellen mogelijk te
maken. Het wordt steeds duidelijker dat met name hl a- g en hl a-e
moleculen nk cellen aanzetten tot de productie van speciﬁeke cytokines
en angiogene factoren, waardoor adequate invasie van trophoblast cellen
in de decidua kan plaatsvinden met als gevolg een goede aanleg van de
placenta.
De implantatie van de foetus blijft voor een groot deel een immunolo-
gisch mysterie. In dit proefschrift is een klein facet, namelijk de rol van
nk cellen tijdens de (pre)implantatie fase, onderzocht. Toekomstig
onderzoek moet uitwijzen of de aan- of afwezigheid van nk cel subsets
als prognostische marker voor de kans op zwangerschap kan fungeren.
Manipulatie van de leukocyten samenstelling of de functie in follikel
vloeistof en endometrium zou de kans op zwangerschap na i v f kunnen
verbeteren. Een hoge zwangerschapskans is een belangrijke voorwaarde
voor goede acceptatie van implementatie van single embryo transfer van
i v f patiënten en i v f specialisten. set is een kosten-effectieve methode
om het grote aantal meerlingzwangerschappen na i v f drastisch te ver-
minderen. Op landelijk niveau kan bijna 13 miljoen euro bespaard wor-
den in 2 jaar tijd na invoering van set , zonder dat dit ten koste gaat van
de zwangerschapskans. Wij pleiten voor een vergoeding van de eerste
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drie complete i v f behandelingen, inclusief terugplaatsing van cryo
embryo’s, op voorwaarde dat ten minste de eerste een set behandeling
zal zijn bij patiënten met een gunstige zwangerschapsprognose. Wan-
neer de eerste i v f behandeling niet vergoed wordt, zoals momenteel in
Nederland het geval is, bestaat het gevaar dat zowel i v f patiënten als i v f
specialisten sneller geneigd zijn om twee embryo’s terug te plaatsen met
alle medische, sociale en economische consequenties van dien.
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